# Singh_2012_Acetylcholinesterase inhibitors for schizophrenia.

Cochrane
Library

Cochrane Database of Systematic Reviews

Acetylcholinesterase inhibitors for schizophrenia (Review)

Singh J, Kour K, Jayaram MB

Singh J, Kour K, Jayaram MB. 
Acetylcholinesterase inhibitors for schizophrenia. 
Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD007967. 
DOI: 10.1002/14651858.CD007967.pub2.

www.cochranelibrary.com

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 1
Global effect: 1a. Medium-term - Average end point score on various outcomes............................................................................
Analysis 1.2. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 2
Global effect: 1b. Medium-term - Average end point score on CGI improvement............................................................................
Analysis 1.3. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 3
Global effect : 1c. Short-term - Average change score on CGI (high = favourable)............................................................................
Analysis 1.4. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 4
Leaving the study early.........................................................................................................................................................................
Analysis 1.5. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 5
Mental State: 1a. Average end point score on various outcomes - PANSS (low = favourable)..........................................................
Analysis 1.6. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 6
Mental state:1b.Average end point score on various outcomes-PANSS (medium-term)..................................................................
Analysis 1.7. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 7
Mental State: 2. Short-term - Average end point score on HAM-D (low = favourable)......................................................................
Analysis 1.8. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 8
Mental State: 3. Short-term - Average end point score on SANS (low = favourable).........................................................................
Analysis 1.9. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 9
Mental state: 4a. Short-term - Average end point score on CDSS (low = favourable).......................................................................
Analysis 1.10. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 10
Mental State: 4b. Medium-term - Average end point score on CDSS (low = favourable)..................................................................
Analysis 1.11. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 11
Mental State: 5. Short-term - Average change score on PANSS (low = favourable)...........................................................................
Analysis 1.12. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 12
General functioning: Medium-term - average end point score on GAF.............................................................................................
Analysis 1.13. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 13
Cognitive function: 1. Short-term - Average end point score on KMMSE (high = favourable)..........................................................
Analysis 1.14. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 14
Cognitive function: 2. Short-term - Average end point score on various subscales of WMS-III (high = favourable).........................
Analysis 1.15. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 15
Cognitive function: 3. Short-term - Average end point score on various subscales of of WAIS III (high = favourable).....................
Analysis 1.16. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 16
Cognitive function: 4. Short-term - Average end point score on various subscales of HVLT (high = favourable).............................
Analysis 1.17. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 17
Cognitive function: 5. Short-term - Average end point score on VFT (high = favourable)................................................................
Analysis 1.18. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 18
Cognitive function: 6. Short-term - Average end point score on BVST (high = favourable)..............................................................
Analysis 1.19. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 19
Cognitive function: 7. Short-term - Average end point score on various subscales of Stroop test..................................................
Analysis 1.20. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 20
Cognitive function: 7. Short-term - Average end point score on Trail making tests A & B (high = favourable).................................

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
3
5
5
5
9
10
19
21
21
22
28
50
59

59

59

60

61

62

63

63

63

63

63

64

64

64

66

67

67

68

68

68

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.21. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 21
Cognitive function: 8. Short-term - Average end point score on CPT................................................................................................
Analysis 1.22. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 22
Cognitive function: 9. Short-term - Average end point score on Grooved pegboard test ( high = favourable)................................
Analysis 1.23. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 23
Cognitive function: 10. Short-term - Average end point score on various scales (skewed data)......................................................
Analysis 1.24. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 24
Cognitive function: 11a. Short-term - Average change score on various scales (skewed data)........................................................
Analysis 1.25. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 25
Cognitive function: 11b. Medium-term - Average change score on various scales (skewed data)...................................................
Analysis 1.26. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 26
Adverse event: 1a. Short-term - Central nervous system...................................................................................................................
Analysis 1.27. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 27
Adverse event: 1b. Medium-term - Central nervous system..............................................................................................................
Analysis 1.28. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 28
Adverse event: 2. Short-term - Metabolic and nutritional..................................................................................................................
Analysis 1.29. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 29
Adverse event: 3. Short-term - Deterioration in menal state.............................................................................................................
Analysis 1.30. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 30
Adverse event: 4. Short-term - Biochemical abnormalities...............................................................................................................
Analysis 1.31. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 31
Adverse event: 5. Short-term - Non specific.......................................................................................................................................
Analysis 1.32. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 32
Adverse event: 6. Short-term - Cardiovascular...................................................................................................................................
Analysis 1.33. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 33
Adverse event: 7. Short-term - Gastrointestinal..................................................................................................................................
Analysis 1.34. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 34
Adverse event: 9. Short-term - Respiratory system............................................................................................................................
Analysis 1.35. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 35
Adverse event: 10. Medium-term - EPSE.............................................................................................................................................
Analysis 1.36. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 36
Adverse event: 11a. Short-term - Average end point score on EPSEs scale (low = favourable)........................................................
Analysis 1.37. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 37
Adverse event: 11b. Medium-term - Average end point score on EPSEs scale (low = favourable)...................................................
Analysis 1.38. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 38
Adverse event: 12a. Short-term - Average end point score on EPSEs scale (low = favourable)........................................................
Analysis 1.39. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 39
Adverse event: 12b. Medium-term - Average end point score on EPSEs scales (skewed data)........................................................
Analysis 1.40. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 40
Adverse event: 13. Short-term - Average change score on EPSEs scales (skewed data)..................................................................
Analysis 1.41. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 41
Adverse event: 14. Short-term - Average change interval on ECG (skewed data).............................................................................
Analysis 1.42. Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic, Outcome 42
Behaviour: 15. Short-term - Smoking (low = favourable)...................................................................................................................
Analysis 2.1. Comparison 2 Acetylcholinesterase inhibitors plus antipsychotics versus antipsychotics alone, Outcome 1 Leaving
the study early.......................................................................................................................................................................................
Analysis 2.2. Comparison 2 Acetylcholinesterase inhibitors plus antipsychotics versus antipsychotics alone, Outcome 2 Mental
state: Short-term - Average end point score on PANSS (low = favourable).......................................................................................
WHAT'S NEW.................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

69

70

70

71

72

73

73

73

74

74

75

75

76

76

77

77

77

77

78

78

78

79

80

81
81
81
81
81
82

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

[Intervention Review]

Acetylcholinesterase inhibitors for schizophrenia

Jasvinder Singh1, Kamalpreet Kour2, Mahesh B Jayaram3

1Department of Psychological Medicine, Humber NHS Foundation Trust, Hull, UK. 2Leeds Partnership Foundation Trust, Leeds, UK.
3CMHT, Leeds Partnership Foundation NHS Trust, Leeds, UK

Contact: Jasvinder Singh, Department of Psychological Medicine, Humber NHS Foundation Trust, 220-236 Anlaby Road, Hull, HU3 2RT,
UK. jcingh@googlemail.com.

Editorial group: Cochrane Schizophrenia Group.
Publication status and date: Edited (no change to conclusions), published in Issue 11, 2012.

Citation:  Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database of Systematic Reviews
2012, Issue 1. Art. No.: CD007967. DOI: 10.1002/14651858.CD007967.pub2.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Antipsychotic medication remains the mainstay of treatment for schizophrenia and has been in use for a long time. As evidenced by ongoing
research and partial effectiveness of the antipsychotics on cognitive and negative symptoms, the search is on for drugs that may improve
these domains of functioning for someone suffering from schizophrenia. Acetylcholinesterase inhibitors have long been in use for treating
cognitive symptoms of dementia.

Objectives

The aim of the review was to evaluate the clinical effects, safety and cost effectiveness of acetylcholinesterase inhibitors for treating people
with schizophrenia

Search methods

We searched the Cochrane Schizophrenia Group's Register (February 2009), and inspected the references of all identified studies for further
trials.

Selection criteria

We included all clinical randomised trials comparing acetylcholinesterase inhibitors with antipsychotics or placebo either alone, or in
combination, for schizophrenia and schizophrenia-like psychoses.

Data collection and analysis

We  extracted  data  independently.  For  dichotomous  data,  we  calculated  risk  ratios  (RR)  and  their  95%  confidence  intervals  (CI)  on  an
intention-to-treat (ITT) basis based on a random-effects model. For continuous data, we calculated mean differences (MD), again based
on a random-effects model.

Main results

The acetylcholinesterase inhibitor plus antipsychotic showed benefit over antipsychotic and placebo in the following outcomes.

1.  Mental  state  -  PANSS  negative  symptoms  average  end  point  score  (2  RCTs,  n  =  31,  MD  -1.69  95%  CI  -2.80  to  -0.57),  PANSS  General
Psychopathology average end point score (2 RCTs, n = 31, MD -3.86 95% CI -5.40 to -2.32), and improvement in depressive symptoms showed
at least by one short-term study as measured by CDSS scale (data skewed).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2. Cognitive domains - attention, (1 RCT, n = 73, MD 1.20 95% CI 0.14 to 2.26), visual memory (2 RCTs, n = 48 , MD 1.90 95% CI 0.52 to 3.28),
verbal memory and language (3 RCTs, n = 42, MD 3.46 95% CI 0.67 to 6.26) and executive functioning (1 RCT, n = 24, MD 17.10 95% CI 0.70
to 33.50).

3. Tolerability - EPSE: AIMS, (1 RCT, n = 35, MD 1.50 95% CI 1.04 to 1.96).

No difference was noted between the two arms in other outcomes. The overall rate of participants leaving studies early was low (13.6 %)
and showed no clear difference between the two groups.

Authors' conclusions

The results seem to favour the use of acetylcholinesterase inhibitors in combination with antipsychotics on a few domains of mental state
and  cognition,  but  because  of  the  various  limitations  in  the  studies  as  mentioned  in  the  main  text,  the  evidence  is  weak.  This  review
highlights the need for large, independent, well designed, conducted and reported pragmatic randomised studies.

P L A I N   L A N G U A G E   S U M M A R Y

Acetylcholinesterase inhibitors versus antipsychotics for schizophrenia either alone or in combination with antipsychotics.

This  review  compares  the  effects  of  acetylcholinesterase  inhibitors  alone,  or  in  combination  with  antipsychotics,  compared  with
antipsychotics alone, or placebo plus antipsychotics. Adding acetylcholinesterase inhibitors with antipsychotics may improve the general
psychopathology/negative symptomatology/depressive symptoms in people with schizophrenia. Also, the combination may be useful in
improving the attention/reaction time and memory areas of cognition. The major limitation of the results was that most of the studies
found were short-term studies. Considering the chronic, severe and enduring nature of schizophrenia, one cannot get a true picture unless
well designed long-term studies are done. We hope that this review will highlight the need for more studies in this area.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
c
e
t
y
l
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i

i

n
h
b
i
t
o
r
s
f
o
r
s
c
h
i
z
o
p
h
r
e
n
i
a
(
R
e
v
i
e
w

)

3

S U M M A R Y   O F   F I N D I N G S

Summary of findings for the main comparison.

Acetylcholinesterase inhibitors plus antipsychotic for schizophrenia

Patient or population: schizophrenia

Settings:

Intervention: Acetylcholinesterase inhibitors plus antipsychotic

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Control

Acetylcholinesterase inhibitors plus an-
tipsychotic

The mean Global effect: 1a. Medium-term
- Average end point score on various out-
comes - CGI-severity (low = favourable) in
the intervention groups was 0.46 higher
(0.15 lower to 1.07 higher)

Global effect: 1a. Medi-
um-term - Average end
point score on various out-
comes - CGI-severity (low =
favourable) 
(follow-up: mean 16 weeks)

Relative effect 
(95% CI)

No of Partici-
pants 
(studies)

Quality of the
evidence 
(GRADE)

Comments

11 
(1)

1,2,3,4

Leaving the study early - Ad-
verse event: Short-term

Medium risk population

RR 1.91 
(0.8 to 4.61)

428 
(6)

12 per 1000

23 per 1000 
(10 to 55)

Mental state: 1b. Average
end point score on various
outcomes-PANSS (medi-
um-term) - Medium-term -
PANSS negative end point
score (low = favourable)

Mental state: 1b.Average
end point score on var-
ious outcomes-PANSS
(medium-term) - Medium
term - PANSS general psy-

The mean Mental state: 1b.Average end
point score on various outcomes-PANSS
(medium-term) - Medium-term -
PANSS negative end point score (low =
favourable) in the intervention groups was
1.69 lower (2.8 to 0.57 lower)

The mean Mental state:1b.Average end
point score on various outcomes-PANSS
(medium term) - Medium term - PANSS
general psychopathology end point score
(low = favourable) in the intervention
groups was 3.86 lower (5.4 to 2.32 lower)

31 
(2)

31 
(2)

1,4,5

1,4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
c
e
t
y
l
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i

i

n
h
b
i
t
o
r
s
f
o
r
s
c
h
i
z
o
p
h
r
e
n
i
a
(
R
e
v
i
e
w

)

4

chopathology end point
score (low = favourable)

Cognitive function: 3.
Short-term - Average end
point score on various sub-
scales of WAIS III (high =
favourable) - Digit symbol
score

Cognitive function: 4. Short-
term - Average end point
score on various subscales
of HVLT (high = favourable) -
Recognition

Adverse event: 11a. Short-
term - Average end point
score on EPSEs scale (low =
favourable) - AIMS

The mean Cognitive function: 3. Short-
term - Average end point score on various
subscales of WAIS III (high = favourable)
- Digit symbol score in the intervention
groups was 
1.2 higher (0.14 to 2.26 higher)

The mean Cognitive function: 4. Short
term - Average end point score on vari-
ous subscales of HVLT (high = favourable)
- Recognition in the intervention groups
was 1.79 higher (0.62 to 2.96 higher)

The mean Adverse event: 11a. Short term
- Average end point score on EPSEs scale
(low = favourable) - AIMS in the interven-
tion groups was 1.5 higher (1.04 to 1.96
higher)

73 
(1)

48 
(2)

35 
(1)

1,2,4

1,4

1,2,4,6

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.

1 Randomised, but randomisation method was not described.
2 Results were available from one study only.
3 It was a direct comparison.
4 Few patients were involved in the study.
5 No explanation was provided
6 No information available on blinding.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Schizophrenia  is  a  severe  and  enduring  mental  health  problem
affecting  the  world's  population,  irrespective  of  geographical
boundaries  and  it  has  a  lifetime  prevalence  of  around  one  per
cent  (Jablensky  1992).  It  is  characterised  by  symptoms  that  can
be divided into three broad categories: 'positive' symptoms, such
as  hallucinations  and  delusions;  'negative'  symptoms,  such  as
emotional blunting and lack of motivation; and 'cognitive domain'
symptoms,  such  as  working  memory,  attention  and  information
processing deficits (Mueser 2004). The severity of symptoms often
causes substantial and long-lasting impairments.

Description of the intervention

The  introduction  of  the  first  antipsychotic  drug  chlorpromazine
in  1952  led  to  optimism  that  pharmaceutical  treatments  may
hold  the  key  for  curing  schizophrenia;  it  also  paved  the  way  to
the  discovery  of  many  other  psychotropic  drugs,  however,  the
concept  of  'cure'  still  remains  elusive.  As  evidenced  by  ongoing
research  and  partial  effectiveness  on  cognitive  and  negative
symptoms,  the  search  is  on  for  drugs  that  may  improve  these
domains of functioning for people suffering from schizophrenia. It
has  been  hypothesised  that  a  number  of  other  neurotransmitter
systems  modulate  the  function  of  dopamine  pathways  in  the
central nervous system (CNS). The role of muscarinic acetylcholine
receptors in modulating dopamine function is now well recognised
(Yeomans  1995).  Acetylcholine  is  a  prominent  neurotransmitter
which  acts  on  these  receptors;  it  is  formed  in  cholinergic
neurons  from  two  precursors,  choline  and  acetyl  coenzyme  A,
with  the  help  of  the  enzyme  choline  acetyltransferase  (Stahl
2000). An acetylcholinesterase inhibitor or anti-cholinesterase is a
chemical  that  inhibits  the  cholinesterase  enzyme  from  breaking
down acetylcholine, thus increasing both the level and duration of
action of the neurotransmitter acetylcholine.

How the intervention might work

The acetylcholinesterase inhibitors have been studied in cognitive
deficit  states  such  as  Alzheimer's  disease  and  others,  and
have  been  in  use  for  sometime.  Those  acetylcholinesterase
inhibitors  which  have  been  used  for  Alzheimer's  disease  include
donepezil, rivastigmine and galantamine (Birks 2006).

its  hydrolysis  by  acetylcholinesterase 

Donepezil  is  a  centrally  acting  reversible  acetylcholinesterase
inhibitor.  It  is  known  chemically  as 
  (±)-2,  3-dihydro-5,  6-
dimethoxy2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-
one  hydrochloride.  Its  main  therapeutic  use  is  to  increase
cortical  acetylcholine  in  the  treatment  of  Alzheimer's  disease.
It  is  postulated  to  exert  its  therapeutic  effect  by  enhancing
cholinergic  function.  This  is  accomplished  through  reversible
thus
inhibition  of 
increasing  the  concentration  of  acetylcholine  (Wishart  2006).
Rivastigmine is a reversible cholinesterase inhibitor and is known
chemically  as  [3-[(1S)-1-dimethylaminoethyl]  phenyl]  N-ethyl-N-
methylcarbamate. It is a cholinesterase inhibitor that inhibits both
acetylcholinesterase  and  butyrylcholinesterase  (Wishart  2006).
Galantamine  is  a  benzazepine  derived  from  norbelladine.  It  is
chemically  known  as  (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-
methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol). It
is  found  in  plants  such  as  galanthus  and  other  Amaryllidaceae.
It  is  also  a  cholinesterase  inhibitor  and  its  proposed  mechanism

Cochrane Database of Systematic Reviews

involves  the 

increase  of  the  concentration  of
of  action 
acetylcholine  through  reversible  inhibition  of  its  hydrolysis  by
acetylcholinesterase.  It  also  interacts  with  nicotinic  acetylcholine
receptors (Wishart 2006). Despite the slight variations in the mode
of  action  of  the  three  acetylcholinesterase  inhibitors,  there  is  no
evidence  of  any  clinically  important  differences  between  them
with respect to efficacy, although direct comparisons among these
drugs are limited (Birks 2006).

Why it is important to do this review

All  of  the  currently  available  antipsychotic  drugs  are  effective
in  improving  the  positive  symptoms  of  schizophrenia  and  are
presumed  to  have  this  effect  predominantly  by  antagonising
various  dopamine  receptors.  Antipsychotic  medications  have
greatly  improved  the  prospects  for  patients  with  schizophrenia
and related disorders, but most individuals continue to experience
symptoms  throughout  their  lives;  probably  no  more  than  one
person in five recovers completely (Gelenberg 2004). Therefore, the
need arises for novel therapeutic approaches, especially therapies
that are effective in multiple domains of schizophrenia, particularly
if they have such effects via mechanisms other than the dopamine
receptor  blockade.  The  antipsychotic-like  actions  of  muscarinic
cholinomimetics  such  as  arecoline  were  first  described  in  the
literature  many  years  ago  (Shekhar  2008).  Also,  it  has  long  been
known that acetylcholine plays an important role in cognition and
that impaired cholinergic transmission contributes to the cognitive
deficits in Alzheimer's disease (Winkler 1998). Acetylcholinesterase
inhibitors  are  a  new  group  of  compounds  being  tried  in  the
treatment  of  schizophrenia.  There  are  no  existing  systematic
reviews of these groups of compounds and there is an urgent need
to critically examine the available evidence to find out whether it is
worth considering these medications either as a first line or second
line option in the treatment of schizophrenia.

O B J E C T I V E S

To  review  the  effects  of  acetylcholinesterase  inhibitors  for  the
treatment of schizophrenia and schizophrenia-like psychoses.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We  considered  all  relevant  randomised  controlled  trials.  If  there
was no implied randomisation in relevant trials, we tried to contact
the  authors  to  clarify  the  randomisation  method.  If  there  had
been  no  randomisation,  we  excluded  the  trials.  If  there  was  no
substantive  difference  within  primary  outcomes  (see  Types  of
outcome  measures)  when  these  'implied  randomisation'  studies
were added, then we included them in the final analysis. If there
was a substantive difference, we only used clearly randomised trials
and described the results of the sensitivity analysis in the text. We
excluded  quasi-randomised  studies,  such  as  those  allocating  by
using  alternate  days  of  the  week.  Where  trials  were  described  as
'double-blind', but it was implied that the study was randomised
and  where  the  demographic  details  of  each  group's  participants
were  similar,  we  included  the  trials  and  undertook  a  sensitivity
analysis to test the presence or absence of these data. Randomised
cross-over studies were eligible but only data up to the point of first
cross-over because of the instability of the problem behaviours and
the likely carry-over effects (Elbourne 2002).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

5

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Types of participants

4. Quality of life/satisfaction with treatment

People  with  schizophrenia  or  other  types  of  schizophrenia-like
psychosis  (e.g.  schizophreniform  and  schizoaffective  disorders),
irrespective of the diagnostic criteria used, age, ethnicity and sex.
There  is  no  clear  evidence  that  the  schizophrenia-like  psychoses
are caused by fundamentally different disease processes or require
different  treatment  (Carpenter  1994).  If  possible,  we  excluded
children,  and  people  with  dementing  illnesses,  depression  and
primary problems associated with substance misuse.

Where  a  study  described  the  participant  group  as  suffering  from
'serious mental illnesses' and did not give a particular diagnostic
grouping,  we  included  these  trials  assuming  that  most  people
suffered from schizophrenia. The exception to this rule was when
the majority of those randomised clearly did not have a functional
non-affective psychotic illness.

Types of interventions

1. Acetylcholinesterase inhibitors given orally alone.

2. Acetylcholinesterase inhibitors in combination with other
drugs.

3. Other intervention, or placebo or no intervention.

Types of outcome measures

We  grouped  outcomes  into  the  short-term  (up  to  12  weeks),
medium-term (13 to 26 weeks) and long-term (over 26 weeks).

Primary outcomes

1. Clinical global response

1.1 Global state: No clinically important response as defined by the
individual studies - for example, global impression less than much
improved or less than 50% reduction on a rating scale - long-term

Secondary outcomes

1. Clinical global response

1.1 Global state: No clinically important response as defined by the
individual studies - for example, global impression less than much
improved or less than 50% reduction on a rating scale - short-term,
medium term
1.2 Relapse (as defined by the individual studies)
1.3 Leaving the studies early (any reason, adverse events, inefficacy
of treatment)
1.4 Compliance with medication

2. Mental state (with particular reference to the positive and negative
symptoms of schizophrenia)

2.1 No clinically important change in general mental state score
2.2 Average end point general mental state score
2.3 Average change in general mental state score
2.4 No clinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
2.5 Average end point specific symptom score
2.6 Average change in specific symptom score

3. General functioning

3.1 No clinically important change in general functioning
3.2 Average end point general functioning score
3.3 Average change in general functioning score

4.1 No clinically important change in general quality of life
4.2 Healthy days
4.3 Average end point general quality of life score
4.4 Average change in general quality of life score

5. Cognitive functioning (as measured by psychometric tests)

5.1 No clinically important change in overall cognitive functioning
5.2 Average end point of overall cognitive functioning score
5.3 Average change of overall cognitive functioning score

6. Service use

6.1 Number of participants hospitalised
6.2 Days in hospital

7. Adverse effect

7.1 Number of participants with at least one adverse effect
7.2  Clinically  important  specific  adverse  effects  (cardiac  effects,
death,  movement  disorders,  probating  increase  and  associated
effects, sedation, seizures, weight gain, effects on white blood cell
count)
7.3 Average end point in specific adverse effect
7.4 Average change in specific adverse effects

8. Economic outcomes

8.1 Direct costs
8.2 Indirect costs

9. Behaviour

9.1 No clinically important change in general behaviour
9.2 Average end point general behaviour score
9.3 Average change in general behaviour scores
9.4 No clinically important change in specific aspects of behaviour
9.5 Average end point specific aspects of behaviour
9.6 Average change in specific aspects of behaviour

10. Engagement with services

Search methods for identification of studies

No  language  restriction  was  applied  within  the  limitations  of  the
search tools.

Electronic searches

We  searched  the  Cochrane  Schizophrenia  Group  Trials  Register
(February 2009) using the phrase:

[(*Acetylcholinesterase*  OR  *Anseculin*    OR  *CHF  2060*    OR
*Donepezil* OR *Eptastigmine* OR *Galantamine* OR *Huperzine
A*  OR  *Icopezil*  OR  *Ipidacrine*  OR  *Itopride*  OR  *Metrifonate*
OR  *Mimopezil*  OR  *Phenserine*  OR  *Physostigmine*  OR
*Pramiracetam* OR *Quilostigmine* OR *Rivastigmine* OR *S 9977*
OR  *Tacrine*  OR  *Velnacrine*  OR  *Zanepesil*  OR  *Zifrosilone*  in
title)  and  (Acetylcholinesterase*  OR  Anseculin*    OR  CHF  2060*
  OR Donepezil* OR Eptastigmine* OR Galantamine* OR Huperzine
A*  OR  Icopezil*  OR  Ipidacrine*  OR  Itopride*  OR  Metrifonate*  OR
Mimopezil* OR Phenserine* OR Physostigmine* OR Pramiracetam*
OR  Quilostigmine*  OR  Rivastigmine*  OR  S  9977*  OR  Tacrine*  OR
Velnacrine* OR Zanepesil* OR Zifrosilone* in title, abstract, index
terms of REFERENCE and intervention in STUDY)]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

6

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

is  compiled  by  systematic  searches  of  major
This  register 
databases, handsearches and conference proceedings (see group
module).

risk of bias of the article such as sequence generation, allocation
concealment,  blinding,  incomplete  outcome  data  and  selective
reporting.

Searching other resources

1. Reference lists

We examined the reference lists of all retrieved articles, previous
reviews and major text books of schizophrenia for additional trials.

2. Authors of studies

We identified the authors of significant papers from authorship of
trials and review articles found in the search. We contacted them, as
well as other experts in the field,and asked for information of other
studies, published or unpublished, relevant to the review.

3. Pharmaceutical companies

We asked relevant pharmaceutical companies to provide relevant
published  and  unpublished  data  regarding  any  studies  they  may
have access to.

Data collection and analysis

Selection of studies

Two review authors (JS and KK) independently inspected citations
identified  from  the  search.  We  identified  potentially  relevant
reports  and  ordered  full  papers  for  reassessment.  The  same  two
review  authors  independently  assessed  the  retrieved  articles  for
inclusion  according  to  the  previously  defined  inclusion  criteria.
We  resolved  any  disagreement  by  consensus  discussions  with
the  third  member  (MJ)  of  the  review  team.  If  it  was  impossible
to  resolve  disagreements,  we  added  these  studies  to  Studies
awaiting classification and contacted the authors of the papers for
clarification. We reported non-concurrence in trial selection.

Data extraction and management

1. Extraction

Review  authors  JS  and  KK 
independently  extracted  data
from  included  studies.  Again,  we  discussed  any  disagreement,
documented decisions and, if necessary, contacted the authors of
studies for clarification. With any remaining problems, MJ helped
clarify issues and we documented those final decisions.

2. Management

We extracted data onto standard, simple forms.

3. Scale-derived data

We  included  continuous  data  from  rating  scales  only  if:  (a)  the
psychometric  properties  of  the  measuring  instrument  had  been
described  in  a  peer-reviewed  journal  (Marshall  2000  );  (b)  the
measuring  instrument  was  not  written  or  modified  by  one  of  the
trialists;  (c)  the  measuring  instrument  was  either  (i)  a  self-report
or  (ii)  completed  by  an  independent  rater  or  relative  (not  the
therapist).

Assessment of risk of bias in included studies

JS and KK worked independently by using criteria described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011)  to  assess  trial  quality.  This  new  set  of  criteria  is  based  on
evidence of associations between overestimate of effect and high

inadequate  details  of 

Where 
randomisation  and  other
characteristics of trials were provided, we contacted authors of the
studies in order to obtain additional information.

We have noted the level of risk of bias in both the text of the review
and in the Summary of findings for the main comparison.

Measures of treatment effect

1. Dichotomous data

Where  possible,  we  attempted  to  convert  outcome  measures  to
dichotomous data. This could be done by identifying cut-off points
on rating scales and dividing participants accordingly into 'clinically
improved'  or  'not  clinically  improved'.  It  was  generally  assumed
that if there had been a 50% reduction in a scale-derived score such
as the Brief Psychiatric Rating Scale (Overall 1962) or the Positive
and  Negative  Syndrome  Scale  (PANSS)  (Kay  1987),  this  could  be
considered as a clinically significant response (Leucht 2005). If data
based on these thresholds were not available, we used the primary
cut-off presented by the original authors.

We  calculated  the  risk  ratio  (RR)  and  its  95%  confidence  interval
(CI) based on the random-effects model, as this takes into account
any  differences  between  studies  even  if  there  is  no  statistically
significant  heterogeneity.  It  has  been  shown  that  RR  is  more
intuitive  (Boissel  1999)  than  odds  ratios  and  that  odds  ratios
tend  to  be  interpreted  as  RR  by  clinicians  (Deeks  2000).  This
misinterpretation then leads to an overestimate of the impression
of  the  effect.  When  the  overall  results  were  significant,  we
calculated the number needed to treat to provide benefit (NNTB)
and  the  number  needed  to  treat  to  induce  harm  (NNTH)  as  the
inverse of the risk difference (RD).

2. Continuous data

2.1 Summary statistic

For  continuous  outcomes,  we  estimated  a  mean  difference  (MD)
between  groups.  MDs  were  based  on  the  random-effects  model
as  this  takes  into  account  any  differences  between  studies  even
if  there  is  no  statistically  significant  heterogeneity.  We  did  not
calculate standardised mean difference (SMD) measures.

2.2 End point versus change data

Since  there  is  no  principal  statistical  reason  why  end  point  and
change  data  should  measure  different  effects  (Higgins  2011),  we
used scale end point data which is easier to interpret from a clinical
point of view. If end point data were not available, we used change
data.

2.3 Skewed data

Continuous  data  on  clinical  and  social  outcomes  are  often  not
normally  distributed.  To  avoid  the  pitfall  of  applying  parametric
tests  to  non-parametric  data,  we  aimed  to  apply  the  following
standards  to  all  data  before  inclusion:  (a)  standard  deviations
(SDs) and means are reported in the paper or obtainable from the
authors;  (b)  when  a  scale  starts  from  the  finite  number  zero,  the
SD,  when  multiplied  by  two,  is  less  than  the  mean  (as  otherwise
the mean is unlikely to be an appropriate measure of the centre of

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

the distribution, (Altman 1996); (c) if a scale starts from a positive
value (such as PANSS which can have values from 30 to 210), the
calculation described above was modified to take the scale starting
point into account. In these cases skew is present if 2 SD > (S-S min),
where S is the mean score and S min is the minimum score. End
point scores on scales often have a finite start and end point and
these  rules  can  be  applied.  When  continuous  data  are  presented
on  a  scale  which  includes  a  possibility  of  negative  values  (such
as  change  data),  it  is  difficult  to  tell  whether  data  are  skewed  or
not.  If  we  had  found  skewed  data  from  studies  of  less  than  200
participants,  we  planned  to  enter  the  data  into  additional  tables
rather than into an analysis. Skewed data pose less of a problem
when looking at means if the sample size is large and are entered
into syntheses.

2.4 Data synthesis

When  standard  errors  (SEs)  instead  of  SDs  were  presented,  we
converted the former to SDs. If SDs were not reported and could not
be calculated from available data, we asked the authors to supply
the data. In the absence of data from authors, we used the mean SD
from other studies.

2.5 Multiple doses

planned  to  synthesise  these  with  other  studies  using  the  generic
inverse variance technique.

2. Cross-over trials

A major concern of cross-over trials is the carry-over effect. It occurs
if an effect (e.g. pharmacological, physiological or psychological) of
the treatment in the first phase is carried over to the second phase.
As  a  consequence  on  entry  to  the  second  phase  the  participants
can differ systematically from their initial state despite a wash-out
phase. For the same reason cross-over trials are not appropriate if
the condition of interest is unstable (Elbourne 2002). As both effects
are very likely in schizophrenia, we planned to use only data of the
first phase of cross-over studies.

3. Studies with multiple treatment groups

Where a study involved more than two treatment arms, if relevant,
we presented the additional treatment arms in additional relevant
comparisons. We did not double count data. Where the additional
treatment arms were not relevant, we did not reproduce these data.

Dealing with missing data

1. Overall loss of credibility

We considered that as a study might investigate a number of fixed
doses of quetiapine, the combining of continuous data from those
different groups would not be possible. In this case, we planned to
use the scores from the highest dose group. None of the included
studies used quetiapine as an intervention.

At some degree of loss of follow-up, data must lose credibility (Xia
2007). We are forced to make a judgment where this is for the trials
likely to be included in this review. Where more than 40% of data
were unaccounted for, we did not reproduce these data or use them
within the analyses.

Unit of analysis issues

1. Cluster trials

Studies  increasingly  employ  'cluster  randomisation'  (such  as
randomisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intraclass correlation in clustered studies, leading to a 'unit of
analysis' error (Divine 1992) whereby P values are spuriously low,
CIs unduly narrow and statistical significance overestimated. This
can lead to type I error or false positive (Bland 1997; Gulliford 1999).
Where  clustering  was  not  accounted  for  in  primary  studies,  we
planned to present the data in a table with a (*) symbol to indicate
the presence of a probable unit of analysis error. If clustering had
been incorporated into the analysis of primary studies, we planned
to  present  these  data  as  if  from  a  non-cluster  randomised  study,
but  we  would  have  adjusted  the  data  for  the  clustering  effect.  In
subsequent  versions  of  this  review  we  will  seek  to  contact  first
authors of studies to obtain intraclass correlation coefficients (ICCs)
of their clustered data and to adjust for this using accepted methods
(Gulliford 1999).

We divided binary data as presented in a report by a 'design effect'.
We  calculated  this  using  the  mean  number  of  participants  per
cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (Donner 2002).
If the ICC was not reported, we assumed it to be 0.1 (Ukoumunne
1999). This assumption may be too high and, should this instance
occur, we had planned to see if taking an ICC of 0.01 would make
any substantive difference for the primary outcome. If it had not we
would have used 0.01 in preference across outcomes.

If  cluster  studies  had  been  appropriately  analysed  taking  into
account  ICCs  and  relevant  data  documented  in  the  report,  we

2. Binary

In  the  case  where  attrition  for  a  binary  outcome  was  between
0%  and  40%  and  outcomes  of  these  people  were  described,  we
included these data as reported. Where these data were not clearly
described,  we  presented  data  on  a  'once-randomised-always-
analyse'  basis,  assuming  an  intention-to-treat  (ITT)  analysis.  We
assumed that those lost to follow-up to have a negative outcome,
with the exception of the outcome of death. For example, for the
outcome of relapse, those who were lost to follow-up all relapsed.
We  undertook  a  final  sensitivity  analysis  to  test  how  prone  the
primary outcomes were to change when 'completer' data only were
compared with the ITT analysis using the negative assumption.

3. Continuous

In the case where attrition for a continuous outcome was between
0%  and  40%  and  completer-only  data  were  reported,  we  have
reproduced these.

4. Intention-to-treat analysis (ITT)

We  used  ITT  analysis  when  available.  We  anticipated  that  in
some  studies,  in  order  to  do  an  ITT  analysis,  the  method  of  last
observation  carried  forward  (LOCF)  would  be  employed  within
the  study  report.  As  with  all  methods  of  imputation  to  deal  with
missing data, LOCF introduces uncertainty about the reliability of
the results. Therefore, we have indicated in the review where we
used LOCF data.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Assessment of heterogeneity

1. Clinical heterogeneity

We  considered  all  included  studies  hoping  to  use  all  studies
together. We planned that where clear unforeseen issues became
apparent that might add obvious clinical heterogeneity, we would
note  these  issues,  consider  them  in  analyses  and  undertake
sensitivity analyses for the primary outcome.

2. Statistical

2.1 Visual inspection

We  visually  inspected  graphs  to  investigate  the  possibility  of
statistical heterogeneity.

2.2 Employing the I2statistic

We  investigated  heterogeneity  between  studies  by  using  the  I2
method (Higgins 2011) and the Chi2 P value. The former provides an

estimate of the percentage of variation in observed results thought
unlikely  to  be  due  to  chance.  We  considered  a  value  equal  to,  or
greater  than,  50%  indicated  heterogeneity  and  we  explored  the
reason for the heterogeneity. If the inconsistency was high and the
clear reasons were found, we presented the data separately.

Assessment of reporting biases

Reporting biases arise when the dissemination of research findings
is  influenced  by  the  nature  and  direction  of  results  (Egger  1997).
These are described in section 10.1 of the Cochrane Handbook for
Systematic  Reviews  of  Interventions  (Higgins  2011)  We  are  aware
that funnel plots may be useful in investigating reporting biases but
are of limited power to detect small-study effects. We did not use
funnel plots for outcomes where there were ten or fewer studies, or
where all studies were of similar sizes. In other cases, where funnel
plots were possible (Figure 1) , we sought statistical advice in their
interpretation.

Figure 1.   Funnel plot of comparison: 1 Acetylcholinesterase inhibitors plus antipsychotics versus placebo plus
antipsychotic, Outcome: 1.3 Leaving the study early

Data synthesis

Where  possible  for  both  dichotomous  and  continuous  data,  we
used  the  random-effects  model  for  data  synthesis  as  this  takes
into  account  any  differences  between  studies  even  if  there  is  no
statistically  significant  heterogeneity.  We  understand  that  there
is  no  closed  argument  for  preference  for  use  of  fixed-effect  or
random-effects models. The random-effects method incorporates
an assumption that the different studies are estimating different,

yet  related,  intervention  effects.  This  does  seem  true  to  us,
however,  random-effects  does  put  added  weight  onto  smaller
studies - those trials that are most vulnerable to bias.

Subgroup analysis and investigation of heterogeneity

If  data  were  clearly  heterogeneous,  we  checked  that  data  were
correctly  extracted  and  entered  and  that  we  had  made  no  unit
of  analysis  errors.  If  the  high  levels  of  heterogeneity  remained,

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

we  did  not  undertake  a  meta-analysis  at  this  point  for  if  there
is  considerable  variation  in  results,  and  particularly  if  there  is
inconsistency  in  the  direction  of  effect,  it  may  be  misleading  to
quote an average value for the intervention effect. We planned to
explore heterogeneity. We did not pre-specify any characteristics of
studies that may be associated with heterogeneity except quality
of trial method. If no clear association could be shown by sorting
studies  by  quality  of  methods,  we  performed  a  random-effects
meta-analysis.  Should  another  characteristic  of  the  studies  have
been  highlighted  by  the  investigation  of  heterogeneity,  perhaps
some  clinical  heterogeneity  not  hitherto  predicted  but  plausible
causes  of  heterogeneity,  we  planned  to  discuss  these  post-hoc
reasons  and  analyse  and  present  the  data.  However,  should
the  heterogeneity  have  been  substantially  unaffected  by  the  use
of  random-effects  meta-analysis  and  no  other  reasons  for  the
heterogeneity have been evident, we planned to present the final
data without a meta-analysis.

Sensitivity analysis

We planned sensitivity analyses a priori for examining the change
in the robustness of the sensitivity to including studies with implied
randomisation (see Criteria for considering studies for this review
-  Types  of  studies),  skewed  and  non-skewed  data,  inappropriate
comparator  doses  of  drug  and  different  clinical  groups  -  the
latter being defined post hoc. If inclusion of studies with implied
randomisation  made  no  substantive  difference  to  the  primary
outcome, we left them in the final analyses. For outcomes with both
skewed  data  and  non-skewed  data,  we  investigated  the  effect  of
combining  all  data  together  and  if  no  substantive  difference  was
noted, then we left the potentially skewed data in the analyses. If
necessary,  we  planned  to  analyse  the  effect  of  including  studies
with high attrition rates in a sensitivity analysis. We recognise that
we may not have considered some clinical causes for heterogeneity
that become more obvious after seeing the data. We are fully aware
that these are weak investigations and only generate and do not
prove hypotheses. We did not anticipate this last sensitivity analysis
but wished to leave the potential for investigating any omission we
may have made in consideration of studies at the stage of writing
the protocol.

R E S U L T S

Description of studies

For a substantial description of each of the included, excluded and
ongoing studies please refer to Characteristics of included studies;
Characteristics of excluded studies and Characteristics of ongoing
studies. We included 17 studies which are described below in the
section on included studies.

Results of the search

The initial search resulted in over 82 citations, of which we included
44  citations  relating  to  17  studies.  We  excluded  17  studies,  four
studies are awaiting classification and seven studies are ongoing.
Two  review  authors  (JS,KK)  independently  inspected  all  reports.
We resolved any disagreement by discussion, and where there was
still doubt, we acquired the full article for further inspection. Once
the full articles were obtained, we independently decided whether
the  studies  met  the  review  criteria.  If  disagreement  could  not  be
resolved by discussion, we sought further information and added
these trials to the list of those awaiting assessment.

Cochrane Database of Systematic Reviews

Included studies

We  included  17  studies  in  our  review.  All  these  studies  were
described as double blind but none of them tested for effectiveness
of blinding in either the participants or the raters. Only one study
(Keefe  2008a)  described  adequate  sequence  generation  for  the
process of randomisation.

1.1 Length of trials

Of all the studies included, 14 reported data on short-term follow-
up. The duration of three studies was eight weeks and 12 weeks for
11 studies.. The remaining three studies reported data on medium-
term follow-up. Two studies lasted 16 weeks (Fagerlund 2007; Tuma
2003) and one study (Sharma 2006 ) 24 weeks. We did not identify
any long-term studies.

1.2 Participants

One  study  included  participants  with  no  clear  diagnostic  criteria
(Dyer  2008).  Nine  trials  included  people  with  a  sole  diagnosis  of
schizophrenia using DSM IV (Diagnostic Statistical Manual version
4) (Akhondzadeh 2008; Caroff 2007; Freudenreich 2005; Friedman
2002c; Kim 2005b; Lee 2005; Tugal 2003) and ICD 10 (International
Statistical Classification of Diseases and Related Health Problems)
(Fagerlund 2007;Tuma 2003). The remaining seven studies included
participants  with  a  diagnosis  of  schizophrenia  or  schizoaffective
disorder  as  per  DSM  IV  (Buchanan  2008;  Chouinard  2007;  Keefe
2008a;  Kohler  2007;  Nahas  2003;  Schubert  2006;  Sharma  2006).
Studies  included  both  male  and  female  participants  with  the
majority of participants being male; two studies included only male
participants (Caroff 2007; Nahas 2003), and in another one the sex
of the participants was not specified (Tuma 2003). The mean age of
study participants ranged from 18 to 60 years.

Three trials did not have definitive exclusion criteria (Kohler 2007;
Nahas  2003;  Tugal  2003).  Thirteen  trials  excluded  people  with
alcohol  and  substance  misuse,  co-morbid  medical  conditions  or
patients who were using medication that might have affected their
cognition.  Fagerlund  2007  excluded  participants  with  treatment-
refractory illness.

1.3 Setting

Three  of  the  17  trials  took  place  in  inpatient  settings  (Chouinard
2007;  Kim  2005b;  Lee  2005).  Six  trials  had  outpatient  settings
(Dyer  2008;  Keefe  2008a;  Kohler  2007;  Nahas  2003;  Tugal  2003;
Tuma  2003).  Six  trials  had  both  inpatients  and  outpatients
(Akhondzadeh 2008; Buchanan 2008; Fagerlund 2007; Freudenreich
2005; Friedman 2002c; Sharma 2006). In the remaining two trials,
we  could  not  find  any  explicit  information  on  the  setting  (Caroff
2007; Schubert 2006).

1.4 Study size

Keefe  2008a  was  the 
largest  trial  with  245  participants
randomised  to  receive  either  risperidone  or  placebo.  Buchanan
2008  randomised  86  participants,  Nahas  2003  randomised  six
participants.The rest of the studies had between 10 and 38 patients
each.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.5 Interventions

1.6.1 Global state scales

1.5.1 Acetylcholinesterase inhibitors

1.6.1.1 Clinical Global Impression Scale (CGI) (Guy 1976)

The  most  commonly  used  acetylcholinesterase  inhibitors  were
donepezil,  rivastigmine  and  galantamine.  The  dose  of  donepezil
administered by the trialists varied from 5 mg a day up to 10 mg a
day, rivastigmine 9 mg to 12 mg and galantamine 16 mg to 24 mg
a day.

This  is  used  to  assess  both  severity  of  illness  and  clinical
improvement,  by  comparing  the  conditions  of  the  person
standardised  against  other  people  with  the  same  diagnosis.  A
seven point scoring system is usually used with low scores showing
decreased severity and/or overall improvement.

1.5.2 Comparison group

Most  of  the  studies  compared  acetylcholinesterase  inhibitors
plus antipsychotics versus placebo and antipsychotics. Chouinard
2007  compared  antipsychotic  plus  acetylcholinesterase  inhibitor
with  antipsychotic  alone.  Both  conventional  and  second
generation  antipsychotics  were  used  along  with  placebo  and
acetylcholinesterase inhibitors.

1.6.1.2 Global Assessment of Functioning (GAF) (DSM-IV-TR)

The GAF scale is a numeric scale (zero through 100) used by mental
health  clinicians  and  physicians  to  rate  subjectively  the  social,
occupational, and psychological functioning of adults. High scores
mean good functioning.

1.6.2 Mental state scales

1.6 Outcomes

1.6.2.1 Positive and Negative Syndrome Scale (PANSS) ( Kay 1986a)

Our  primary  outcome  was  Global  state  -  no  clinically  important
response  as  defined  by  the  individual  studies  -  long-term.  Out
of  the  17  trials  included  in  our  meta-analysis,  four  of  them
reported  the  global  change  using  the  Clinical  Global  Impressions
(CGI) scale (Buchanan 2008; Kim 2005b; Lee 2005; Schubert 2006)
and  Fagerlund  2007  used  both  CGI  and  Global  Assessment  of
Functioning (GAF) scales. Buchanan 2008, Lee 2005 and Kim 2005b
did not have any usable data on global functioning. For Schubert
2006, data were skewed.

Several  different  rating  scales  were  used  in  the  trials  to  report
on  the  mental  state.  For  the  purpose  of  this  review,  we  used
the  Positive  and  Negative  Syndrome  Scale  (PANNS),  Hamilton
Depression  Rating  Scale  (HAM-D),  Calgary  Depression  Severity
Scale  (CDSS)  and  Brief  Psychiatric  Rating  Scale  (BPRS).  Seven
studies (Buchanan 2008; Caroff 2007; Freudenreich 2005; Friedman
2002c;  Keefe  2008a;  Kim  2005b;  Kohler  2007)  did  not  have  any
usable data on the mental state. The rest of the trials used either the
PANSS, HAM-D, CDSS or the BPRS scale to measure their outcome.
Wherever possible, we used the binary data from these measures,
but the validity of dichotomising these measures, although widely
accepted, is nevertheless unclear.

Adverse events are an important outcome measure from any trial.
We were able to pool data on the adverse events from all the trials
except  four  (Caroff  2007;  Kohler  2007;  Nahas  2003;  Tugal  2003)
which  did  not  have  any  usable  data  for  adverse  events.  There
were no deaths reported in any of the studies. All but three trials
(Fagerlund 2007; Nahas 2003; Tugal 2003) provided usable data on
the number of participants leaving the study early. Quality of life
data were not available in any of the trials.

Cognitive 
functioning  was  assessed  using  a  battery  of
neuropsychological  scales  and  subscales.  We  were  able  to  pool
data from the nine studies (Buchanan 2008; Dyer 2008; Friedman
2002c;  Kim  2005b;  Lee  2005;  Nahas  2003;  Schubert  2006;  Tugal
2003; Tuma 2003) but the remaining studies did not have any usable
data on this parameter.

Details  of  scales  that  provided  usable  data  are  shown  below.
Reasons  for  exclusion  of  data  from  other  instruments  are  given
under 'Outcomes' in the Characteristics of included studies.

This schizophrenia scale has 30 items, each of which can be defined
on a seven-point scoring system varying from one (absent) to seven
(extreme). It can be divided into three subscales for measuring the
severity  of  general  psychopathology,  positive  symptoms  (PANSS-
P) and negative symptoms (PANSS-N). A low score indicates lesser
severity.

1.6.2.2 Brief Psychiatric Rating Scale (BPRS) (Overall 1962)

This is used to assess the severity of abnormal mental state. The
original scale has 16 items, but a revised 18-item scale is commonly
used. Each item is defined on a seven-point scale varying from 'not
present'  to  'extremely  severe',  scoring  from  zero  to  six  or  one  to
seven. Scores can range from zero to 126 with high scores indicating
more severe symptoms.

1.6.2.3  Scale  for  the  Assessment  of  Negative  Symptoms  (SANS)
(Andreasen 1989)

This six-point scale gives a global rating of the following negative
symptoms: alogia, affective blunting, avolition-apathy, anhedonia-
associality and attention impairment. Higher scores indicate more
symptoms.

1.6.2.4  Scale  for  the  Assessment  of  Positive  Symptoms  (SAPS)
(Andreasen 1984)

This four-point scale gives a global rating of the following positive
symptoms: hallucination, delusion, bizarre attitudes and positive
formal thought disorder.

1.6.2.5 The Hamilton Depression Rating Scale (HDRS abbreviated to
HAM-D) (Hamilton 1980)

The HAM-D is a multiple choice questionnaire that clinicians may
use  to  rate  the  severity  of  a  patient's  major  depression.  A  lower
score indicates less severity.

The  questionnaire  rates  the  severity  of  symptoms  observed  in
depression  such  as  low  mood,  insomnia,  agitation,  anxiety  and
weight  loss.  The  questionnaire  is  presently  one  of  the  most
commonly used scales for rating depression in medical research.

1.6.2.6 Calgary Depression Severity Scale (CDSS) (Addington 1993)

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A  nine-item  scale  specifically  developed  for  assessment  of
depression in patients with schizophrenia.

All items are rated on a four-point scale: zero = absent; 1 = mild; 2
=moderate; 3 = severe. A lower score indicates less severity.

1.6.3 Quality of Life scales

1.6.6 Other adverse effects

Other adverse effects were reported as continuous variables for QTc
prolongation  (ms),  cholesterol  level  (mg/dL),  glucose  level  (mg/
dL), prolactin level (ng/dL) and weight (kg). Other adverse events
were reported in a dichotomous manner in terms of the number of
people with a given effect.

1.6.3.1 Quality of Life Scale (QLS) (Carpenter 1994)

1.6.7 Cognitive functions

The QLS is a 21-item scale rated from a semi-structured interview
providing  information  on  symptoms  and  functioning  during  the
preceding  four  weeks.  It  is  intended  to  be  administered  by  a
trained clinician and requires about 45 minutes to complete. Each
item  is  rated  on  a  seven-point  scale  and  ,  in  all  but  two  cases,
requires  a  judgment  by  the  clinician/interviewer.  Each  item  is
composed of three parts: (1) a brief descriptive statement to focus
the interviewer on the judgment to be made; (2) a set of suggested
probes; (3) the seven-point scale with descriptive anchors for every
other  point.  The  specific  descriptions  vary  among  items,  but  the
high  end  of  the  scales  (scores  of  five  and  six)  reflects  normal  or
unimpaired functioning and the low end of the scales (scores of zero
and  one)  reflects  severe  impairment  of  the  function  in  question.
The interviewer is instructed to probe around each item until he or
she has an adequate basis for making the required judgment, and
is encouraged to go beyond the suggested probes with questions
tailored  for  the  individual  patient.  The  experience  of  both  the
patient  and  the  interviewer  is  thus  similar  to  a  careful  clinical
interview.

1.6.4 Service use

Described as the number of patients rehospitalised during the trial.

1.6.5 Adverse effects scales

1.6.5.1 Abnormal Involuntary Movement Scale (AIMS) (Guy 1976)

This has been used to assess tardive dyskinesia, a long-term, drug-
induced movement disorder and short-term movement disorders
such as tremor.

1.6.5.2 Barnes Akathisia Scale (BAS) (Barnes 1989)

The  scale  comprises 
items  rating  the  observable,  restless
movements that characterise akathisia, a subjective awareness of
restlessness and any distress associated with the condition. These
items  are  rated  from  zero  -  normal  to  three  -  severe.  In  addition,
there is an item for rating global severity (from zero - absent to five
- severe). A low score indicates low levels of akathisia.

1.6.5.3  Extrapyramidal  Symptom  Rating  Scale  (ESRS)  (Chouinard
1993)

This  is  a  questionnaire  relating  to  parkinsonian  symptoms  (nine
items), a physician's examination for Parkinsonism and dyskinetic
movements  (eight  items),  and  a  clinical  global  impression  of
tardive dyskinesia. High scores indicate severe levels of movement
disorder.

1.6.5.4 Simpson Angus Scale (SAS) (Simpson 1970)

This is a 10-item scale, with a scoring system of zero to four for each
item,  measures  drug-induced  Parkinsonism,  a  short-term  drug-
induced  movement  disorder.  A  low  score  indicates  low  levels  of
Parkinsonism.

1.6.7.1 Wisconsin Card Sorting Test Scale (WCST) (Heaton 1993)
The  WCST  is  a  neuropsychological  test  of  executive  functions.
It  taps  a  variety  of  executive  abilities,  including  maintenance
of  task  set,  flexibility  in  response  to  feedback  or  changing
circumstances,  and  perseverative  tendencies.  The  test  can  be
administered  to  those  6.5  years  to  89  years  of  age  and
takes  20  to  30  minutes  to  complete.  It  is  widely  used  by
psychiatrists and clinical psychologists to test patients with brain
injuries,  neurodegenerative  diseases  and  mental  illnesses  such
as  schizophrenia.  For  a  128  card  trial,  the  typical  number  of
perseverative  errors  for  “well  educated  young  adults”  is  11.  With
reasonable executive control, scoring tends to improve as the test
progresses.  So  for  a  64  card  trial,  an  equivalent  score  would  be
about six or seven. Categories completed can range from zero, for
someone who has no idea what to do, to a maximum of six (when
the test is stopped).

1.6.7.2  Wechsler  Adult  Intelligence  Scale-Third  Edition  (WAIS-III)
(Wechsler 1997a)
This  is  a  neuropsychological  test  in  which  different  facets  of
neurological  cognitive  functioning  are  tapped  by  the  various
subtests. It contains of a total of 14 subtests. It provides two sets of
summary scores. First, in addition to the global full scale, the WAIS
subtests can be organised in the traditional manner into the verbal
scale and performance scale. Average Score = 10 in each subtest.
Scores below eight show significant deficits (Kraus 2007).

1.6.7.3 Wechsler Memory scale-Third Edition (WMS-III) (Wechsler
1997b)
This is a neuropsychological test to assess learning and memory
functioning  of  individuals  aged  16  to  89  years.  It  has  six  primary
subtests  and  five  optional  subtests.  It  has  three  main  scores
-  Immediate  memory,  Delayed  memory  and  Working  memory.
Scores range from low to very superior. Low scores indicate poor
results.  When  used  in  conjunction  with  the  WAIS-III,  meaningful
comparisons  between  intellectual  ability  and  memory  functions
can be made.

1.6.7.4 Hopkins Verbal learning Test (HVLT) (Brandt 1991)
This  is  a  brief  assessment  of  verbal  learning  and  memory  for
individuals aged 16 years and older. The test consists of three trials
of free recall of 12 items, semantically categorised list, and followed
by yes/no recognition. The maximum score possible for the HVLT
total score is 36 and for the HVLT recognition score is 12. A high score
means good verbal learning and memory.

1.6.7.5 Verbal Fluency Test (VFT) (Miller 1984)
The  VFT  is  a  neuropsychological  test  to  evaluate  executive
functions  and  language.  In  this  test,  participants  have  to  say  as
many  words  as  possible  from  a  category  within  a  given  time
-  usually  60  seconds.  This  category  can  be  semantic,  such  as
animals or fruits or phonemic, such as words. The most common
performance measure is the total number of words.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

1.6.7.6 Brief Visual Memory Test (BVMT) (Benedict 1996)
The BVMT is a neuropsychological test that is designed for use as
a criterion measure of visuospatial memory within a large battery
of neuropsychological tests, as a screening measure within a brief
neuropsychological battery, and as a repeat measure to document
changes in neurocognitive skills over time. It has been standardised
and  is  commonly  used  in  adults  between  the  ages  of  18  and  79.
It  includes  six  equivalent  alternate  forms,  its  administration  is
limited  to  an  immediate  and  25-minute  delayed  free  recall  trial.
This  is  a  test  to  measure  selective  attention,  cognitive  flexibility
and processing speed, and it is used as a tool in the evaluation of
executive functions.

1.6.7.7 The Stroop test (Stroop 1935)
The  Stroop  effect  is  a  demonstration  of  reaction  time  of  a  task.
When the name of a colour (e.g., "blue," "green," or "red") is printed
in a colour not denoted by the name (e.g., the word "red" printed
in  blue  ink  instead  of  red  ink),  naming  the  colour  of  the  word
takes longer and is more prone to errors than when the colour of
the ink matches the name of the colour. An increased interference
effect is found in disorders such as brain damage, dementias and
other  neurodegenerative  diseases,  attention-deficit  hyperactivity
disorder,  or  a  variety  of  mental  disorders  such  as  schizophrenia,
addictions, and depression.

1.6.7.8 Trail Making Test (TMT) (Tombaugh 2004)
The  TMT  is  one  of  the  most  popular  neuropsychological  tests
and is included in most test batteries. It provides information on
visual search, scanning, speed of processing, mental flexibility, and
executive functions. The TMT consists of two parts. TMT-A requires
an  individual  to  draw  lines  sequentially  connecting  25  encircled
numbers  distributed  on  a  sheet  of  paper.  Task  requirements
are  similar  for  TMT-B  except  the  person  must  alternate  between
numbers and letters (e.g., 1, A, 2, B, 3, C, etc.). The score on each
part represents the amount of time required to complete the task.

1.6.7.9 Continuous Performance Test (CPT) (Conners 2000)
The  CPT  is  a  psychological  test  which  measures  a  person's
sustained  and  selective  attention  and  impulsivity.  While  scoring
varies from test to test, there are four main scores that are used.
Correct  Detection:  This  indicates  the  number  of  times  the  client
responded to the target stimulus. Higher rates of correct detections
indicate better attentional capacity.
Reaction  time:  This  measures  the  amount  of  time  between  the
presentation of the stimulus and the client's response.
Omission  errors:  This  indicates  the  number  of  times  the  target
was  presented,  but  the  client  did  not  respond/click  the  mouse.
High  omission  rates  indicate  that  the  person  is  either  not  paying
attention to stimuli or has a sluggish response. Commission errors:
This score indicates the number of times the client responded but
no target was presented.
A  fast  reaction  time  and  high  commission  error  rate  points
to  difficulties  with  impulsivity.  A  slow  reaction  time  with  high
commission and omission errors, indicates inattention in general.
These client's scores are compared with the normative scores for
the age, group and gender of the person being tested.

1.6.7.10 Grooved Pegboard Test (Klove 1964)
The Grooved Pegboard is a manipulative dexterity test consisting
of 25 holes with randomly positioned slots. This test requires more
complex  visual-motor  coordination  than  most  pegboards.  Scores

Cochrane Database of Systematic Reviews

represent time in seconds required to complete the test with each
hand, with high scores reflecting lower levels of performance.

for 

1.6.7.11  Repeatable  Battery 
the  Assessment  of
Neuropsychological Status (RBANS) (Randolph 1998; Wilk 2002)
The  RBANS  is  a  screening  battery  designed  for  five  cognitive
domains:  attention  and  processing  speed,  expressive  language,
visual-spatial  and  constructional  abilities,  and  immediate  and
delayed memory. The entire battery takes less than 30 minutes to
administer. The score is measured as total score and five specific
cognitive ability index scores.

1.6.7.12 Korean version-Mini Mental State Examination (K-MMSE)
(Kang 1997)
The  Mini  Mental  State  Examination  (MMSE)  was  developed  to
evaluate  a  person's  orientation,  memory,  attention,  calculation,
and  visuospatial  and  language  abilities.  Kang  et  al.  conducted  a
study  to  examine  the  validity  of  newly  constructed  K-MMSE.  It
contains 30 questions, and the possible scores range from zero to
30.

1.6.7.13 Rey-Osterrieth Complex Figure Test (ROCFT) (Meyers 1995)
The  ROCF  is  a  neuropsychological  test  in  which  examinees
are  asked  to  reproduce  a  complicated  line  drawing,  first  by
copying  and  then  from  memory.  The  test  permits  the  evaluation
of  different  functions,  such  as  visuospatial  abilities,  memory,
attention,  planning,  and  working  memory  (executive  functions).
The  RCFT  provides  an  objective  and  standardized  approach  to
scoring  drawings  based  on  the  widely  used  36-point  scoring
system. The same scoring criteria apply to all three drawing trials.
Each  of  the  18  scoring  units  is  scored  based  on  accuracy  and
placement criteria. Unit scores range from two (accurately drawn,
correctly  placed)  to  zero  (inaccurately  drawn,  incorrectly  placed,
unrecognisable, omitted). Higher scores mean better performance.

Excluded studies

We  excluded  17  studies  from  the  review.  Seven  trials  were
not  randomised  (Edelstein  1981;  El-Yousef  1973;  Ingram  1983;
Janowsky 1972; Moore 1980; Risch 1981; Risch 2001). Three trials
included  participants  who  were  not  ill  (Davis  1981;  Kristiansen
2001;  Pesco-Koplowitz  2000c).  Two  trials  included  participants
with  the  main  diagnosis  of  tardive  dyskinesia  (Lieberman  1988;
Tamminga  1977);  one  trial  included  participants  with  Parkinson
disease  (Okereke  2002);  and  another  had  the  main  diagnosis  as
major depression or bipolar affective disorder (NCT00566735). We
excluded  one  of  the  trials  as  it  was  conducted  on  elderly  people
with a possible diagnosis of dementia (Mazeh 2006) and an other
trial  as  it  was  conducted  on  patients  receiving  electroconvulsive
therapy (ECT) (Ophir 2004). One trial did not have any usable data
(Stryjer 2004a). For further details see Characteristics of excluded
studies.

Awaiting classification

Four  studies  are  awaiting  classification  (Fleming  2003;  Hussain
2003; Kelleher 2008; Modestin 1973). We contacted the authors for
more information and the reply is awaited. For further details see
Characteristics of studies awaiting classification.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ongoing studies

Seven  randomised  trials  (Ball  2005;  Evins  2006;  Gaskins  2007;
George  2007;  Glenthoj  2005;  Johnson  2004;  Nachshoni  2007)  are
ongoing. For further details see Characteristics of ongoing studies.

Risk of bias in included studies

Ten out of the 17 trials that were included in our review were funded
by  pharmaceutical  companies  or  had  some  affiliation  (Buchanan
2008;  Caroff  2007;  Chouinard  2007;  Dyer  2008;  Fagerlund  2007;
Freudenreich  2005;  Friedman  2002c;  Keefe  2008a;  Nahas  2003;
Tugal  2003).  Seven  trials  did  not  appear  to  have  any  affliation
with  pharmaceutical  companies  (Akhondzadeh  2008;  Kim  2005b;
Kohler 2007; Lee 2005; Schubert 2006; Sharma 2006; Tuma 2003)
We collected as much information as possible and they have been
enlisted in the following paragraphs.

Allocation

All included studies were said to be randomised. However, 15 of the
17 included studies did not explicitly describe the method by which
this was done. Keefe 2008a used a computer-generated schedule,
patients  were  stratified  before  randomisation  and  within  each
stratum,  patients  were  randomised  1:1  to  the  experimental  and
control group. Dyer 2008 used concealed allocation with a 1:1 ratio,
in blocks of four. The concealment procedure was not explained.
None  of  the  other  studies  reported  allocation  concealment.  The
concealment of allocation has repeatedly been shown to be of key
importance in excluding selection biases (Jüni 2001).

Blinding

  All  17  included  studies  were  described  as  double  blind  however
none  of  the  studies  reported  any  test  of  blinding.  Three  studies
(Akhondzadeh  2008;  Freudenreich  2005;  Schubert  2006)  used
identical tablets/capsules to make blinding more robust. Buchanan
2008 used equal number of matched tablets. Blinding is essential
for minimising observation bias and we were expecting that testing
for blinding would have been a priority.

Incomplete outcome data

Friedman  2002c  used  ITT  analysis.  Four  studies  (Dyer  2008;  Lee
2005;  Schubert  2006;  Sharma  2006)  used  the  LOCF  method  to
account  for  their  loss  to  follow-up.  Keefe  2008a  used  ITT  for  the
efficacy  data  and  LOCF  for  the  safety  data.  Akhondzadeh  2008,
Nahas  2003  and  Tugal  2003  had  no  drop  outs  in  the  duration  of
their 12-week studies. There is no information about the losses to
follow-up in seven studies (Buchanan 2008; Caroff 2007; Chouinard
2007; Fagerlund 2007; Kim 2005b; Kohler 2007; Tuma 2003). None
of the trials made attempts to validate assumptions by following
up people who did drop out early.The reasons for loss to follow-up
were reasonably well reported and we have recorded these in the
outcomes.

Selective reporting

Seven  of  the  17  included  studies  (Akhondzadeh  2008;  Buchanan
2008; Chouinard 2007; Fagerlund 2007; Friedman 2002c; Schubert
2006; Tuma 2003) reported all of the outcomes mentioned in their
methods. Of the remaining eleven studies, outcomes reported were
incomplete or lacking in useable information. Of the seven studies
which  did  report  the  outcomes,  protocols  were  unavailable  and
hence we were unaware if the trialists reported all outcomes they
intended to use. Most of the trials reported at least one measure for

Cochrane Database of Systematic Reviews

mental state and they all had reported adverse effects even though
some of them were incomplete.

Other potential sources of bias

No  study  was  clearly  free  of  other  potential  sources  of  bias,  with
the  risk  of  bias  being  unclear  in  eight  of  them.  Nine  studies
were  linked  with  pharmaceutical  companies,  either  sponsored
or  the  authors  had  some  affiliation  with  the  pharmaceutical
companies  (Buchanan  2008;  Caroff  2007;  Chouinard  2007;  Dyer
2008; Fagerlund 2007; Freudenreich 2005; Friedman 2002c; Nahas
2003; Tugal 2003). There is evidence that industry-sponsored trials
tend to be beneficial towards the intervention that they promote
(Heres 2006). Poor quality reporting led to a lot of data that were
not useable. Findings which were presented as graphs, percentiles
or reported as inexact P values were of little use to us as reviewers.
Some studies failed to provide SDs when reporting mean changes.
We sought additional data from the first authors of relevant trials
when required, however, none of the authors responded.

Effects of interventions

See: Summary of findings for the main comparison

The initial search resulted in over 82 citations. We were only able
to  include  17  of  these  studies  from  which  usable  data  could  be
extracted. We used information obtained from drug companies that
was available to the Cochrane Schizophrenia Group regarding data
from unpublished trials.

Comparison 1: Acetylcholinesterase inhibitor(s) plus
antipsychotics versus placebo plus antipsychotic

Sixteen  studies  with  a  total  of  659  participants  fell  into  this
comparison

1.1. Global effects: various outcome

Fagerlund  2007  reported  average  end  point,  medium-term  CGI
-  severity  score  which  indicates  global  severity  of  the  illness.
There  were  no  differences  between  the  acetylcholinesterase  plus
antipsychotic  and  placebo  plus  antipsychotic  groups  on  this
measure at 16 weeks (1 RCT, n = 11, mean difference (MD) 0.46 95%
confidence interval (CI) -0.15 to 1.07). The same study also reported
on  CGI  -  improvement  average  end  point  score  which  indicates
global improvement, there were no differences on this measure (1
RCT, n = 11, MD 0.57 95% CI -0.50 to 1.64). Schubert 2006 reported
average change short-term CGI score but the data were skewed. The
very small differences were not stated to be significant.

1.2 Leaving the study early 

The overall rate of participants leaving studies early was low (13.6
%) and showed no clear difference between groups. Nevertheless,
this finding was based mainly on short-term trials and only from
one  medium-term  trial  limiting  interpretation.  There  were  no
significant  differences  in  the  number  of  participants  leaving  the
studies early due to - any reason (9 RCTs, n = 513, risk ratio (RR) 0.89
95% CI 0.61 to 1.28 ), adverse events (6 RCTs, n = 428, RR 1.94 95%
CI 0.83 to 4.49 ), intercurrent illness (2 RCTs, n = 122, RR 2.91 95% CI
0.31 to 27.06), mental state deterioration (2 RCTs, n = 103, RR 0.65
95% CI 0.09 to 4.68), lost to follow-up (1 RCTs, n = 245, RR 1.02 95%
CI 0.26 to 4.01), protocol violation (2 RCTs, n = 262, RR 0.24, 95% CI
0.04 to 1.38) and to unwillingness to participate (1 RCT, n = 245, RR
1.02, 95% CI 0.30 to 3.45). There was no significant difference in the

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

number of participants leaving the study early in one medium-term
study (Tuma 2003) due to deterioration in mental state (1 RCT, n =
17, RR 2.18 95% CI 0.10 to 46.92).
The attrition rates from all these studies were variable ranging from
none in (Akhondzadeh 2008) to over 19% in (Keefe 2008a). As to why
this variation occurs is hard to estimate, some of it could be due to
the study design and some due to the individual drug administered.

1.3 Mental state

1.3.1 Mental state: average end point score on PANSS-short-term

1.3.1.1 PANSS Total: average total end point score

Two  short-term  studies  (Nahas  2003;  Tugal  2003)  reported  no
significant differences (2 RCTs, n = 18, MD 3.29 95% CI -8.82 to 15.40).

by one of the two studies, whereas Dyer 2008 reported benefit of
acetylcholinesterase inhibitor plus antipsychotic over placebo and
antipsychotic.

1.3.5.2 CDSS: average end point score

One  medium-term  study  (Fagerlund  2007)  reported  benefit  of
acetylcholinesterase inhibitor plus antipsychotic over placebo and
antipsychotic. But the baseline scores of most of the participants
in  the  acetylcholinesterase  inhibitor  group  were  already  low
compared with the placebo group. Also, the number of participants
in  both  arms  were  different;  there  were  more  in  the  intervention
arm compared with the placebo group. The result therefore has to
be read with caution. The data were skewed and are presented in
tabular form.

1.3.1.2 PANSS Positive symptoms: average end point score

1.3.6 Mental state: average change score on PANSS

Tugal 2003 reported no significant difference (1 RCT, n = 12, MD 1.50
95% CI -4.44. to 7.44).

1.3.1.3 PANSS Negative symptoms: average end point score

Tugal 2003 reported no significant difference (1 RCT, n = 12, MD 3.50
95% CI -3.66 to 10.66).

1.3.1.4 PANSS general psychopathology: average end point score

Tugal 2003 reported no significant difference (1 RCT, n = 12, MD 1.80
95% CI -4.81 to 8.41).

One  short-term  study  (Schubert  2006)  reported  data  on  PANSS
total,  positive  and  negative  symptoms  average  change  score  but
these were skewed. The very small differences were not stated to
be statistically significant.

1.4 General functioning

1.4.1 GAF: average end point score

One  medium-term  study  (Fagerlund  2007)  had  data  on  this
outcome and reported no difference (1 RCT, n = 11, MD 4.60 95% CI
-5.88 to 15.08).

1.3.2 Mental state: average end point score on PANSS- medium-term

1.5 Quality of life

1.3.2.1 PANSS Total: average end point score

Fagerlund 2007; Sharma 2006 reported no significant difference (2
RCTs, n = 31, MD -4.32 95% CI -11.56 to 2.92).

1.3.2.2 PANSS Positive symptoms: average end point score

Fagerlund 2007; Sharma 2006 reported no significant difference (2
RCTs, n = 31, MD 0.65 95% CI -0.12 to 1.43).

1.3.2.3 PANSS Negative symptoms: average end point score

Fagerlund  2007;  Sharma  2006  favoured  acetylcholinesterase
inhibitor  plus  antipsychotic  over  placebo  plus  antipsychotic  (2
RCTs, n = 31, MD -1.69 95% CI -2.80 to - 0.57).

1.3.2.4 PANSS General psychopathology: average end point score

Fagerlund  2007;  Sharma  2006  favoured  acetylcholinesterase
inhibitor  plus  antipsychotic  over  placebo  plus  antipsychotic  (2
RCTs, n = 31, MD -3.86 95% CI -5.40 to - 2.32).

1.3.3 Mental state: average end point score on HAM-D - short-term

Akhondzadeh 2008 reported no significant difference (1 RCT, n = 30,
MD -0.60 95% CI -1.82 to 0.62).

1.3.4 Mental state: average end point score on SANS - short-term

Dyer 2008 reported no significant difference (1 RCT, n = 20, MD -5.00
95% CI -21.33 to 11.33).

1.3.5 Mental state: average change score on CDSS

1.3.5.1 CDSS: average end point score - short-term

Two  studies  (Dyer  2008;  Tugal  2003)  reported  average  change,
short-term CDSS score. The data were skewed and are presented
in tabular form. There were no significant differences as reported

There  were  no  data  available  on  quality  of  life  from  any  of  the
studies.

1.6 Cognitive functioning

1.6.1 Cognitive functioning: average end point score on K-MMSE

Two short-term studies (Kim 2005b; Lee 2005) reported an average
end  point  KMMSE  score  which  indicated  cognitive  improvement.
We  found  no  differences  between  acetylcholinesterase  inhibitors
and conventional antipsychotics versus placebo and conventional
antipsychotics (2 RCTs, n = 48, MD 1.29 95% CI -0.18 to 2.77).

1.6.2 Cognitive functioning: average end point score on various
subscales of WMS III which indicate learning and memory

1.6.2.1 Digit span forward

Two  short-term  studies  (Lee  2005;  Tugal  2003)  reported  data
on  digit  span  forward  scale  which  indicated  superiority  of
placebo  and  antipsychotics  over  acetylcholinesterase  inhibitors
and antipsychotics (2 RCTs, n = 36, MD -0.89 95% CI -1.68 to -0.10).

1.6.2.2 Digit span backward

Two  short-term  studies  (Lee  2005;  Tugal  2003)  reported  data  on
digit span backward which indicated superiority of the placebo plus
antipsychotics  arm  compared  to  acetylcholinesterase  inhibitors
plus  antipsychotic  arm  (2  RCTs,  n  =  36,  MD  -0.69  95%  CI  -1.35  to
-0.02).

1.6.2.3 Figural memory test

(Tugal  2003)  reported  average  end
One  short-term  study 
point  score.  The  study 
reported  no  difference  between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 12, MD -1.30 95% CI -0.74 to 3.34).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.6.2.4 Visual reproduction 1

1.6.3.5 Letter number span test without reordering

One  short-term  study  (Tugal  2003)  reported  data  on  average  end
point,  visual  reproduction  1  score.  There  were  no  differences
between  acetylcholinesterase  inhibitors  plus  antipsychotics  and
placebo and antipsychotics (1 RCT, n = 12, MD -1.30 95% CI -5.21 to
7.81).

1.6.2.5 Visual reproduction 2

One  short-term  study  (Dyer  2008)  showed  no  difference between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 20, MD -1.60 95% CI -4.19 to 0.99).

1.6.3.6 Letter number span test with ordering

One short-term study (Dyer 2008) showed no difference (1 RCT, n =
20, MD 0.50 95% CI -3.27 to 2.27).

Tugal  2003  reported  data  on  average  end  point  score,
visual  reproduction  2.  There  were  no  differences  between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 12, MD -1.50 95% CI -8.69 to 5.69).

1.6.4 Cognitive functioning: average end point score on various
subtests of HVLT which indicate verbal learning and memory

1.6.4.1 Immediate recall and delayed recall

1.6.2.6 Verbal paired associates 1

One  short-term  study  (Tugal  2003)  reported  data  on  average
end  point  score 
found  no  difference  between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 12, MD 3.20 95% CI -7.28 to 0.88).

  which 

1.6.2.7 Verbal paired associates 2

One short-term study (Tugal 2003) showed no difference between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 12, MD -0.60 95% CI -1.92 to 0.72).

1.6.2.8 Logical memory 1

(Tugal  2003)  showed  no  difference  between  acetylcholinesterase
inhibitors  plus  antipsychotics  and  placebo  and  antipsychotics  (1
RCT, n = 12, MD -4.60 95% CI -12.72 to 3.52).

1.6.2.9 Logical memory 2

(Tugal  2003)  showed  no  difference  between  acetylcholinesterase
inhibitors  plus  antipsychotics  and  placebo  and  antipsychotics  (1
RCT, n = 12, MD -4.60 95% CI -13.26 to 4.06 ).

1.6.3 Cognitive functioning: average end point score on various
subscales of WAIS III which indicate different facets of cognitive
functioning

1.6.3.1 Block design test

One short-term study (Tugal 2003) showed no difference between
acetylcholinesterase  inhibitors  plus  antipsychotics  and  placebo
and antipsychotics (1 RCT, n = 12, MD 3.10 95% CI -9.71 to 15.91).

1.6.3.2 Letter number sequencing test

Buchanan 2008 reported average end point score on this test. There
were  no  differences  between  acetylcholinesterase  inhibitors  plus
antipsychotics and placebo and antipsychotics (1 RCT, n = 73, MD
0.60 95% CI -0.48 to 1.68 ).

1.6.3.3 Digit symbol test

Buchanan  2008  (short-term  study),  reported  results  from  the
acetylcholinesterase 
inhibitor  plus  antipsychotics  arm  were
statistically significant compared with placebo and antipsychotics
group (1 RCT, n = 73, MD 1.20 95% CI 0.14 to 2.26).

1.6.3.4 Symbol search score

One  short-term  study,  (Buchanan  2008)  showed  no  difference
between  acetylcholinesterase  inhibitors  plus  antipsychotics  and
placebo and antipsychotics (1 RCT, n = 73, MD 0.30 95% CI -0.92 to
1.52).

One  short-term  study  (Lee  2005)  reported  average  end  point,
immediate  recall  and  delayed  recall  scores.  There  were  no
differences on immediate recall score (1 RCT, n = 24, MD 3.00 95% CI
-0.76 to 6.76) and delayed recall score (1 RCT, n = 24, MD 1.50 95%
CI -0.20 to 3.20).

1.6.4.2 Recognition

The  pooled  data  of  two  short-term  studies  (Lee  2005;  Kim
2005b)  showed  superiority  of  acetylcholinesterase  inhibitors  and
antipsychotic over placebo and antipsychotics (2 RCTs, n = 48 , MD
1.90 95% CI 0.52 to 3.28).

1.6.5 Cognitive functioning: average end point score on Verbal Fluency
Test which evaluates verbal memory and language (High score
indicates better performance)

The  data  from  three  short-term  studies  (Lee  2005;  Nahas
2003;  Tugal  2003)  showed  superiority  of  acetylcholinesterase
inhibitors  when  combined  with  antipsychotic  over  placebo  and
antipsychotics in the treatment of schizophrenia (3 RCTs, n = 42, MD
3.46 95% CI 0.67 to 6.26 ).

1.6.6 Cognitive functioning: average end point score on BVST
which evaluates visuospatial memory (High score means better
performance)

One  short-term  study  (Buchanan  2008)  showed  no  difference
between  acetylcholinesterase  inhibitors  plus  antipsychotics  and
placebo and antipsychotics (1 RCT, n = 73, MD -0.50 95% CI -1.42 to
0.42).

1.6.7 Cognitive functioning: average end point score on various
subtests of Stroop test which evaluate executive functioning

1.6.7.1 Stroop Letter test

One  short-term  study  (Lee  2005)  reported  average  end  point,
Stroop  letter  test  score.  High  score  means  better  performance.
There were no differences between acetylcholinesterase inhibitors
plus antipsychotics and placebo and antipsychotics (1 RCT, n = 24,
MD -1.50 95% CI -12.15 to 9.15).

1.6.7.2 Stroop Colour test

One  short-term  study  (Lee  2005)  reported  average  end  point,
Stroop  colour  test  score.  High  score  means  better  performance.
The results significantly favour acetylcholinesterase inhibitors over
placebo  when  combined  with  antipsychotics  (1  RCT,  n  =  24,  MD
17.10 95% CI 0.70 to 33.50).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

1.6.7.3 Stroop interference test

One short-term study (Dyer 2008) reported no difference between
acetylcholinesterase inhibitors and placebo when combined with
antipsychotics (1 RCT, n = 20, MD -2.60 95% CI -6.68 to 1.48 ).

1.6.8 Cognitive functioning: average end point score on Trail making
tests A & B which evaluate executive functioning (High score means
better performance)

1.6.8.1 Trail making part A

Two  short-term  studies  (Lee  2005;  Tugal  2003)  reported  no
significant difference in the average end point score (2 RCTs, n = 24,
MD -8.72 95% CI -28.91 to 11.47 ).

1.6.8.2 Trail making part B

One  short-term  study  (Tugal  2003)  reported  no  significant
 difference (1 RCT, n = 24, MD 16.40 95% CI -32.33 to 65.13).

Cochrane Database of Systematic Reviews

are  presented  in  tabular  form.  There  did  not  appear  to  be  any
significant differences between the two comparators.

1.7 Service use

No data were available for this outcome.

2.8 Adverse events

1.8.1 Central nervous system

1.8.1.1 Dizziness

Four  short-term  studies  (Akhondzadeh  2008;  Buchanan  2008;
Keefe  2008a;  Lee  2005)  reported  data  on  dizziness.  There
were  no  significant  differences  for  this  outcome  between
acetylcholinesterase inhibitors plus antipsychotics versus placebo
plus antipsychotics (4 RCTs, n = 279, RR 0.77 95% CI 0.35 to 1.72).

1.8.1.2 Sialorrhea

1.6.9 Cognitive functioning: average end point score on CPT which
evaluate sustained and selective attention

1.6.9.1 Reaction time (High score = better performance)

One  short-term  study  (Freudenreich  2005)  reported  data  on  this
outcome and no significant differences were noted (1 RCT, n = 36,
RR 6.30 95% CI 0.35 to 113.81).

One  short-term  study  (Dyer  2008)  reported  no  significant
difference  between  acetylcholinesterase  inhibitors  and  placebo
when combined with antipsychotics. (1 RCT, n = 20, MD -5.20 95%
CI -70.74 to 60.34).

1.8.1.3 Headache

Data from two short-term studies (Keefe 2008a; Lee 2005) reported
no significant differences for this outcome (2 RCTs, n = 269, RR 0.51
95% CI 0.24 to 1.09).

1.6.9.2 Random errors (Low score = better performance)

1.8.1.4 Insomnia

One  short-term  study  (Dyer  2008)  reported  no  significant
difference  between  acetylcholinesterase  inhibitors  and  placebo
when combined with antipsychotics (1 RCT, n=20, MD -0.20 95% CI
-1.71 to 1.31).

1.6.10 Cognitive functioning: average end point score on Grooved
pegboard test which evaluates motor functioning (High score means
better performance)

Two  short-term  studies  (Buchanan  2008;  Dyer  2008)  reported
average  end  point,  average  peg  score.  There  were  no  significant
differences  between  acetylcholinesterase  inhibitors  and  placebo
when combined with antipsychotics (2 RCTs, n = 93, MD -0.29 95%
CI -3.11 to 2.53).

Two short-term studies (Akhondzadeh 2008; Keefe 2008a) reported
data on this event. There were no significant differences (2 RCTs, n
= 269, RR 0.47 95% CI 0.18 to 1.20).

1.8.1.5 Somnolence

One  short-term  study  (Keefe  2008a)  reported  data  on  this  event.
There were no differences between the comparators (1 RCT, n = 245,
RR 0.44 95% CI 0.12 to 1.66).

1.8.1.6 Nonspecific central nervous system adverse event

Fagerlund 2007, a medium-term study reported data on this event,
with no significant differences (1 RCT, n = 11, RR 1.88 95% CI 0.09 to
37.63).

1.6.11 Cognitive functioning: average end point score on various
scales

1.8.2. Metabolic and nutritional

The result from the three short-term studies (Dyer 2008; Lee 2005;
Tugal  2003)  showed  data  on  various  subscales:  ROCFT,  Letter
number span with and without reordering, Wisconsin card sorting
test, Visual paired associates 1 & 2, CPT, Stroop interference test.
The  results  reported  were  skewed  and  are  presented  in  tabular
form. There did not appear to be any significant trends favouring
one intervention over another.

1.6.12 Cognitive functioning: average change score on various scales

Two short-term studies (Friedman 2002c; Schubert 2006) reported
mean  change  data  on  various  subscales  RAVLT,  CPT,  RBANS.  The
data were skewed and are presented in tabular form. There did not
appear to be any significant differences between the interventions.

1.6.13 Cognitive functioning: average change score on various scales

One  medium-term  study  (Tuma  2003)  reported  data  on  various
subscales: category fluency test, trail making test, logical memory,
WCST, ROCFT, verbal paired associate. The data were skewed and

1.8.2.1 Weight loss - (number of participants with a significant weight
loss as defined by authors).

Two short-term studies (Buchanan 2008; Lee 2005) reported data
on this and found no differences between the two groups (2 RCTs,
n = 102, RR 0.33 95% CI 0.10 to 1.06).

1.8.2.2 Glucose-number of participants with abnormally high fasting
glucose.

Keefe  2008a,  a  short-term  study  reported  data  on  this  event  and
found no significant differences (1 RCT, n = 102, RR 0.46 95% CI 0.14
to 1.44).

1.8.3 Deterioration in mental state

Two short-term studies (Buchanan 2008; Schubert 2006) reported
data on this event. There were no significant differences (2 RCTs, n
= 102, RR 0.62 95% CI 0.09 to 4.38).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.8.4 Biochemical - important rise in creatinine kinase levels

1.8.7.5 Any gastrointestinal event

One short-term study (Keefe 2008a) reported data on this adverse
event. There were no significant differences (1 RCT, n = 102, RR 1.17
95% CI 0.44 to 3.13).

One  short-term  study  (Keefe  2008a)  reported  data  on  any
gastrointestinal  adverse  event.  There  were  no  significant
differences (1 RCT, n = 245, RR 0.92 95% CI 0.58 to 1.46).

1.8.5 Non specific

1.8.5.1 Severe adverse event and serious adverse event

One  short-term  study  Keefe  2008a  reported  data  on  a  severe
adverse event (1 RCT, n = 245, RR 0.93 95% CI 0.41 to 2.11) and a
serious adverse event (1 RCT, n = 245, RR 1.02 95% CI 0.37 to 2.83)
and found no significant differences between acetylcholinesterase
inhibitor and placebo arms when combined with antipsychotics.

1.8.5.2 Alcohol relapse: number of participants who had a relapse of
alcohol.

One short-term study (Buchanan 2008) find no difference (1 RCT, n
= 86, RR 3.14 95% CI 0.13 to 74.98).

1.8.5.3 Muscle cramp: number of participants who developed muscle
cramps.

Two short-term studies (Akhondzadeh 2008; Dyer 2008) reported no
significant differences (2 RCTs, n = 44, RR 3.00 95% CI 0.52 to 17.21).

1.8.5.4 Agitation and uncooperativeness: participants who showed
agitation and uncooperativeness.

One  short-term  study  (Friedman  2002c)  found  no  significant
difference (1RCT, n = 36, RR 5.00 95% CI 0.26 to 97.37).

1.8.6 Cardiovascular: number of participants who had a
cardiovascular event

One  short-term  study  (Keefe  2008a)  reported  data  and  found  no
significant differences (1 RCT, n = 245, RR 0.51 95% CI 0.23 to 1.15).

1.8.7 Gastrointestinal-short-term

1.8.7.1 Vomiting: number of participants who reported this adverse
event.

Four short-term studies (Akhondzadeh 2008; Buchanan 2008; Keefe
2008a; Lee 2005) reported data on this event and found significant
differences (4 RCTs, n = 371, RR 0.80 95% CI 0.38 to 1.69).

1.8.7.2 Abdominal pain and diarrhoea: number of participants who
reported this adverse event.

One  short-term  study  (Kim  2005b)  reported  data  on  this  adverse
event. There were no significant differences (1 RCT, n = 24, RR 3.00
95% CI 0.13 to 67.06).

1.8.7.3 Diarrhoea: number of participants who reported this adverse
event.

Four  short-term  studies  (Akhondzadeh  2008;  Keefe  2008a;  Lee
2005; Schubert 2006) reported data on this event. There were no
significant differences (4 RCTs, n = 371, RR 1.21 95% CI 0.55 to 2.62).

1.8.7.4 Nausea: number of participants who reported this adverse
event.

Three  short-term  studies  (Akhondzadeh  2008;  Keefe  2008a;  Lee
2005)  reported  data  on  nausea.  There  were  no  significant
differences (3 RCTs, n = 293, RR 1.14 95% CI 0.46 to 2.80).

1.8.8 Respiratory system: number of participants who developed
respiratory adverse event as pneumonia

One  short-term  study  (Buchanan  2008)  reported  data  on  this
adverse event. There were no significant differences (1 RCT, n = 86,
RR 3.14 95% CI 0.13 to 74.98).

1.8.9 Extrapyramidal effects

1.8.9.1 EPSE: number of participants who developed this adverse
event.

One  medium-term  study  (Fagerlund  2007)  reported  data  on  this
event. There were no significant differences (1 RCT, n = 11, RR 4.38
95% CI 0.28 to 68.06).

1.8.9.2 EPSE: average end point score on AIMS.

One  short-term  study  (Caroff  2007)  reported  data  on  EPSE  as
measured  on  AIMS.  Low  score  is  favourable.  This  study  favoured
acetylcholinesterase inhibitor plus antipsychotic over placebo and
antipsychotic (1 RCT, n = 35, MD 1.50 95% CI 1.04 to 1.96).

1.8.9.3 EPSE: average end point score on SAS.

One  medium-term  study  (Sharma  2006)  reported  data  on  this
event as measured on SAS. Low score is favourable. There were no
significant differences (1 RCT, n = 21, MD -0.16 95% CI -0.38 to 0.06).

1.8.9.4 EPSE: average end point score on various scales.

There were no significant differences on various scales SARS, AIMS
and ESRS in two short-term studies (Akhondzadeh 2008; Buchanan
2008). The data were skewed and are presented in tabular form.

1.8.9.5 EPSE: average end point score on various scales.

There  were  no  significant  differences  in  one  medium-term  study
(Sharma 2006) on AIMS and BARS. The data were skewed and are
reported in tabular form.

1.8.9.6 EPSE: average change score on EPSE scales

One short-term study (Schubert 2006) reported  mean change score
on AIMS and SAS scales which is presented in tabular form as the
data were skewed.

1.8.9.7 ECG: average change interval on ECG-short-term.

One  short-term  study  (Buchanan  2008)  reported  change  interval
score - PR, QRS, and QTc. The data were skewed and are presented
in  tabular  form.  There  did  not  appear  to  be  any  significant
difference.

1.9 Economic outcomes

There are no data available on economic outcomes.

1.10 Behaviour

1.10.1 Smoking expired CO measures.

One  short-term  study  (Buchanan  2008)  reported  data  on  this
behaviour. There were no significant differences (1 RCT, n = 41, MD
0.10 95% CI -6.25 to 6.45).

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.10.2 Smoking - FTND interview score.

D I S C U S S I O N

One  short-term  study  (Buchanan  2008)  reported  data  on
average  end  point  score.  There  was  a  significant  superiority  of
placebo over acetylcholinesterase inhibitors when combined with
antipsychotics (1 RCT, n = 41, MD 1.50 95% CI 0.09 to 2.91).

1.11 Engagement with services

There were no data available on this outcome.

2. Comparison 2: Acetylcholinesterase inhibitors plus
antipsychotic versus antipsychotic alone

Only one study (Chouinard 2007) met the inclusion criteria for this
comparison. The data were available for only two outcomes.

2.1 Leaving the study early

There were no significant differences in the number of participants
leaving the study early due to any reason (1 RCT, n = 24, RR 7.71 95%
CI 0.46 to 129.18), due to deterioration in mental state (1 RCT, n = 24,
RR 2.57 95% CI 0.12 to 57.44) or due to suicidal ideas (1 RCT, n = 24
RR 2.57 95% CI 0.12 to 57.44).

2.2. Mental state: average end point score on PANSS

2.2.1 Negative symptoms

The study reported data on the above outcome but there were no
significant differences (1 RCT, n = 24, MD -0.60 95% CI -4-14 to 2.94).

2.2.2 Positive symptoms

There were no significant differences on this outcome (1 RCT, n = 24,
MD 1.10 95% CI -2.59 to 4.79).

2.2.3 Disorganisation/cognitive

The data on this outcome reported no difference (1 RCT, n = 24, MD
0.50 95% CI -2.04 to 3.04).

2.2.4 Hostility/excitement: average end point score on PANSS
dimensional scores

There were no significant differences (1 RCT, n = 24, MD 0.20 95% CI
-1.56 to 1.96).

2.2.5 Anxiety/depressive: average end point score on PANSS
dimensional scores

There were no significant differences (1 RCT, n = 24, MD 0.00 95% CI
-0.93 to 0.93).

2.2.6 PANSS total

The study reported no significant difference (1 RCT, n = 24, MD 1.80
95% CI -4.47 to 8.07).

3. Publication bias

We  assessed  for  publication  bias  using  the  studies  that  were
included for the outcome of leaving the study early (Figure 1) which
showed no evidence of possible biases.

4. Investigation of heterogeneity and sensitivity analysis

The reasons for the pre-planned sensitivity analysis did not apply
and were therefore not performed

The results of the pooled data seem to favour acetylcholinesterase
inhibitors  over  placebo  when  combined  with  antipsychotics  in
some  of  the  outcome  measures.  Two  medium-term  studies
suggested  an  improvement  in  negative  symptoms  and  general
psychopathology  as  measured  on  PANSS.  One  short-term  study
showed  improvement  in  depressive  symptoms  as  measured  by
CDSS.  On  cognitive  functioning,  acetylcholinesterase  inhibitors
showed benefit over placebo when combined with antipsychotics
in  various  areas  of  cognition  including:  memory,  recognition,
attention, executive functioning, psychomotor speed and reaction
time  as  measured  by  different  standardised  tests.  Concerning
tolerability,  there  were  no  significant  differences  in  terms  of
different adverse effects but acetylcholinesterase inhibitors had a
comparably better profile on EPSE as measured on AIMS end point
score. Nevertheless, the validity of all results is challenged by the
quality of the study design; especially, the small duration of studies
with small number of participants.

Summary of main results

General

We  were  able  to  include  17  studies;  however,  data  reporting  in
most of these studies was poor. Our primary outcome of interest
was  reported  in  only  five  studies.  The  two  secondary  outcomes
(negative  symptoms  and  cognition)  which  we  expected  to  show
improvement  did  show  some  positive  results  but  the  quality  of
the studies was poor. The studies were of short-term duration and
the number of the participants were low. Cognitive impairment is
usually  a  slow  process  of  decline  often  progressing  over  months
and  sometimes  years.  To  evaluate  change  in  these  parameters
requires studies to be of longer-term duration. Unfortunately, we
did  not  find  any  long-term  studies.  Fourteen  of  the  studies  were
short-term  and  three  were  medium-term.  In  a  chronic  disease
such  as  schizophrenia  with  possible  progressive  deterioration,
treatment  efficacy  may  decline  as  the  disease  worsens.  A  recent
study  (Chen  2010)  has  emphasised  the  need  for  trials  of  longer
duration in assessing the efficacy of compound in question (Craig
2010).  Lack  of  studies  in  the  long-term,  therefore,  limits  our
generalisability of findings.

This  analysis  of  the  effects  of  acetylcholinesterase  inhibitors  in
combination  with  an  antipsychotic,  or  alone,  compared  with
placebo and antipsychotics drugs in the treatment of schizophrenia
currently  includes  17  studies,  reporting  data  on  only  six  of  ten
possible  secondary  outcomes.  In  addition,  16  of  the  17  included
studies  randomised  less  than  100  people.  The  duration  of  the
trials was usually short and we identified only three medium-term
studies and no long-term studies. Short-term trials are not ideal to
judge efficacy and tolerability of treatments for a chronic disease.
Evidence is clear that industry sponsorship leads to results being
biased towards the compound that the company promotes (Smith
2003  ).  Nine  of  the  17  studies  were  totally  grant  funded  by  the
pharmaceutical industry and one of the studies (Sharma 2006) was
partly funded by a pharmaceutical company. This is likely to be a
further problem.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1. Comparison 1: Acetylcholinesterase inhibitors plus
antipsychotic versus placebo plus antipsychotic

were lost to follow-up. As a result of these limitations, these results
should be interpreted with significant caution.

1.1 Global effect

1.4 Cognitive functioning

Global  effect  remains  an  important  outcome  for  estimating  the
overall  improvement.  In  an  age  where  rating  scales  seem  to  be
predominate  outcome  assessments,  this  is  perhaps  one  of  very
few  scales  that  indicate  a  more  pragmatic  outcome.  Although
widely used in trials, the quality of reporting tends to vary. Of the
17  included  studies,  only  two  studies  (Fagerlund  2007;  Schubert
2006) reported data on this important outcome and the results of
one study were skewed (Schubert 2006). There was no difference
between the two comparators for this outcome.

1.2 Leaving the study early

Losses  to  follow-up  are  often  significant  in  schizophrenia  trials.
Some  reviews  have  reported  studies  that  have  lost  more  than
half  the  participants  (Komossa  2010),  however,  the  number  of
participants leaving the study early was comparatively low in this
review  (13.6  %)  and  showed  no  significant  difference  between
groups.  It  may  be  possible  that  participants  in  the  included
studies  were  inherently  different  from  other  schizophrenia  trials;
however, we were not able to hypothesise as to why this difference
in  attrition  rates  could  have  occurred.  The  included  trials  were
predominantly  short-term  in  nature,  which  could  account  to
some  extent  for  the  reduced  attrition  rates.  Medium-term  data
were  only  available  from  one  study  (Tuma  2003)  and  the  study
reported no significant difference in participants leaving the study
early  between  acetylcholinesterase  inhibitors  and  placebo  when
combined with antipsychotics. Lack of any meaningful long-term
data and no significant findings in the short-term, would indicate
that  there  is  not  much  to  choose  between  acetylcholinesterase
inhibitors and placebo.

1.3 Mental state

In  this  review,  PANSS  appears  to  have  been  the  commonly  used
measuring  tool  as  it  is  with  most  other  schizophrenia  trials.
Three  short-term  studies  that  looked  at  efficacy,  as  measured
on  PANSS  end  point,  did  not  show  any  differences  between
acetylcholinesterase inhibitors plus antipsychotics versus placebo
plus  antipsychotics,  or  versus  antipsychotic  alone.  Two  medium-
term studies, however, showed superiority of acetylcholinesterase
inhibitors  over  placebo  when  combined  with  antipsychotics  in
negative  symptoms  and  general  psychopathology  as  measured
on  PANSS  end  point  data.  These  results  require  caution  in  their
interpretation. The Fagerlund 2007 study had only 11 participants,
who were distributed rather unevenly (seven in the donepezil group
and  four  in  the  placebo  group)  with  no  mention  of  why  this  was
the case. The study also had low baseline scores of participants on
negative symptoms and general psychopathology scales compared
with placebo. This can lead to a possibility of overestimating the
treatment effects of the experimental intervention compared with
the control, which in this case happens to be the compound, the
manufacturers  of  which,  funded  the  study.  Data  for  participants
who left the study early were not reported, which again raises the
possibility of whether the participants who left the trial early were
in any way different compared with those who stayed in the trial.
We were unable to ascertain if more than 40% of participants left
the study early or not. In the other study (Sharma 2006), the number
of participants who left the study was quite high, nearly 40%. It was
not clear from the data how participants were accounted for if they

Cognitive functioning was tested using a set of neuropsychometric
tests.  The  data  were  taken  from  both  the  main  tests  and
subtests;  all  were  checked  for  validity  and  reliability.  The
results  gave  a  mixed  picture,  few  studies  favoured  placebo  over
acetylcholinesterase  inhibitors  and  vice  versa.  Of  the  various
subtests,  acetylcholinesterase  inhibitors  showed  superiority  in
different  areas  of  cognition  such  as:  memory,  executive
functioning, attention and reaction time; whereas, placebo showed
superiority on attention aspect as measured by digit span forward/
backward tests.

The  results  favouring  acetylcholinesterase  inhibitors  cannot  be
considered  robust  as  the  findings  were  from  short-term  studies
and  they  did  not  appear  to  be  of  high  quality.  Tugal  2003  had
affiliation with the pharmaceutical company. The study had a cross-
over design and we used the data before the first cross-over (i.e. up
to six weeks). The sample size was small - six in each arm. Lee 2005,
we also did not have quality information about the randomisation
process and the blinding was not tested. Nahas 2003 had similar
issues; it was a cross-over design so we used results up to the first
cross-over (six weeks).The number of participants in each arm was
only three. The above findings can affect the robustness of a study
especially when the condition in question is a chronic and enduring
one,  and  there  is  no  report  on  long-term  effects.  Buchanan  2008
seemed to be the only study with a good number of participants
(n  =  86)  and  a  low  attrition  rate  (16%).  It  showed  superiority  of
acetylcholinesterase  inhibitor  over  placebo  in  areas  of  attention
and psychomotor speed as assessed by the digit symbol test.

1.5 General functioning and quality of life

Very  limited  data  on  these  important  outcomes  were  available.
Only one study Fagerlund 2007 reported data on global functioning
and  there  were  no  differences  between  acetylcholinesterase
inhibitors and placebo when combined with antipsychotics.

There were no data indicating a difference in measures of quality of
life.

1.6 Adverse effects

Adverse  effects  were  available  for  cardiac  effects,  extrapyramidal
symptoms,  central  nervous  system  symptoms,  gastrointestinal
system symptoms, respiratory system, biochemical abnormalities,
non-specific  and  deterioration  in  mental  state.  There  were  no
significant differences between acetylcholinesterase inhibitors and
placebo  when  combined  with  antipsychotics  on  all  the  available
adverse  effect  outcomes.  Results  on  at  least  one  adverse  effect,
extrapyramidal  symptom  -  AIMS  end  point  score,  indicated  an
advantage for acetylcholinesterase over placebo (Caroff 2007). The
quality  of  the  study  is  in  question;  blinding  was  not  specified,
selective reporting was noted and the authors had affiliation with
the pharmaceutical company.

1.6 Behaviour

The only behaviour for which data were collected was for smoking.
One  study,  Buchanan  2008  showed  superiority  of  placebo  over
acetylcholinesterase inhibitors on FTND interview score.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.7 Missing outcomes

A U T H O R S '   C O N C L U S I O N S

Unfortunately, only little is known from evaluation studies about
service outcomes, engagement with services, economic outcomes
and  satisfaction  with  treatment.  Exactly  how  much  patient  care
gains from these compounds remains unclear.

2. Comparison 2: Acetylcholinesterase inhibitors plus
antipsychotic versus antipsychotic alone

Data were available for two outcomes; leaving the study early and
mental state. There were no significant differences in either arms of
the study in the above two outcomes.

Overall completeness and applicability of evidence

Of  the  17  included  studies  14  were  short-term.  We  did  not
identify  a  single  high  quality  study  which  could  have  compared
most  of  the  possible  comparisons  of  acetylcholinesterase
inhibitors  plus  antipsychotic  with  placebo  and  antipsychotic,  or
acetylcholinesterase  inhibitors  with  placebo  and  antipsychotic
drugs, or acetylcholinesterase alone with placebo.

Evidence,  therefore,  is  incomplete.  None  of  the  studies  were
long-term  thus  limiting  applicability  of  the  evidence,  for;  after
all,  schizophrenia  is  often  a  chronic,  often  life-long,  disorder.
Furthermore,  most  of  the  included  studies  were  efficacy  studies,
therefore,  external  validity  is  limited  and  further  more  pragmatic
effectiveness studies are needed.

Quality of the evidence

All studies were randomised and at least single-blind, but details
were rarely presented. Therefore, it is unclear in almost all studies
whether  randomisation  and  blinding  were  really  appropriately
done.  Furthermore,  the  majority  of  the  studies  were  short-term,
only  three  were  medium-term  and  none  long-term;  leading  to
questions  about  the  validity  of  the  findings.  None  of  the  studies
compared  acetylcholinesterase  inhibitors  alone  with  placebo;  it
was  mostly  add-on  therapy  with  antipsychotics.  This  also  limits
the evidence because the antipsychotics used were from different
classes  which  would  have  led  to  difference  in  results.  Selective
reporting was evident in half of the studies and half of the studies
were  industry  sponsored  or  had  affiliation  with  pharmaceutical
companies. All these factors limit the quality of the evidence.

Potential biases in the review process

We are not aware of obvious flaws in our review process.

Agreements and disagreements with other studies or
reviews

None known.

Implications for practice

1. For people with schizophrenia

Current available evidence is not good enough for recommending
acetylcholinesterase inhibitors routinely as an add-on intervention
along  with  antipsychotics  to 
improve  efficacy  or  cognitive
symptoms in those suffering from schizophrenia.

2. For clinicians

The  majority  of  the  studies  were  short-term  with  only  three
medium-term studies, of which two were of poor methodological
quality.  The  overall  results  do  not  suggest  that  the  intervention
is  better  than  placebo.  It  could  perhaps  be  tried  when  all  other
interventions have failed, but its effects need to be assessed and
treatment withdrawn if there is no evidence of any clinical benefit.
This combination may be useful in improving the different aspects
of  cognition  such  as  attention,  reaction  time  and  psychomotor
speed, again the evidence base for which is quite limited.

3. For managers/policy makers

Little  information  on  service  use  (such  as  time  in  hospital),  and
economic outcomes is available. There may be higher overall costs
in some settings. Only one study had data on general functioning
and it did not favour the drug in question.

Implications for research

1. General

Reporting  of  trials  continues  to  remain  poor.  There  needs  to
be  better  description  of  the  randomisation  process  and  better
accountability  of  patients  leaving  the  trial.  As  highlighted  in
other Cochrane reviews, authors must give consideration to better
adherence to the CONSORT statement (Schulz 2010).

2. Specific

Most  of  the  studies  were  short-term  studies.  Most  of  the  data
reported  within  existing  comparisons  are  almost  without  value
because of the assumptions and biases within them. It is therefore
essential  that  longer-term,  better  reported  more  pragmatic  trials
are  needed  before  the  evidence  could  be  assessed  objectively  to
conclude whether or not this intervention would be of benefit to
patients.

A C K N O W L E D G E M E N T S

We  would  like  to  thank  the  editorial  base  of  the  Cochrane
Schizophrenia Group for its assistance. We would also like to thank
the  following  people  Jun  Xia,  Parthi  Sivaraman  who  continue  to
provide support and encouragement in finishing this review.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies included in this review

Dyer 2008 {published data only}

R E F E R E N C E S

Akhondzadeh 2008 {published data only}

Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N,
Ghoreishi A, Abbasi SH, Rezazadeh SA. A 12-week, double-blind,
placebo-controlled trial of donepezil adjunctive treatment
to risperidone in chronic and stable schizophrenia. Progress
in Neuro-Psychopharmacology and Biological Psychiatry
2008;32(8):1810-5. [EMBASE: 2008551286]

Buchanan 2008 {published data only}

Boggs DL, Conley R, Nelson M, Feldman S, Ball P, McMahon R,
Buchanan R. Galantamine does not significantly effect
positive or negative symptoms in patients with schizophrenia.
Schizophrenia Bulletin 2007;33(2):422.

Boggs DL, Conley RR, Nelson MW, Feldman S, Ball P,
McMohan RP, Buchanan RW. Galantamine does not
significantly effect positive or negative symptoms in with
schizophrenia. Proceedings of the 11th International Congress
on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado
Springs, Colorado, USA 2007.

Buchanan RW, Conley RC, Dickinson D, Nelson MW, Gold JM,
McMahon RP. Galantamine for the treatment of cognitive
impairments in patients with schizophrenia. Schizophrenia
Bulletin 2007;33(2):424.

Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S,
Gold JM, McMahon RP. Galantamine for the treatment of
cognitive impairments in people with schizophrenia. American
Journal of Psychiatry 2008;165(1):82-9. [CINAHL: 2009760048;
EMBASE: 2008245589; MEDLINE: 17986678]

Caroff 2007 {published data only}

Caroff SN. Treatment of tardive dyskinesia with galantamine.
http://www.clinicaltrials.gov 2005.

Caroff SN, Walker P, Campbell C, Lorry A, Petro C, Lynch K,
Gallop R. Treatment of tardive dyskinesia with galantamine:
a randomized controlled crossover trial. Journal of Clinical
Psychiatry 2007;68(3):410-5. [EMBASE: 2007160853; MEDLINE:
17388711]

Chouinard 2007 {published data only}

Chouinard S, Stip E, Poulin J, Melun JP, Godbout R,
Guillem F, Cohen H. Rivastigmine treatment as an add-
on to antipsychotics in patients with schizophrenia and
cognitive deficits. Current Medical Research and Opinion
2007;23(3):575-83. [MEDLINE: 17355738]

Dyer MA, Freudenreich O, Culhane MA, Pachas GN,
Deckersbach T, Murphy E, Goff DC, Evins AE. High-dose
galantamine augmentation inferior to placebo on attention,
inhibitory control and working memory performance in
nonsmokers with schizophrenia. Schizophrenia Research
2008;102(1-3):88-95. [EMBASE: 2008316513; MEDLINE:
18325740; PSYCINFO: 2008-08739-011]

Fagerlund 2007 {published data only}

Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY.
Effects of donepezil adjunctive treatment to ziprasidone on
cognitive deficits in schizophrenia: a double-blind, placebo-
controlled study. Clinical Neuropharmacology 2007;30(1):3-12.
[EMBASE: 2007070507; MEDLINE: 17272964]

Freudenreich 2005 {published data only}

Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC,
Cather C, Goff DC. Added donepezil for stable schizophrenia:
a double-blind, placebo-controlled trial. Psychopharmacology
2005;181(2):358-63. [EMBASE: 2005474481; MEDLINE: 15778880]

Friedman 2002c {published data only}

Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G,
Temporini H, White L, Parrella M, Davis KL. A double blind
placebo controlled trial of donepezil adjunctive treatment to
risperidone for the cognitive impairment of schizophrenia.
Biological Psychiatry 2002;51(5):349-57. [MEDLINE: 11904128;
MEDLINE: 21900569]

Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G,
Temporini H, White L, Parrella M, Davis KL. A double blind
placebo controlled trial of donepezil adjunctive treatment to
risperidone for the cognitive impairment of schizophrenia.
Schizophrenia Research 2002;53(3 Suppl 1):9.

Friedman JI, Adler DN, Howanitz E, Temporini H, Harvey PD,
Davis KL. Effects of donepezil on cognition, symptoms, and
movement disorders in patients with chronic schizophrenia.
Proceedings of the 39th Annual Meeting of the American College
of Neuropsychopharmacology; 2000 Dec 10-14; San Juan,
Puerto Rico. 2000.

Friedman JI, Adler DN, Howanitz E, Temporini H, Harvey PD,
Davis KL. Effects of donepezil on cognition, symptoms, and
movement disorders in patients with chronic schizophrenia.
Schizophrenia Research 2001;49(1, 2):228. [EMBASE:
2007070507; MEDLINE: 17272964]

Keefe 2008a {published data only}

Guillem F, Chouinard S, Poulin J, Godbout R, Lalonde P, Melun P,
Bentaleb LA, Stip E. Are cholinergic enhancers beneficial
for memory in schizophrenia? An event-related potentials
(ERPs) study of rivastigmine add-on therapy in a crossover
trial. Progress in Neuro-Psychopharmacology and Biological
Psychiatry 2006;30(5):934-45. [EMBASE: 2006254188; MEDLINE:
16580765]

Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW,
Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of
donepezil in patients with schizophrenia or schizoaffective
disorder: significant placebo/practice effects in a 12-
week, randomized, double-blind, placebo-controlled trial.
Neuropsychopharmacology 2008;33(6):1217-28. [EMBASE:
2008181698; MEDLINE: 17625502]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kim 2005b {published data only}

Kim Y, Shim JC, Suh YS, Lee BJ. A 12 week, double - blind,
placebo controlled trial of donepezil adjunctive to haloperidol
for the cognitive impairments in patients with chronic
schizophrenia. Schizophrenia Bulletin 2005;31:490.

Kim YH, Lee BJ. A 12 week, double-blind, placebo controlled
trial of donepezil adjunctive to haloperidol for the cognitive
impairments in patients with chronic schizophrenia.
Proceedings of the XIII World Congress of Psychiatry; 2005
10-15th Sept; Cairo, Egypt. 2005.

Lee B-J, Lee J-G, Kim Y-H. A 12-week, double-blind,
placebo-controlled trial of donepezil as an adjunct to
haloperidol for treating cognitive impairments in patients
with chronic schizophrenia. Journal of Psychopharmacology
2007;21(4):421-7. [EMBASE: 2007350347; MEDLINE: 17092979]

Kohler 2007 {published data only}

Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No
effect of donepezil on neurocognition and social cognition
in young persons with stable schizophrenia. Cognitive
Neuropsychiatry 2007;12(5):412-21. [EMBASE: 2007400587;
MEDLINE: 17690999]

Lee 2005 {published data only}

Lee S-W, Kim Y-H. A 12-week, double-blind, placebo-
controlled trial of galantamine adjunctive treatment to
conventional antipsychotics for cognitive impairments in
chronic schizophrenia. Clinical Psychopharmacology and
Neuroscience 2005;3(1):10-5. [EMBASE: 129490]

Lee S-W, Lee J-G, Lee B-J, Kim YH. A 12-week, double-
blind, placebo-controlled trial of galantamine adjunctive
treatment to conventional antipsychotics for the cognitive
impairments in chronic schizophrenia. International Clinical
Psychopharmacology 2007;22(2):63-8. [MEDLINE: 17293705]

Nahas 2003 {published data only}

Nahas Z, George MS, Horner MD, Markowitz JS, Li X,
Lorberbaum JPOSD, McGurk S, DeVane L, Risch SC. Augmenting
atypical antipsychotics with a cognitive enhancer (donepezil)
improves regional brain activity in schizophrenia patients:
a pilot double-blind placebo controlled BOLD fMRI study.
Neurocase 2003;9(3):274-82. [CINAHL: 2003155586; MEDLINE:
22806993]

Schubert 2006 {published data only}

Schubert MH, Young KA, Hicks PB. Galantamine improves
cognition in schizophrenic patients stabilized on risperidone.
Biological Psychiatry 2006;60(6):530-3. [EMBASE: 2006456302;
MEDLINE: 16806095]

Schubert MH, Young KA, Justice SB, Durgam SK, Schmitz WM,
House MD, Hicks PB. Cognitive improvement in schizophrenia
and schizoaffective disorder by augmentation of risperidone
with galantamine. Schizophrenia Bulletin 2005;31:503.

Sharma 2006 {published data only}

Aasen I, Kumari V, Sharma T. Effects of rivastigmine on sustained
attention in schizophrenia: an fMRI study. Journal of Clinical
Psychopharmacology 2005;25(4):311-7.

Aasen I, Kumari V, Sharma T. Enhanced attention with
rivastigmine in schizophrenia: an fmri study. Schizophrenia
Research 2004;67(1):140.

Kumari V, Aasen I, Ffytche D, Williams SCR, Sharma T.
Neural correlates of adjunctive rivastigmine treatment
to antipsychotics in schizophrenia: a randomized,
placebo-controlled, double-blind fMRI study. Neuroimage
2006;29(2):545-56. [MEDLINE: 16181792]

Kumari V, Aasen I, Sharma T. Neural correlates of rivastigmine
treatment in schizophrenia: an fMRI study. European
Neuropsychopharmacology 2004;14(Suppl 3):S286.

Sharma T. Cognitive enhancement with revistagmine in
schizophrenia. National Research Register 2002; Vol. 1.

Sharma T, Hughes C, Kumari V. A placebo-controlled double-
blind investigation of cognitive effects of rivastigmine in
schizophrenia. Schizophrenia Research 2004;67(1):208.

Sharma T, Hughes C, Kumari V, Aasen I. A placebo-controlled
double-blind investigation of cognitive effects of rivastigmine
in schizophrenia. European Neuropsychopharmacology
2004;14(Suppl 3):S284.

Sharma T, Kumari V. Adjunctive rivastigmine for people with
schizophrenia who have cognitive impairment. Stanley
Foundation Research Programs 2000.

Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of
adjunctive 24-weeks rivastigmine treatment to antipsychotics
in schizophrenia: a randomized, placebo-controlled, double-
blind investigation. Schizophrenia Research 2006;85(1-3):73-83.
[EMBASE: 2006303259; MEDLINE: 16797163]

Tugal 2003 {published data only}

Tugal O, Yazici KM, Yagcioglu AEA, Gogus A. A double-blind,
placebo controlled, cross-over trial of adjunctive donepezil for
cognitive impairment in schizophrenia. International Journal
of Neuropsychopharmacology 2004;7(2):117-23. [MEDLINE:
14741060]

Tugal O, Yazici KM. A double-blind, placebo controlled, cross-
over trial of adjunctive donepezil for the cognitive impairment
of schizophrenia. European Neuropsychopharmacology
2003;13(4):S294.

Tuma 2003 {published data only}

Tuma I, Lenderova Z, Zemanova M, Kadlecova E, Perez M.
Donepezil as an adjunctive treatment of cognitive dysfunction
in schizophrenia. European Neuropsychopharmacology
2003;13(4):S348.

Tuma I, Lenderova Z, Zemanova M, Kadlecova E, Perez M.
Donepezil as an adjunctive treatment of cognitive dysfunction
in schizophrenia. Proceedings of the16th European College of
Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague,
Czech Republic. 2003.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies excluded from this review

Davis 1981 {published data only}

Davis KL, Faull KF, Hollister LE, Barchas JD, Berger PA.
Alterations in cerebrospinal fluid dopamine metabolites
following physostigmine infusion. Psychopharmacology
1981;72(2):155-60.

Journal of Psychiatry 1980;137(10):1202-5. [MEDLINE: 6106390;
MEDLINE: 81019282]

NCT00566735 {published data only}

NCT00566735. The use of galantamine HBr (reminyl) in
electroconvulsive therapy: impact on mood and cognitive
functioning. http://www.clinicaltrials.gov 2007.

Edelstein 1981 {published data only}

Okereke 2002 {published data only}

Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver DL.
Physostigmine and lithium response in the schizophrenias.
American Journal of Psychiatry 1981;138(8):1078-81. [MEDLINE:
7258385; MEDLINE: 81253193]

El-Yousef 1973 {published data only}

El-Yousef K, Janowsky DS, Davis JM, Sekerke HJ. Reversal of
antiparkinsonian drug toxicity by physostigmine: a controlled
study. American Journal of Psychiatry 1973;130(2):1973.
[MEDLINE: 7028800; MEDLINE: 82053617]

Ingram 1983 {published data only}

Ingram NA, Newgreen DB. The use of tacrine for tardive
dyskinesia. American Journal of Psychiatry 1983;140:1629-31.
[MEDLINE: 6650699; MEDLINE: 84077361]

Janowsky 1972 {published data only}

Janowsky D, El-Yousef MK, Davis JM. The elicitation of psychotic
symptomatology by methylphenidate. In: Cole JO editor(s).
Psychopathology and Psychopharmacology. Baltimore: John
Hopkins University Press, 1973:113-32.

Janowsky DS, El-Yousef K, Davis JM, Sekerke HJ. Antagonistic
effects of physostigmine and methylphenidate in man.
American Journal of Psychiatry 1973;130(12):1370-6.

Janowsky DS, El-Yousef K, Davis JM, Sekerke HJ.
Parasympathetic suppression of manic symptoms by
physostigmine. Archives of General Psychiatry 1973;28:542-6.
[EMBASE: 2007400587; MEDLINE: 17690999]

Kristiansen 2001 {published data only}

Kristiansen KT, Mackeprang T, Fink-Jensen A, Hemmingsen RP,
Glenthoj BY. Effects of antipsychotics and other agents on
prepulse inhibition of the startle response (ppi). Schizophrenia
Research 2001;49(1, 2):216.

Lieberman 1988 {published data only}

Lieberman J, Pollack S, Lesser M, Kane J. Pharmacologic
characterization of tardive dyskinesia. Journal of Clinical
Psychopharmacology 1988;8(4):254-60. [MEDLINE: 3209717;
MEDLINE: 89093492]

Mazeh 2006 {published data only}

Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. Donepezil
for negative signs in elderly patients with schizophrenia: an
add-on, double-blind, crossover, placebo-controlled study.
International Psychogeriatrics 2006;18(3):429-36. [MEDLINE:
16478570]

Moore 1980 {published data only}

Moore DC, Bowers MB. Identification of a subgroup of tardive
dyskinesia patients by pharmacologic probes. American

Okereke CS, Kumar D, Cullen EI, Pratt RD, Hahne WF. Safety
and pharmacokinetics profile of concurrent donepezil hcl
and levodopa/carbidopa. Proceedings of the 155th Annual
Meeting of the American Psychiatric Association; 2002 May
18-23; Philadelphia, Pennsylvania, USA. 2002.

Ophir 2004 {published data only}

Ophir D, Stryer R, Bar F, Ullman A, Strous RD, Kotler M,
Weizman A. Rivastigmine therapy for memory deficits in
schizophrenia patients receiving electroconvulsive treatment.
European Neuropsychopharmacology 2004;14(Suppl 3):S126.

Pesco-Koplowitz 2000c {published data only}

Pesco-Koplowitz L, Parier J-L, Zhao Q, Heron J.
Pharmacokinetics of risperidone/donepezil combination.
Proceedings of the 38th Annual Meeting of the American College
of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco,
Mexico. 1999.

Pesco-Koplowitz L, Parier JL, Zhao Q, Heron J.
Pharmacokinetics of risperidone/donepezil combination.
Biological Psychiatry 2000;47:167S.

Risch 1981 {published data only}

Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in
affective illness: behavioral and neuroendocrine correlates.
Journal of Clinical Psychopharmacology 1981;1(4):186-92.
[MEDLINE: 7028800; MEDLINE: 82053617]

Risch 2001 {published data only}

Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M,
Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J,
George MS. A double-blind placebo-controlled case study of
the use of donepezil to improve cognition in a schizoaffective
disorder patient: functional MRI correlates. Neurocase
2001;7(2):105-10. [MEDLINE: 11320158]

Stryjer 2004a {published data only}

Stryjer R, Strous R, Bar F, Shaked G, Shiloh R, Rozencwaig S,
Grupper D, Buchman N, Kotler M, Rabey JM, Weizman A.
Donepezil augmentation of clozapine monotherapy in
schizophrenia patients: a double blind cross-over study. Human
Psychopharmacology 2004;19(5):343-6. [EMBASE: 2004358370;
MEDLINE: 15252826]

Tamminga 1977 {published data only}

Tamminga CA, Smith RC, Ericksen SE, Chang S, Davis JM.
Cholinergic influences in tardive dyskinesia. American Journal
of Psychiatry 1977;134(7):769-74. [MEDLINE: 7028800; MEDLINE:
82053617]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

References to studies awaiting assessment

Fleming 2003 {published data only}

Fleming K, Potkin SG. A 26-week, double-blind, placebo-
controlled antipsychotic augmentation study of memantine
plus donepezil in the treatment of 60 outpatients with
schizophrenia. Stanley Foundation Research Programs 2003.

Hussain 2003 {published data only}

Hussain MZ, Chaudhry ZA. Rivastigmine and galantamine
treatment for schizophrenic cognitive impairment. Proceedings
of the 156th Annual Meeting of the American Psychiatric
Association; 2003 May 17-22; San Francisco, California, USA.
2003.

Hussain MZ, Chaudhry ZA. Rivastigmine and galantamine
treatment of schizophrenic cognitive impairment. Proceedings
of the 157th Annual Meeting of the American Psychiatric
Association; 2004 May 1-6; New York, New York, USA. 2004.

Kelleher 2008 {published data only}

Kelleher JP, Shinnar MR, Olshanskiy V, Malhotra A, Kane J,
Sonnenberg M, Lascher S. Galantamine treatment of comorbid
nicotine dependence in patients with schizophrenia or
schizoaffective disorder. Proceedings of the 161st Annual
Meeting of the American Psychiatric Association; 2008 May 3-8,
Washington DC, USA. 2008.

Modestin 1973 {published data only}

Modestin J, Schwartz RB, Hunger J. Investigation about an
influence of physostigmine on schizophrenic symptoms
(author's transl) [Zur frage der beeinflussung schizophrener
symptome durch physostigmin]. Pharmakopsychiatrie und
Neuropsychopharmakologie 1973;6(6):300-4. [MEDLINE:
4603643; MEDLINE: 74293998]

References to ongoing studies

Ball 2005 {published data only}

Ball MP, Buchanan RW. Adjunctive galantamine for treatment
of cognitive impairments in patients with schizophrenia. http://
www.clinicaltrials.gov 2005.

Evins 2006 {published data only}

Evins AE. Effect of nicotine agonist galantamine added to
high potency medications for cognitive function in patients
with schizophrenia and schizoaffective disorder. http://
www.clinicaltrials.gov 2006.

Gaskins 2007 {published data only}

Gaskins BL, Deutsch SI, Schwartz BL, Rosse RB, Schooler N.
Interventions to test the alpha7 nicotinic receptor model in
schizophrenia. http://www.clinicaltrials.gov 2007.

George 2007 {published data only}

George TP, Sacco KA, Vessicchio J. Galantamine for cognitive
deficits in schizophrenia. http://www.clinicaltrials.gov 2007.

Glenthoj 2005 {published data only}

Glenthoj B. Pharmacological treatment of cognitive deficits
in schizophrenic patients: the effects of central cholinergic

Cochrane Database of Systematic Reviews

augmentation on cognitive deficits and psychopathology.
http://www.clinicaltrials.gov 2005.

Johnson 2004 {published data only}

Johnson & Johnson Pharmaceutical Research and
Development. A study of galantamine hbr as an adjunctive
treatment to atypical antipsychotic medications in outpatients
with schizophrenia and associated cognitive deficits. http://
www.clinicaltrials.gov 2004.

Nachshoni 2007 {published data only}

Nachshoni T, Kupchik M. Donepezil double blind trial for ECT
memory dysfunction. http://www.clinicaltrials.gov 2007.

Additional references

Addington 1993

Addington D, Addington J, Maticka-Tyndale E. Assessing
depression in schizophrenia: the Calgary Depression Scale.
British Journal of Psychiatry 1993;22:39-44.

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary
information. BMJ 1996;313(7066):1200.

Andreasen 1984

Andreasen NC. Scale for the Assessment of Positive Symptoms
(SAPS). University of Iowa, 1984.

Andreasen 1989

Andreasen NC. Scale for the assessment of negative symptoms
(SANS). British Journal of Psychiatry 1989;7:53-8.

Barnes 1989

Barnes TR. A rating scale for drug-induced akathisia. British
Journal of Psychiatry 1989;154:672-6.

Benedict 1996

Benedict RHB, Schretlen D, Groninger L, Dobraskia M, Shpritz B.
Revision of the brief visuospatial memory test: studies of
normal performance, reliability, and validity. Psychological
Assessment 1996;8(2):145-53.

Birks 2006

Birks J. Cholinesterase inhibitors for Alzheimer's disease.
Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI:
10.1002/14651858.CD005593]

Bland 1997

Bland JM, Kerry SM. Statistics notes. Trials randomised in
clusters. BMJ 1997;315:600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M,
Boutitie F, Nony P, Haugh M, Mignot G. The problem of
therapeutic efficacy indices. 3. Comparison of the indices and
their use. Therapie 1999;54(4):405-11.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Brandt 1991

Gelenberg 2004

Brandt J. The hopkins verbal learning test: Development
of a new memory test with six equivalent forms. Clinical
Neuropsychology 1991;5:125-42.

Carpenter 1994

Carpenter WT Jr, Buchanan RW. Schizophrenia. New England
Journal of Medicine 1994;10(330):681-90.

Chen 2010

Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, Tso S,
Pang EP, Chan KT, Wong YC, Mo FY, Chan KP, Yao TJ, Hung SF,
Honer WG. Maintenance treatment with quetiapine versus
discontinuation after one year of treatment in patients with
remitted first episode psychosis: randomised controlled trial.
BMJ 2010;341:c4024. [PUBMED: 20724402]

Chouinard 1993

Chouinard G, Arnott W. Clinical review of risperidone. Canadian
Journal of Psychiatry 1993;38(Suppl 3):89-95.

Conners 2000

Conners CK, MHS Staff. Connersê Continuous Performance
Test II: Computer Program for Windows Technical Guide and
Software Manual. North Tonwanda, NY: Mutli-Health Systems,
2000.

Craig 2010

Craig JC, Webster AC, Loy C. How long should treatments be
continued?. BMJ 2010; Vol. 341:c4102. [PUBMED: 20724403]

Gelenberg AJ, Levy P, Manoukian SV. Maintaining metabolic
and cardiovascular health in patients with schizophrenia:
perspectives in long-term care. http://cme.medscape.com/
viewarticle/491506 (accessed 08 May 2009).

Gulliford 1999

Gulliford MC. Components of variance and intraclass
correlations for the design of community-based surveys and
intervention studies: data from the Health Survey for England
1994. American Journal of Epidemiology 1999;149:876-83.

Guy 1976

Guy U. ECDEU assessment manual for psychopharmacology.
Revised. Rockville: National Institute of Mental Health, 1976.

Hamilton 1980

Hamilton M. Rating depressive patients. Journal of Clinical
Psychiatry 1980;41:21-4.

Heaton 1993

Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin
Card Sorting Test Manual: Revised and Expanded, Psychological
Assessment Resources. Odessa, 1993.

Heres 2006

Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why
olanzapine beats risperidone, risperidone beats quetiapine, and
quetiapine beats olanzapine. American Journal of Psychiatry
2006;163:185-94.

Deeks 2000

Higgins 2011

Deeks JJ. Issues in the selection of a summary statistic for meta-
analyses of binary data. Proceedings of the 8th International
Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa.
Cape Town: Cochrane Collaboration, 2000.

Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.

Divine 1992

Jablensky 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in
studies about physicians' patient care behavior. Journal of
General Internal Medicine 1992;7(6):623-9.

Donner 2002

Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A,
Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations,
incidence and course in different cultures. A World Health
Organization ten-country study. Psychological Medicine.
Monograph Supplement 1992;20:1-97.

Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971-80.

Jüni 2001

DSM-IV-TR

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4. Wahsington DC: APA, 1994.

Egger 1997

Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias
in meta-analysis detected by a simple, graphical test. BMJ
1997;13:629-34.

Elbourne 2002

Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV,
Vail A. Meta-analyses involving cross-over trials: methodological
issues. International Journal of Epidemiology 2002;31(1):140-9.

Jüni P, Altman DG, Egger M. Systematic reviews in health
care: Assessing the quality of controlled clinical trials. BMJ
2001;323:42-6.

Kang 1997

Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-
Mental State Examination (K-MMSE) in dementia patients.
Korean Neurological Association 1997;15:300-8.

Kay 1986a

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome
Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health
Systems, 1986.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kay 1987

Shekhar 2008

Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome
scale (PANSS) manual. Schizophrenia Bulletin 1987;13(2):261-76.

Klove 1964

Matthews CG, Klove H. Instruction Manual for the Adult
Neuropsychology Test Battery. Madison, WI: University of
Wisconsin Medical School, 1964.

Komossa 2010

Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S,
Srisurapanont M, Kissling W, Leucht S. Quetiapine versus
other atypical antipsychotics for schizophrenia. Cochrane
Database of Systematic Reviews 2010, Issue 1. [DOI:
10.1002/14651858.CD006625.pub2]

Kraus 2007

Michael S, Kraus MA, Keefe RSE. Cognition as an outcome
measure in schizophrenia. British Journal of Psychiatry
2007;191(50):s46-51.

Leucht 2005

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S,
Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective
muscarinic receptor agonist xanomeline as a novel treatment
approach for schizophrenia. American Journal of Psychiatry
2008;165:1033-9.

Simpson 1970

Simpson GM, Angus JWS. A rating scale for extrpyramidal
side-effects. Acta Psychiatrica Scandinavica Supplementum
1970;212:11-9.

Smith 2003

Smith R. Medical journals and pharmaceutical companies:
uneasy bedfellows. BMJ 2003;326(7400):1202-5. [PUBMED:
12775625]

Stahl 2000

Stahl SM. Psychopharmacology of reward and drugs of abuse.
Essential Psychopharmacology. 2nd Edition. Cambridge
University Press, 2000:469-70.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR.
What does the PANSS mean?. Schizophrenia Research
2005;79(2-3):231-8.

Stroop 1935

Stroop JR. Studies of interference in serial verbal reactions.
Journal of Experimental Psychology 1935;18:643-62.

Marshall 2000

Tombaugh 2004

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52.

Meyers 1995

Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition
Trial: Professional Manual. Psychological Assessment Resource,
1995.

Tombaugh TN. Trail making test A and B: Normative
data stratified by age and education. Archives of Clinical
Neuropsychology 2004;19(2):203-14.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.
Methods for evaluating area-wide and organisation-based
intervention in health and health care: a systematic review.
Health Technology Assessment 1999;3(5):iii-92.

Miller 1984

Wechsler 1997a

Miller E. Verbal fluency as a function of a measure of
verbalintelligence and in relation to different types of cerebral
pathology. British Journal of Clinical Psychology 1984;8:385-94.

Wechsler D. Wechsler Adult Intelligence Scale- Administration
And Scoring Manual. 3rd Edition. New York: The Psychological
Corporation, Harcourt Brace & Company, 1997.

Mueser 2004

Wechsler 1997b

Mueser KT, McGurkn SR. Schizophrenia. The Lancet
2004;363(9426):2063-72.

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale.
Psychological Reports 1962;10:799-812.

Randolph 1998

Randolph, C. Repeatable battery for the assessment of
neuropsychological status. Psychological Corporation 1998.

Wechsler D. Wechsler Memory Scale- Administration and
Scoring Manual. 3rd Edition. New York: The Psychological
Corporation, Harcourt Brace & Company, 1997.

Wilk 2002

Wilk CM, Gold JM, Bartko JJ, Dickerson F, Fenton WS, Knable M,
Randolph C, Buchanan RW. Test and retest stability of the
repeatable battery for the assessment of neuropsychological
status in schizophrenia. American Journal of Psychiatry
2002;159:838-44.

Schulz 2010

Winkler 1998

Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement:
Updated guidelines for reporting parallel group randomised
trials. Journal of Clinical Epidemiology 2010;63(8):834-40.
[PUBMED: 20346629]

Winkler J, Thal LJ, Gage FH, Fisher LJ. Cholinergic strategies
for alzheimer's disease. Journal of Molecular Medicine
1998;76:555-67.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wishart 2006

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M,
Stothard P, Chang Z, Woolsey J. Drug Bank: a comprehensive
resource for in silico drug discovery and exploration. Nucleic
Acids Research 2006;34:D668-72.

Xia 2007

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H,
Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Cochrane Database of Systematic Reviews

(LOSS) Study. Proceedings of the 15th Cochrane Colloquium;
2007 Oct 23-27; Sao Paulo. 2007.

Yeomans 1995

Yeomans JS. Role of tegmental cholinergic neurons in
dopaminergic activation, antimuscarinic psychosis and
schizophrenia. Neuropsychopharmacology 1995;12(1):3-16.

Akhondzadeh 2008 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised in 1:1 pattern. 
Blindness: double blind. 
Duration: 12 weeks. 
Design: not specified.

Diagnosis: schizophrenia (DSM-IV). 
N = 30. 
Age: 22 to 44 years. 
Duration of illness: intervention group 85.6 ± 46.6 months, placebo 89.2 ± 50.2 months. 
Sex: 11 F,19 M. 
Setting: inpatient and outpatient. 
Inclusion criteria: treated with a stable dose of risperidone - 8 weeks, minimum period of 4 weeks sta-
bility, total performance score at least 20 on MMSE. 
Exclusion criteria: any medical diagnosis, on any medication that may have affected cognitive perfor-
mance, abusing substances within 6 months of entry into study, pregnant or lactating women.

1. Donepezil: dose up to 10 mg/day plus risperidone 4 to 6 mg/day.N = 15. 
2. Placebo plus risperidone 4 to 6 mg/day. N = 15.

Leaving the study early. 
Mental state: PANSS, HAM-D. 
Cognitive functioning. 
Adverse events. 
Unable to use: PANSS

Donepezil and placebo were prepared in identical appearing tablets.

Authors' judgement

Support for judgement

Unclear risk

No information available.

High risk

Not done.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Iden-
tical appearing tablets were used, effectiveness of this method was not men-
tioned.

Incomplete outcome data
(attrition bias) 

Low risk

No missing outcome data.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Akhondzadeh 2008  (Continued)

All outcomes

Selective reporting (re-
porting bias)

Low risk

All of the study's pre-specified outcomes are reported.

Other bias

Unclear risk

No information available.

Buchanan 2008 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised. 
Blindness: double blind. 
Duration: 12 weeks. 
Design: not specified.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
N= 86. 
Age: 18 to 60 years. 
Duration of illness: mean age - 24.9 years, intervention group; mean age - 25.9 years, placebo group. 
Sex: 74 M, 12 F. 
Setting: inpatients and outpatients. 
Inclusion criteria: clinically stable and in a non acute (chronic) phase of their illness, to have at least a
minimal level of cognitive impairment, on antipsychotics other then clozapine, absence of concomi-
tant anticholinergic treatment and significant extrapyramidal symptoms. 
Exclusion criteria: Patients who met the criteria for a DSM-IV diagnosis of alcohol or substance abuse
within the last 6 months, with second-degree A-V block, CNS disorder (e.g., seizure disorder, stroke), or
mental retardation

1. Galantamine: dose up to 24 mg/day plus antipsychotic. N = 42 
2. Placebo and antipsychotic.N = 44.

Mental state: BPRS, SANS. 
Global functioning: CGI. 
Leaving the study early. 
Adverse events: Simpson & Angus Neurological Rating Scale for Extrapyramidal Effects, Abnormal In-
voluntary Movement Scale (AIMS), weight loss, vomiting, ECG and QTc prolongation, biochemical val-
ues. 
Cognitive functioning: Neuropsychological tests. 
Expired CO measures. 
Unable to use: CGI-S. BPRS, SANS.

Seven participants left the study early in the galantamine group and six in the placebo group for vari-
ous reasons. Both the participants and trialists were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Buchanan 2008  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

No information available.

Low risk

All outcomes measured and reported.

Other bias

Unclear risk

Funded by independent bodies, but authors reported affiliation to various
drug companies.

Caroff 2007 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Allocation: randomised. 
Blinding: not specified. 
Duration: 12 weeks. 
Design: uni-centre, cross-over.

Diagnosis: schizophrenia (DSM-IV). 
N = 38. 
Age: 56.4 ± 9.9 years. 
Duration of illness: 29.6 ± 8.0 years. 
Sex: male. 
Setting: not clear. 
Inclusion criteria: patients with schizophrenia with tardive dyskinesia. 
Exclusion criteria: patients with acute medical illness, could not be withdrawn from anticholinergic
medication or vitamin E supplements.

1. Galantamine up to 24 mg /day plus antipsychotic medication. N = 20. 
2. Placebo plus antipsychotic medication. N = 18.

Mental state: BPRS. 
Cognition: MMSE. 
Adverse events: AIMS, SAS, BAS. 
Leaving the study early. 
Unable to use: BPRS, SAS, MMSE, BAS.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Unclear risk

No information available.

Unclear risk

No information available.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Caroff 2007  (Continued)

Selective reporting (re-
porting bias)

Low risk

Not enough information available.

Other bias

High risk

Mention of support from drug company Pfizer.

Chouinard 2007 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised. 
Blindness: double blind. 
Duration: 12 weeks. 
Design: uni-centre, cross-over.

Diagnosis: Schizophrenia and schizoaffective disorder (DSM-IV). 
Duration of illness: mean age - 8.77 (7.99), intervention group; mean age - 4.25 (5.28), control group. 
N = 24. 
Age: 28.85 ± 7.92 years. 
Sex: M and F. 
Settings: inpatients. 
Inclusion criteria: patients with schizophrenia who scored less than 75 on the immediate or delayed
memory indices. 
Exclusion criteria: patients with history of substance use, axis 1 and III diagnosis, pronounced suicidal
tendencies.

1. Rivastigmine: dose up to max 4.5 mg bd plus antipsychotic. N=9. 
2. Antipsychotic alone. N=11.

Mental state: PANSS 
Cognitive functioning: CANTAB. 
Adverse events. 
Leaving the study early. 
Unable to use: CANTAB.

Twenty four patients were recruited but only twenty completed the study. Both the participants and
trialists were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

No information available.

Low risk

All outcomes measured and reported.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chouinard 2007  (Continued)

Other bias

High risk

Cochrane Database of Systematic Reviews

Novartis Canada, a pharmaceutical company name was mentioned in the
grant section.

Dyer 2008 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised, concealed allocation with a 1:1 ratio, in blocks of 4. 
Blinding: not clear. 
Duration: 8 weeks. 
Design: single centre, parallel group.

Diagnosis: schizophrenia or schizoaffective disorder of depressed type.  
Duration of illness: not mentioned. 
N=20. 
Age: mean age - 44.3 (11.9) years, in galantamine group; mean age - 50.5 (4.7) years, in placebo. 
Sex: M and F. 
Setting: outpatients. 
Inclusion criteria: stable, adult outpatients with schizophrenia or schizoaffective disorder depressed
type, had been on stable dose of antipsychotic medication for at least 8 weeks. 
Exclusion Criteria: participants who were taking an anticholinergic medication or who reported use of
an illicit  drug or nicotine containing product in the past 3 months or who had expired carbon monox-
ide > 9ppm.

1. Galantamine plus antipsychotic: dose up to 16 mg twice daily, N = 10 
2. Placebo plus antipsychotic: N = 10.

Mental state: PANSS, SANS, CDSS. 
Leaving the study early. 
Cognitive functioning: Neuropsychological tests. 
Adverse events. 
Unable to use: AIMS, SAS, Barnes Akathisia Scales.

Two participants left the study; data of these two candidates were included in the LOCF analysis. Both
the participants and trialists were blind to the intervention.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information available.

Allocation concealment
(selection bias)

Unclear risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Blinding (performance
bias and detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

No information available.

Low risk

LOCF analysis was performed.

High risk

Not all outcomes were reported.

Other bias

Unclear risk

There is a mention of drug company affiliation.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Fagerlund 2007 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Allocation: randomised. 
Blindness: double blind. 
Duration: 16 weeks. 
Design: multi-centre parallel group.

Diagnosis: schizophrenia using SCAN 2.1 interview, (ICD-10). 
Duration of illness: 1 to 17 years. 
N = 11. 
Age: 23 to 43 years. 
Sex: M and F. 
Setting: inpatients and outpatients. 
Inclusion criteria: schizophrenic patients, patients on ziprasidone. 
Exclusion criteria: treatment refractory patients.

1. Donepezil: dose up to 10 mg/day plus ziprasidone. N = 7. 
2. Placebo plus ziprasidone. N = 4.

Mental state - PANSS, CDS. 
Global functioning - CGI, GAF. 
Cognitive functioning. 
Leaving the study early. 
Adverse events. 
Unable to use: Cognitive functioning.

SSRIs and BZD were allowed through out the study. Patients were treated with ziprasidone for a mini-
mum duration of eight weeks and were thereafter randomised to four-month double blind adjunctive
treatment with donepezil or placebo. The total number of participants at the start of the trial were 21,
10 had to be excluded but it was not clear how many were excluded from each group. Both the partici-
pants and trialists were blinded to the intervention.

Authors' judgement

Support for judgement

High risk

No information available.

High risk

No information available.

Low risk

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

No mention about the data for the patients who left the study early for various
reasons.

Low risk

All outcomes were measured and reported.

Other bias

Unclear risk

Supported by Pfizzer Denmark.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Freudenreich 2005 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised. 
Blindness: double blind. 
Duration: 8 weeks. 
Design: multi-site parallel group.

Diagnosis: schizophrenia (DSM-IV). 
Duration of illness: average 25 years (range 13 to 4113-41 years). 
N = 36. 
Age: average - 48.7 years (range 24 to 64 years). 
Sex: M and F. 
Setting: Inpatient and outpatient. 
Inclusion criteria: patients with schizophrenia, stable on an antipsychotic medication. 
Exclusion criteria: patients with active substance use disorder, any cognitive disorder, on antipsy-
chotics that are strongly anticholinergic, e.g. clozapine.

1. Donepezil:dose up to 10 mg/day plus antipscyhotic.N = 19. 
2. Placebo plus antipsychotic.N = 17.

Adverse events: SARS, BARS, AIMS. 
Leaving the study early. 
Cognitive functioning:cognitive battery of tests. 
Mental state: PANSS,SANS,CDSS. 
Unable to use: Mental state: PANSS, SANS, CDSS. 
Adverse events: SARS, BARS, AIMS.

Four participants did not finish the 8-week trial, leaving 32 study completers. Not clear which group
they left from. One participant left the study from the intervention group. Donepezil and placebo were
prepared in identical appearing tablets.The most commonly used antipsychotic was olanzapine fol-
lowed by risperidone.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Iden-
tical appearing tablets were used, effectiveness of this method was not men-
tioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

LOCF analysis was performed.

High risk

Not all the outcomes were reported.

Other bias

High risk

Sponsored by Pfizer.

Friedman 2002c 

Methods

Allocation: randomised in 1:1 fashion. 

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Friedman 2002c  (Continued)

Participants

Duration: 12 weeks. 
Blinding: double blind. 
Design: multi-centre, parallel group study.

Diagnosis: schizophrenia (DSM-IV). 
N = 36. 
Age: mean age - 48.8 (11.1) years, intervention group; mean age - 50.3 (10.1) years, placebo. 
Duration of illness: donepezil group = 25.9 (13.9), placebo = 26.9 (9.6). 
Gender: M and F. 
Setting: inpatient and outpatient. 
Inclusion criteria: on stable dose of risperidone, 4-week symptom stability, minimum level of cognition
impairment as performance on learning trials 1 to 5 on the CVLT. 
Exclusion criteria: if they had any medical diagnoses or were receiving medications that may have
affected cognitive performance or if they were abusing substances within 6 months of entry into the
study.

Interventions

Outcomes

1. Donepezil: dose up to 10 mg/day plus risperidone = 18. 
2. Placebo plus risperidone = 18.

Leaving the study early. 
Mental state: PANSS. 
Cognitive functioning: battery of tests. 
Adverse events: ESRS. 
Unable to use: PANSS, ESRS, battery of neuropsychological tests.

Notes

Mean daily dose of risperidone was 6.4 mg and 5.9 mg.

Ten participants were randomised to receive 5 mg/day of donepezil for the entire 12 weeks, while 8
patients had their dose of donepezil increased to 10 mg per day for the last 8 weeks of the study. Thir-
ty-four participants completed the entire protocol. Two participants in the donepezil 10 mg group ter-
minated early from the study shortly after the dose increase due to increased agitation and uncooper-
ativeness with study procedures, but both were able to complete midpoint (week 4) cognitive assess-
ments. ITT was done. Both the participants and trialists were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Unclear risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Low risk

ITT analysis was performed.

High risk

Not all outcomes were reported.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Other bias

High risk

Funding was provided by Janssen Research Foundation.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Keefe 2008a 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Allocation: randomised with 1:1 ratio, computer generated. 
Blinding: double. 
Duration: 12 weeks. 
Design: placebo controlled, multi-centre study with two parallel groups.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
Duration of illness:mean age -18.0 years, donepezil; mean age - 14.8 years, placebo. 
Age: 18 to 55 years. 
Gender: M and F. 
N: 245 
Setting: outpatients. 
Inclusion criteria: clinically stable for at least 6 months, on a second generation antipsychotic medica-
tion, have a minimal cognitive impairment as performed on BACS, have minimum of 6th grade reading
level. 
Exclusion criteria: no history of DSM-IV defined substance abuse or dependence, any diagnosis on
DSM-IV of axis I psychiatric disorder, risk of suicide, violent behaviour, history of seizure, previous use
of cholinesterase inhibitors, on anticholinergics, antiparkinsonian medication or on typical antipsy-
chotics.

1.Donepezil: dose up to 10 mg/day plus second generation antipsychotic.N = 121. 
2.Placebo plus second generation antipsychotic.N = 124.

Mental state: PANSS, MADRS. 
Adverse events: AIMS, BAS, SAS. 
Leaving the study early. 
Cognitive functioning. 
Unable to use: Cognitive functioning, Mental state, Adverse events.

All results shown were derived from the ITT sample. For LOCF analysis there were no significant differ-
ence between the treatment group. Film-coated tablets were used. Use of adjunctive anticholinergic
medications for emergent EPSE's was not permitted. Both the participants and trialists were blinded to
the intervention.

Authors' judgement

Support for judgement

Low risk

Stratified randomisation with 1:1 ratio, computer generated.

Unclear risk

No information available.

Unclear risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Low risk

ITT and LOCF data analysis was performed.

Low risk

All outcomes measured and reported.

Other bias

High risk

It was supported and funded by Eisai Inc and Pfizer Inc.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kim 2005b 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised in a 1:1 pattern. 
Blinding: double blind. 
Duration: 12 week. 
Design: single centre, parallel group study.

Diagnosis: schizophrenia (DSM-IV). 
Duration of illness: mean age (13.1) years, donepezil group; mean age - (15.9) years, placebo. 
Age: mean age - 44.2 years. 
N = 24. 
Gender: M and F. 
Setting: inpatients. 
Inclusion criteria: participants to be stabilised on current dose of haloperidol for a minimum period
of 3 months. The level of cognitive impairment required for participation was defined as a total perfor-
mance score between 15 and 24 on the K-MMSE. 
Exclusion criteria: who had history of CNS-stimulating drug misuse, clinically significant physical ab-
normalities.

1. Donepezil: dose up to 5 mg/day plus haloperidol = 12. 
2. Placebo plus haloperidol = 12.

Adverse events. 
Mental state: BPRS. 
Leaving the study early. 
Global functioning: CGI-I. 
Cognitive functioning: Neuropsychological tests. 
Unable to use: BPRS, CGI-I, neuropsychological tests.

Antiparkinsonian, anticholinergics and benzodiazepines were allowed if their dose did not change dur-
ing the previous 12 weeks. One patient dropped out from intervention group after week 8. No serious
adverse reported that would have led to participant withdrawal. Both the participants and trialists
were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

Randomised in 1:1 pattern.

Unclear risk

Randomised in 1:1 pattern.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

No mention of ITT or LOCF.

Unclear risk

Not enough information available.

Other bias

Unclear risk

Was funded in part by Inje university, Busan, South Korea.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kohler 2007 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Allocation: randomised 
Blindness: double blind 
Duration: 12 weeks 
Design: not specified.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
Duration of illness: less than 10 years. 
Age: 18 to 40 years. 
N = 26. 
Setting: outpatients. 
Gender: 18 M and 8 F. 
Inclusion criteria: clinically stable during the last 3 months, Brief Psychiatric Rating Scale score of?
35.All treated with second generation antipsychotics at standard daily dosages. Participants were not
treated with clozapine, antidepressants, mood stabilisers, benzodiazepines or anticholinergics. 
Exclusion criteria: not clearly specified.

1. Donepezil: dose up to 10mg/day plus second generation=11. 
2. Placebo plus second generation antipsychotic. N=11.

Cognitive functioning: neurocognitive, social cognition. 
Leaving the study early. 
Mental state: PANSS, HAM-D. 
Adverse events 
Unable to use: PANSS, HAM-D. 
Adverse events.

Four participants, two on donepezil and two on placebo dropped out of the trial. Reasons included
stopping the medication for unspecific reasons (n=2), agitation and dizziness. Both the participants
and trialists were blind to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

No ITT or LOCF analyses were performed.

Unclear risk

Not enough information available.

Other bias

Unclear risk

No information available.

Lee 2005 

Methods

Allocation: randomised. 

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lee 2005  (Continued)

Participants

Blindness: double blind. 
Duration: 12 weeks. 
Design: uni-centre.

Diagnosis: schizophrenia (DSM-IV). 
Duration of illness: mean - 15.8 (5.7) years, intervention group; mean - 18.8 (7.2) years, placebo. 
N = 24. 
Age: mean age - 39.5 (3.2) years, intervention group; mean age - 41.5 (3.2) years, placebo group. 
Sex: M and F. 
Setting: inpatients. 
Inclusion criteria: patients stabilised on antipsychotics, total performance score between 18 and 24 on
KMMSE. 
Exclusion criteria: patients with any acute medical conditions or taking medications that would have
affected their cognition.

Interventions

Outcomes

1. Galantamine: dose up to 16 mg/day plus antipsychotic = 12. 
2. Placebo plus antipsychotic = 12.

Mental state: BPRS, HAM-D. 
Global functioning: CGI-Severity and improvement scale. 
Adverse events. 
Cognitive functioning. 
Unable to use: Mental state, Global functioning.

Notes

Antiparkinsonian anticholinergics and benzodiazepine drugs were permitted if the dose did not change
during the previous 12 weeks.

Two patients dropped out from the galantamine group. LOCF analysis was performed. Both the partici-
pants and trialists were blinded to the intervention.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

LOCF analysis was performed.

Unclear risk

Not enough information available.

Other bias

Unclear risk

No information available.

Nahas 2003 

Methods

Allocation: randomised. 
Blindness: double blind 

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nahas 2003  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Duration: 12 weeks. 
Design: uni-centre, cross-over.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
Duration of illness: not mentioned. 
Age: 22 to 53 years. 
N = 6. 
Sex: Male. 
Settings: outpatients. 
Include: patients stable on antipsychotic medication.

1.Donepezil: dose up to 10 mg/day plus antipsychotic.N = 3. 
2.Placebo plus antipsychotic.N = 3.

Mental state: PANSS. 
Cognitive functioning: VFT. 
Leaving the study early.

Both the participants and trialists were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

All patients completed the study.

Unclear risk

Not enough information available.

Other bias

High risk

Mention of the name of few pharmaceutical companies.

Schubert 2006 

Methods

Participants

Allocation: randomised. 
Blinding: double. 
Duration: 8 weeks. 
Design: not specified.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
Duration of illness: not specified. 
N = 16. 
Age: 26 to 55 years. 
Sex = 16 M and 1 F. 
Setting = not specified. 

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schubert 2006  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria = participants with history of intolerance to cholinesterase inhibitors/ substance de-
pendence, use of anticholinergic medication.

1. Galanatmine: dose 8 to 24 mg/day plus risperidone: dose 4 to 6 mg/day. N = 8. 
2. Placebo plus risperidone: dose 4 to 6 mg/day. N = 8.

Cognitive functioning: RBANS. 
Mental state: PANSS 
Side effects. 
Adverse events: AIMS, SAS. CGI.

Three patients from the placebo wing left the study earlier. LOCF was performed. Both the participants
and trialists were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

LOCF analysis was performed.

Low risk

All outcomes measured were reported.

Other bias

Unclear risk

No information available.

Sharma 2006 

Methods

Participants

Allocation: randomised. 
Blindness: double blind.  
Duration: 24 weeks.

Diagnosis:  schizophrenia or schizoaffective disorder (DSM-IV).  
Duration of illness: 17.45(8.58), rivastigmine;16.50 (12.57), placebo. 
N = 20. 
Age: 18 to 60 years. 
Sex: M and F. 
Setting: inpatients and outpatients. 
Inclusion criteria: receiving stable treatment with an atypical antipsychotic and have stable psychotic
symptoms, no adjunctive anticholinergic treatment required since initiation of the antipsychotic, nega-
tive urine screening for illicit drugs and negative pregnancy test for female patients, cooperative, able
to ingest oral medication and willing to undertake repeated cognitive testing, able to provide written
informed consent, reading ability of not more than 40 errors on National Adult Reading Test, between 1

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sharma 2006  (Continued)

Cochrane Database of Systematic Reviews

and 2 SD below expected performance on the basis of age and education level on the California Vernal
Learning Test.

1. Rivastigmine: dose up to 12 mg/day plus other second generation antipsychotic = 11.     
2. Placebo plus other second generation antipsychotic = 10.        

Mental state: PANSS 
Cognitive functioning: neuropsychological tests. 
Leaving the study early. 
Adverse events: AIMS, SAS, BARS. 
Unable to use: Cognition.

Both groups received identical appearing capsules.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

LOCF analysis was performed.

Unclear risk

Insufficient information..

Other bias

Unclear risk

Not much information available.

Tugal 2003 

Methods

Participants

Allocation: randomised. 
Blindness: double blind. 
Duration: 12 weeks. 
Design: uni-centre, cross-over.

Diagnosis: schizophrenia (DSM-IV). 
Duration of illness: 16 ± 9.0 years. 
N = 12. 
Age: 18 to 45 years. 
Sex: M and F. 
Setting: outpatients. 
Inclusion criteria: patients on high potency typical antipsychotics. Stable for 3 months, minimum edu-
cation of high school graduation.

Interventions

1.Donepezil:dose up to 5 mg/day plus antipsychotic.N = 6. 
2.Antipsychotic plus placebo. N = 6.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tugal 2003  (Continued)

Outcomes

Mental state: PANSS,CDS 
Cognitive functioning.

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

All participants completed the study.Treatment was well tolerated. Both the participants and trialists
were blinded to the intervention.

Authors' judgement

Support for judgement

Unclear risk

No information available.

Unclear risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

All participants completed the study.

Low risk

All outcomes were measured and reported.

Other bias

Unclear risk

Linked with pharmaceutical company-Pfizer.

Tuma 2003 

Methods

Participants

Allocation: randomised. 
Blinding: double blind. 
Duration: 16 weeks. 
Design: not specified.

Diagnosis: schizophrenia (ICD-10). 
Duration of illness: not specified. 
Age: average - 32 years ± 8.6 years. 
N: 16. 
Sex: not specified. 
Setting: outpatients. 
Inclusion criteria: patients stabilized on risperidone monotherapy, cognitive deficit in at least one do-
main of cognitive functioning.

Exclusion criteria: psychiatric or somatic co-morbidity, history of alcohol or drug abuse, ECT during
previous 6 months, administration of depot neuroleptics during previous 3 months.

Interventions

Outcomes

1. Donepezil: dose up to 10 mg/day plus risperidone = 9. 
2. Placebo and risperidone = 7.

Mental state: PANSS. 
Adverse events: BARS, SARS. 
Cognitive functioning: Neuropsychological tests.

Notes

Both the participants and trialists were blinded to the intervention.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tuma 2003  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

High risk

No information available.

High risk

No information available.

Blinding (performance
bias and detection bias) 
All outcomes

Low risk

Both the participants and investigators were blinded to the intervention. Effec-
tiveness of this method was not mentioned.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Drop-outs were not included.

High risk

All outcome measures were not reported.

Other bias

Unclear risk

Not much information available.

Diagnostic tools:
DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.
ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.
BMI - Body Mass Index.
Rating Scales:
Global rating scales:
GAF - Global Assessment of Functioning
CGI - Clinical Global Impressions.
CGI-S - Clinical Global Impression-Severity.
CGI-I - Clinical Global Impression-Improvement.
HAM-D - Hamilton Depression Rating Scale
Mental state:
BPRS - Brief Psychiatric Rating Scale.
MADRS - Montgomery-Asberg Depression Rating Scale.
MMSE - Wiing Mini Mental State Examination.
PANSS - Positive and Negative Syndrome Scale.
SANS - Scale for the Assessment of Negative Symptoms.
CDSS - Calgary Depression Severity Scale.
Cognition:RBANS - Repeatable Battery for the Assessment of Neuropsychological Status
WMS III- Welsch Memory Scale Edition III.
WAIS III - Welsch Adult Intelligence Scale
VFT - Verbal Fluency Test

Side effects:
AIMS - Abnormal Involuntary Movement Scale.
BARS - Barnes Akathisia Rating Scale.
BMI - Body mass index.
EPS- Extrapyramidal symptoms.
ESRS - Extrapyramidal Syndrome Rating Scale.
HAS - Hillside Akathisia Scale.
SAS - Simpson-Angus Index - for neurological side effects.
QoL - Quality of Life Scale.
SWN -Subjective Well-being List.
Other:
CNS - central nervous system

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ECG - electrocardiogram
ECT - electroconvulsive therapy
ITT - intention-to-treat
LOCF - last observation carried forward

Characteristics of excluded studies [ordered by study ID]

Study

Davis 1981

Reason for exclusion

Allocation: randomised. 
Participants: normal people.

Edelstein 1981

Allocation: non randomised.

El-Yousef 1973

Allocation: non randomised.

Ingram 1983

Allocation: non randomised.

Janowsky 1972

Allocation: non randomised.

Kristiansen 2001

Lieberman 1988

Allocation: randomised. 
Participants: normal people.

Allocation: randomised. 
Participants: people with tardive dyskinesia. No mention of schizophrenia or schizoaffective disor-
der.

Mazeh 2006

Allocation: randomised, cross-over. 
Participants:elderly patients with diagnosis of schizophrenia and dementia.

Moore 1980

Allocation: non randomised.

NCT00566735

Okereke 2002

Ophir 2004

Allocation: randomised. 
Participants: patients with diagnosis of major depression, bipolar depression, schizoaffective dis-
order-depressed type.

Allocation: randomised,double blind, cross-over. 
Participants: patients with Parkinson's disease.

Allocation: randomised. 
Participants: patients receiving ECT.

Pesco-Koplowitz 2000c

Allocation: randomised. 
Participants: normal, healthy participants

Risch 1981

Risch 2001

Stryjer 2004a

Allocation: non randomised.

Allocation: non randomised.

Allocation: randomised. 
Participants: patients with schizophrenia. 
Design: cross-over design. 
Intervention: donepezil plus clozapine versus placebo plus clozapine. 
Outcome: no usable data.

Tamminga 1977

Allocation: randomised. 
Participants: patients with tardive dyskinesia.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Characteristics of studies awaiting assessment [ordered by study ID]

Fleming 2003 

Methods

randomised,double blind,placebo controlled.

Participants

Participants were 60 patients with diagnosis of schizophrenia,

Interventions

memantine plus donepezil

Outcomes

Notes

PANSS,CGI-S,Cognitive battery

full version not found,authors contacted.

Hussain 2003 

Methods

Participants

Interventions

Outcomes

Randomised, cross over, double blind.

Participants were 39 patients, 16 males and 23 females, aged 
20-58 years (mean = 38.03), with a duration of illness of six 
to 30 years, (mean = 15.84) and two to 11 years of taking 
clozapine (mean 5.38), two to five years of taking 
olanzapine (mean = 3.19), or two to seven years of taking 
risperidone (mean = 4.73).

double-blind, placebo-controlled trial of rivastigmine (1.5 mg bid) and galantamine (3 mg bid) as
adjunctive treatment in stable 
schizophrenic patients with cognitive impairment receiving 
clozapine, risperidone, or olanzapine.

Positive and Negative Syndrome Scale for Schizophrenia (PANSS) 
Quality of life 
Cognitive function 
Employment outcomes 
Educational achievement 
Treatment attrition 
Smoking abstinence

Notes

Awaiting more information from authors for clarification.

Kelleher 2008 

Methods

randomised,double blind trial

Participants

patients with schizophrenia or schizoaffective disorder.

Interventions

Galantamine up to dose of 24mg/day.

Outcomes

Notes

BPRS,SCANS,Cognition.

Full paper not available,authors are not contactable.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Modestin 1973 

Methods

Participants

Interventions

Outcomes

Notes

bid: twice daily

Paper in non English language, awaiting translation.

Characteristics of ongoing studies [ordered by study ID]

Ball 2005 

Trial name or title

Efficacy study of Galantamine for cognitive impairment in schizophrenia.

Methods

Treatment, Randomized, Double-Blind, Placebo Control,Parallel design.

Participants

120 participants with a diagnosis of schizophrenia or schizoaffective disorder.

Interventions

Galantamine and Placebo.

Outcomes

Cognitive functions. 
Mental state. 
Side effects.

Starting date

May 2002.

Contact information

ClinicalTrials.gov

Notes

ClinicalTrials.gov Identifier:NC00176423

Evins 2006 

Trial name or title

Galantamine for Cognition in People With Schizophrenia.

Methods

Treatment, Randomized, Double-Blind, Placebo Control.

Participants

Twenty adult participants,aged 18-60.

Interventions

Galatamine and Placebo.

Outcomes

Improvement from baseline in performance on the cognitive battery: Stroop, 
Cornblatt CPT-IP, CDR Battery, letter number span, Grooved peg board, 
Tower of London, and Signal Detection Task.

Improvement from baseline in negative symptoms (SANS), depressive 
symptoms (CDSS) and impulsivity (PANSS aggression item).

Starting date

January 2004.

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Evins 2006  (Continued)

Contact information

North Suffolk Mental Health Association 
Janssen Medical Affairs.

Notes

ClinicalTrials.gov Identifier: NCT00320736.

Gaskins 2007 

Trial name or title

Methods

Participants

The Use of Galantamine and CDP-Choline to Treat Adults With 
Schizophrenia(STAR 1).

Randomized, Double-Blind, Placebo Control.

Adults age 18-70 years,mixed gender,meets DSM-IV criteria for schizophrenia or schizoaffective dis-
order

Interventions

Galantamine and CDP-choline in improving symptoms associated with schizophrenia.

Outcomes

Clinical Global Impression (CGI) 
Positive and Negative Syndrome Scale for Schizophrenia (PANSS) 
Memory 
Safety 
Urinalysis 
Electrocardiogram (ECG) 
Efficacy 
Negative symptoms 
Blood samples 
Processing speed 
Side effects 
Concentration 
Attention 
Nicotine use 
Cognitive Test

Starting date

September 2007

Contact information

ClinicalTrials.gov

Notes

ClinicalTrials.gov identifier NCT00509067

George 2007 

Trial name or title

Galantamine for Cognitive Deficits in Schizophrenia

Methods

Treatment, Randomized, Double-Blind, Placebo Control, 
Parallel Assignment, Safety/Efficacy Study

Participants

Adults between 18 to 65 years of age,mixed gender ,schizophrenic smokers and non smokers.

Interventions

Galantamine and Placebo.

Outcomes

Positive and Negative Syndrome Scale for Schizophrenia (PANSS) 
Hamilton Depression Scale (HAM-D / HDRS) 
Extrapyramidal symptoms 
Cognitive function 

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

George 2007  (Continued)

Safety 
Prepulse inhibition 
VIG - sustained attention 
Adverse events 
Efficacy 
Neurocognitive functioning 
Neurocognitive tests 
Spatial working memory test 
Cognitive Test

Starting date

September 2007

Contact information

ClinicalTrials.gov

Notes

ClinicalTrials.gov identifier NCT00463879

Glenthoj 2005 

Trial name or title

Methods

Participants

Cholinergic Augmentation of Cognitive Deficits 
in Schizophrenia

Randomized, Double-Blind, Placebo Control, 
Parallel Assignment, Efficacy Study

Men and women between the ages 18 to 55 who meet 
the ICD-10 criteria for schizophrenia and healthy men and women.

Interventions

Donepezil (5-10 mg/day), Ziprasidone (flexible doses),Placebo

Outcomes

PANSS (Positive and Negative Symptom Scale) 
CGI (Clinical Global Impression scale) 
ESRS (Extrapyramidal Symptom Rating Scale) 
Cognitive functions: A comprehensive test battery focuses on 
central cognitive deficits in schizophrenia: i.e. memory functions, 
attention, executive functions, reaction time, as well as pre- 
morbid and current intelligence. 

Secondary Outcome Measures: 
• MRI 
• fMRI

Starting date

December 2002

Contact information

ClinicalTrials.gov Identifier,Center for Neuropsychiatric Schizophrenia Research (CNSR)

Notes

ClinicalTrials.gov Identifier: NCT00206947

Johnson 2004 

Trial name or title

Methods

A study of the effectiveness and safety of Galantamine on cognitive impairment in patients with
schizophrenia.

Treatment, Randomized, Double-Blind, Placebo Control, 
Single Group Assignment, Safety/Efficacy Study

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Johnson 2004  (Continued)

Participants

Patients with a diagnosis of schizophrenia.

Interventions

Galantamine and Placebo.

Outcomes

Cognitive functions. 
Mental state. 
Side effects.

Starting date

March 2003.

Contact information

ClinicalTrials.gov

Notes

ClinicalTrials.gov identifier NCT00077727.

Nachshoni 2007 

Trial name or title

Donepezil Double Blind Trial for ECT Memory Disfunction

Methods

Participants

Interventions

Randomized, Double-Blind, Placebo Control,Parallel Assignment, Efficacy Study

Age:between 18 to 60 years 
Gender:mixed 
Diagnosis:schizophrenia or schizoaffective disorder-DSM-IV

1.Donepezil 
2.Placebo

Outcomes

memory and neurocognitive measures will be examined

Starting date

May 2007

Contact information

ClinicalTrials.gov

Notes

ClinicalTrials.gov identifier NCT00465283

D A T A   A N D   A N A L Y S E S

Comparison 1.   Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Global effect: 1a. Medium-term - Aver-
age end point score on various outcomes

1.1 CGI-severity (low = favourable)

2 Global effect: 1b. Medium-term - Aver-
age end point score on CGI improvement

1

1

1

11

11

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.46 [-0.15, 1.07]

Mean Difference (IV, Ran-
dom, 95% CI)

0.57 [-0.50, 1.64]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 CGI-improvement (high = favourable)

1

11

3 Global effect : 1c. Short-term - Average
change score on CGI (high = favourable)

4 Leaving the study early

11

4.1 Adverse event: Short-term

4.2 Any reason: Short-term

4.3 Deterioration in mental state: 1a.
Short-term

4.4 Deterioration in mental state: 1b.
Medium-term

4.5 Lost to follow up: Short-term

4.6 Protocol violation: Short-term

4.7 Unwilling to participate further in the
study: Short-term

4.8 Due to intercurrent medical illness:
Short-term

5 Mental State: 1a. Average end point
score on various outcomes - PANSS (low =
favourable)

5.1 Short-term - PANSS total end point
score (low = favourable)

5.2 Short-term - PANSS positive end point
score (low = avourable)

5.3 Short-term - PANSS negative end
point score (low = favourable)

5.4 Short-term - PANSS general psy-
chopathology end point score (low =
favourable)

6 Mental state:1b.Average end point
score on various outcomes-PANSS (medi-
um-term)

6

9

2

1

1

2

1

2

2

2

1

1

1

2

428

513

103

17

245

262

245

122

18

12

12

12

Mean Difference (IV, Ran-
dom, 95% CI)

0.57 [-0.50, 1.64]

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.91 [0.80, 4.61]

Risk Ratio (M-H, Random,
95% CI)

0.87 [0.59, 1.28]

Risk Ratio (M-H, Random,
95% CI)

0.66 [0.09, 5.10]

Risk Ratio (M-H, Random,
95% CI)

2.18 [0.10, 46.92]

Risk Ratio (M-H, Random,
95% CI)

1.02 [0.26, 4.01]

Risk Ratio (M-H, Random,
95% CI)

0.25 [0.04, 1.43]

Risk Ratio (M-H, Random,
95% CI)

1.02 [0.30, 3.45]

Risk Ratio (M-H, Random,
95% CI)

2.91 [0.31, 27.07]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

3.29 [-8.82, 15.40]

Mean Difference (IV, Ran-
dom, 95% CI)

1.5 [-4.44, 7.44]

Mean Difference (IV, Ran-
dom, 95% CI)

3.50 [-3.66, 10.66]

Mean Difference (IV, Ran-
dom, 95% CI)

1.80 [-4.81, 8.41]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.1 Medium-term - PANSS total end point
score (low = favourable)

6.2 Medium-term - PANSS positive end
point score (low = favourable)

6.3 Medium-term - PANSS negative end
point score (low = favourable)

6.4 Medium-term - PANSS general psy-
chopathology end point score (low =
favourable)

7 Mental State: 2. Short-term - Aver-
age end point score on HAM-D (low =
favourable)

8 Mental State: 3. Short-term - Aver-
age end point score on SANS (low =
favourable)

9 Mental state: 4a. Short-term - Aver-
age end point score on CDSS (low =
favourable)

10 Mental State: 4b. Medium-term - Av-
erage end point score on CDSS (low =
favourable)

11 Mental State: 5. Short-term - Average
change score on PANSS (low = favourable)

11.1 total

11.2 positive

11.3 negative

12 General functioning: Medium-term -
average end point score on GAF

12.1 GAF (high = favourable)

13 Cognitive function: 1. Short-term - Av-
erage end point score on KMMSE (high =
favourable)

14 Cognitive function: 2. Short-term - Av-
erage end point score on various sub-
scales of WMS-III (high = favourable)

14.1 Digit span forward

2

2

2

2

1

1

1

1

2

2

2

31

31

31

31

30

20

11

11

48

36

Mean Difference (IV, Ran-
dom, 95% CI)

-4.32 [-11.56, 2.92]

Mean Difference (IV, Ran-
dom, 95% CI)

0.65 [-0.12, 1.43]

Mean Difference (IV, Ran-
dom, 95% CI)

-1.69 [-2.80, -0.57]

Mean Difference (IV, Ran-
dom, 95% CI)

-3.86 [-5.40, -2.32]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.60 [-1.82, 0.62]

Mean Difference (IV, Ran-
dom, 95% CI)

-5.0 [-21.33, 11.33]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

Other data

Other data

No numeric data

No numeric data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

4.60 [-5.88, 15.08]

Mean Difference (IV, Ran-
dom, 95% CI)

4.60 [-5.88, 15.08]

Mean Difference (IV, Ran-
dom, 95% CI)

1.29 [-0.18, 2.77]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.68, -0.10]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.2 Digit span backward

14.3 Figural memory test

14.4 Visual reproduction 1

14.5 Visual reproduction 2

14.6 Verbal paired associates 1

14.7 Verbal paired associates 2

14.8 Logical memory 1

14.9 Logical memory 2

15 Cognitive function: 3. Short-term - Av-
erage end point score on various sub-
scales of of WAIS III (high = favourable)

15.1 Block design

15.2 Letter number sequencing

15.3 Digit symbol score

15.4 Symbol search score

15.5 Letter number span without reorder-
ing

15.6 Letter number span with ordering

16 Cognitive function: 4. Short-term - Av-
erage end point score on various sub-
scales of HVLT (high = favourable)

16.1 Immediate recall

16.2 Delayed recall

2

1

1

1

1

1

1

1

3

1

1

1

1

1

1

2

1

1

36

12

12

12

12

12

12

12

12

73

73

73

20

20

24

24

Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-1.35, -0.02]

Mean Difference (IV, Ran-
dom, 95% CI)

1.30 [-0.74, 3.34]

Mean Difference (IV, Ran-
dom, 95% CI)

1.30 [-5.21, 7.81]

Mean Difference (IV, Ran-
dom, 95% CI)

-1.5 [-8.69, 5.69]

Mean Difference (IV, Ran-
dom, 95% CI)

-3.20 [-7.28, 0.88]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.60 [-1.92, 0.72]

Mean Difference (IV, Ran-
dom, 95% CI)

-4.60 [-12.72, 3.52]

Mean Difference (IV, Ran-
dom, 95% CI)

-4.60 [-13.26, 4.06]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

3.10 [-9.71, 15.91]

Mean Difference (IV, Ran-
dom, 95% CI)

0.60 [-0.48, 1.68]

Mean Difference (IV, Ran-
dom, 95% CI)

1.20 [0.14, 2.26]

Mean Difference (IV, Ran-
dom, 95% CI)

0.30 [-0.92, 1.52]

Mean Difference (IV, Ran-
dom, 95% CI)

-1.60 [-4.19, 0.99]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.5 [-3.27, 2.27]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

3.0 [-0.76, 6.76]

Mean Difference (IV, Ran-
dom, 95% CI)

1.5 [-0.20, 3.20]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.3 Recognition

17 Cognitive function: 5. Short-term -
Average end point score on VFT (high =
favourable)

17.1 Verbal fluency

18 Cognitive function: 6. Short-term - Av-
erage end point score on BVST (high =
favourable)

18.1 Brief Visuospatial Memory Test

19 Cognitive function: 7. Short-term - Av-
erage end point score on various sub-
scales of Stroop test

19.1 Stroop letter end point score (high =
favourable)

19.2 Stroop color end point score (high =
favourable)

19.3 Stroop Interference T end point
score (low = favourable)

20 Cognitive function: 7. Short-term - Av-
erage end point score on Trail making
tests A & B (high = favourable)

20.1 Trail making A

20.2 Trail making B

21 Cognitive function: 8. Short-term - Av-
erage end point score on CPT

21.1 CPT - Reaction time (high =
favourable)

21.2 CPT - Random errors (low =
favourable)

22 Cognitive function: 9. Short-term - Av-
erage end point score on Grooved peg-
board test ( high = favourable)

22.1 Grooved pegboard - Average pegs

2

3

3

1

1

2

1

1

1

2

2

1

1

1

1

2

2

48

42

42

73

73

24

24

20

48

36

12

20

20

93

93

Mean Difference (IV, Ran-
dom, 95% CI)

1.79 [0.62, 2.96]

Mean Difference (IV, Ran-
dom, 95% CI)

3.46 [0.67, 6.26]

Mean Difference (IV, Ran-
dom, 95% CI)

3.46 [0.67, 6.26]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.5 [-1.42, 0.42]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.5 [-1.42, 0.42]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.5 [-12.15, 9.15]

Mean Difference (IV, Ran-
dom, 95% CI)

17.10 [0.70, 33.50]

Mean Difference (IV, Ran-
dom, 95% CI)

-2.60 [-6.68, 1.48]

Mean Difference (IV, Ran-
dom, 95% CI)

-5.53 [-30.67,
19.61]

Mean Difference (IV, Ran-
dom, 95% CI)

-11.83 [-44.14,
20.49]

Mean Difference (IV, Ran-
dom, 95% CI)

16.40 [-32.33,
65.13]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-5.20 [-70.74,
60.34]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-1.71, 1.31]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-3.11, 2.53]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-3.11, 2.53]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

23 Cognitive function: 10. Short-term - Av-
erage end point score on various scales
(skewed data)

23.1 ROCFT-Immediate recall ( high =
favourable)

23.2 ROCFT-Delayed recall (high =
favourable)

23.3 ROCFT-Recognition (high =
favourable)

23.4 WAIS III-Letter number span without
reordering (high = favourable)

23.5 WAIS III-Letter number span with re-
ordering (high = favourable)

23.6 WCST-Categories completed (high =
favourable)

23.7 WCST-Perseverative errors (low =
favourable)

23.8 Visual paired associates 1 (high =
favourable)

23.9 CPT-random errors (low =
favourable)

23.10 Stroop Interfernece Test (low =
favourable)

23.11 Visual paired associates 2 (high =
favourable)

24 Cognitive function: 11a. Short-term -
Average change score on various scales
(skewed data)

24.1 RAVLT-Delayed recall (high =
favourable)

24.2 CPT-Omission of errors (low =
favourable)

24.6 RAVLT-total word list learning (high =
favourable)

24.9 CPT (high = favourable)

24.12 RBANS total score (high =
favourable)

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

Other data

No numeric data

No numeric data

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

25 Cognitive function: 11b. Medium-term
- Average change score on various scales
(skewed data)

25.1 Category fluency test (high =
favourable)

25.2 Trail making test A-time (high =
favourable)

25.3 Stroop test-interference index (low =
favourable)

25.4 Logical memory (high = favourable)

25.5 Wisconsin Card Sorting Test-perse-
verative errors (low = favourable)

25.6 Wisconsin Card Sorting-number of
completed categories (high = favourable)

25.7 Rey Osterrieth Complex Figure Test
(high = favourable)

25.8 Verbal pair Association-global score
(high = favourable)

26 Adverse event: 1a. Short-term - Central
nervous system

26.1 Dizziness

26.2 Sialorrhea

26.3 Headache

26.4 Insomnia

26.5 Somnolence

26.6 Deterioration in mental state: 1b.
Medium-term

27 Adverse event: 1b. Medium-term - Cen-
tral nervous system

28 Adverse event: 2. Short-term - Meta-
bolic and nutritional

6

4

1

2

2

1

1

1

3

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

Other data

No numeric data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.76 [0.30, 1.94]

Risk Ratio (M-H, Random,
95% CI)

6.30 [0.35, 113.81]

Risk Ratio (M-H, Random,
95% CI)

0.52 [0.24, 1.12]

Risk Ratio (M-H, Random,
95% CI)

0.47 [0.19, 1.20]

Risk Ratio (M-H, Random,
95% CI)

0.44 [0.12, 1.66]

Risk Ratio (M-H, Random,
95% CI)

2.18 [0.10, 46.92]

Risk Ratio (M-H, Random,
95% CI)

1.88 [0.09, 37.63]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

379

36

269

269

245

17

11

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28.1 Weight loss

28.2 Glucose

29 Adverse event: 3. Short-term - Deterio-
ration in menal state

30 Adverse event: 4. Short-term - Bio-
chemical abnormalities

30.1 Creatine kinase

31 Adverse event: 5. Short-term - Non
specific

31.1 Severe AE

31.2 Serious AE

31.3 Relapse of alcohol

31.4 Muscle cramp

31.5 Agitation and uncooperativeness

32 Adverse event: 6. Short-term - Cardio-
vascular

33 Adverse event: 7. Short-term - Gas-
trointestinal

33.1 Vomiting

33.2 Abdomial pain and diarrhoea

33.3 Diarrhoea

33.4 Nausea

33.5 Any

2

1

2

1

1

5

1

1

1

2

1

1

6

4

1

4

3

1

102

245

102

245

245

245

86

44

36

245

371

24

309

293

245

Risk Ratio (M-H, Random,
95% CI)

0.54 [0.04, 6.96]

Risk Ratio (M-H, Random,
95% CI)

0.46 [0.14, 1.44]

Risk Ratio (M-H, Random,
95% CI)

0.63 [0.08, 4.86]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.17 [0.44, 3.13]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.41, 2.11]

Risk Ratio (M-H, Random,
95% CI)

1.02 [0.37, 2.83]

Risk Ratio (M-H, Random,
95% CI)

3.14 [0.13, 74.98]

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.52, 17.20]

Risk Ratio (M-H, Random,
95% CI)

5.00 [0.26, 97.37]

Risk Ratio (M-H, Random,
95% CI)

0.51 [0.23, 1.15]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.79 [0.25, 2.48]

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.13, 67.06]

Risk Ratio (M-H, Random,
95% CI)

1.23 [0.56, 2.70]

Risk Ratio (M-H, Random,
95% CI)

1.12 [0.45, 2.78]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.58, 1.46]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

34 Adverse event: 9. Short-term - Respira-
tory system

34.1 Pneumonia

35 Adverse event: 10. Medium-term -
EPSE

36 Adverse event: 11a. Short-term - Aver-
age end point score on EPSEs scale (low =
favourable)

36.1 AIMS

37 Adverse event: 11b. Medium-term - Av-
erage end point score on EPSEs scale (low
= favourable)

37.1 SAS

38 Adverse event: 12a. Short-term - Aver-
age end point score on EPSEs scale (low =
favourable)

1

1

1

1

1

1

1

38.1 SARS

38.2 AIMS

38.3 ESRS

39 Adverse event: 12b. Medium-term - Av-
erage end point score on EPSEs scales
(skewed data)

39.1 AIMS

39.4 BARS

40 Adverse event: 13. Short-term - Av-
erage change score on EPSEs scales
(skewed data)

40.1 AIMS

40.2 SAS

41 Adverse event: 14. Short-term - Aver-
age change interval on ECG (skewed data)

41.1 PR interval

41.2 QRS interval

86

11

35

21

21

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

3.14 [0.13, 74.98]

Risk Ratio (M-H, Random,
95% CI)

4.38 [0.28, 68.06]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

1.5 [1.04, 1.96]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.38, 0.06]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.38, 0.06]

Other data

No numeric data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

Other data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

No numeric data

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

41.3 QTc interval

Other data

No numeric data

42 Behaviour: 15. Short-term - Smoking
(low = favourable)

42.1 Expired CO measures

42.2 FTND intervew score

1

1

1

41

41

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.10 [-6.25, 6.45]

Mean Difference (IV, Ran-
dom, 95% CI)

1.50 [0.09, 2.91]

Analysis 1.1.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 1 Global effect: 1a. Medium-term - Average end point score on various outcomes.

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.1.1 CGI-severity (low = favourable)

Fagerlund 2007

Subtotal ***

3.7 (0.5)

7

7

3.3 (0.5)

4

4

Heterogeneity: Not applicable

Test for overall effect: Z=1.49(P=0.14)

100%

100%

0.46[-0.15,1.07]

0.46[-0.15,1.07]

Favours ACHI & AP

-1

-0.5

0

0.5

1

Favours Placebo & AP

Analysis 1.2.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 2 Global effect: 1b. Medium-term - Average end point score on CGI improvement.

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.2.1 CGI-improvement (high = favourable)

Fagerlund 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.04(P=0.3)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.04(P=0.3)

7

7

7

2 (0.8)

2.6 (1)

4

4

4

100%

100%

0.57[-0.5,1.64]

0.57[-0.5,1.64]

100%

0.57[-0.5,1.64]

Favours Placebo and AP

-5

-2.5

0

2.5

5

Favours ACHI and AP

Analysis 1.3.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 3 Global effect : 1c. Short-term - Average change score on CGI (high = favourable).

Study

Intervention

Mean change

SD

N

Global effect : 1c. Short-term - Average change score on CGI (high = favourable)

Schubert 2006

Schubert 2006

ACHI & AP

AP & Placebo

-.57

.0

.78

.6

8

6

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 4 Leaving the study early.

Study or subgroup

ACHI & An-
tipsychotic

n/N

Placebo and
Antipsychotic

n/N

1.4.1 Adverse event: Short-term

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Buchanan 2008

Dyer 2008

Friedman 2002c

Keefe 2008a

Lee 2005

Schubert 2006

Subtotal (95% CI)

3/42

1/10

2/18

6/121

1/12

0/8

211

2/44

0/10

0/18

3/124

0/12

1/9

217

Total events: 13 (ACHI & Antipsychotic), 6 (Placebo and Antipsychotic)

Heterogeneity: Tau2=0; Chi2=1.72, df=5(P=0.89); I2=0%

Test for overall effect: Z=1.45(P=0.15)

1.4.2 Any reason: Short-term

Buchanan 2008

Caroff 2007

Dyer 2008

Friedman 2002c

Keefe 2008a

Kim 2005b

Kohler 2007

Lee 2005

Schubert 2006

Subtotal (95% CI)

7/42

3/17

1/10

2/18

6/44

9/18

1/10

0/18

23/121

27/124

1/12

2/13

2/12

0/8

253

0/12

2/13

0/12

3/9

260

Total events: 41 (ACHI & Antipsychotic), 48 (Placebo and Antipsychotic)

Heterogeneity: Tau2=0; Chi2=7.65, df=8(P=0.47); I2=0%

Test for overall effect: Z=0.7(P=0.49)

1.4.3 Deterioration in mental state: 1a. Short-term

Buchanan 2008

Schubert 2006

Subtotal (95% CI)

1/42

0/8

50

Total events: 1 (ACHI & Antipsychotic), 2 (Placebo and Antipsychotic)

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=0.4(P=0.69)

1.4.4 Deterioration in mental state: 1b. Medium-term

Tuma 2003

Subtotal (95% CI)

1/10

10

Total events: 1 (ACHI & Antipsychotic), 0 (Placebo and Antipsychotic)

1/44

1/9

53

0/7

7

25.51%

1.57[0.28,8.94]

8.08%

8.75%

41.5%

7.99%

8.17%

100%

14.68%

11.69%

2.14%

1.68%

60.13%

1.54%

4.56%

1.72%

1.86%

100%

3[0.14,65.9]

5[0.26,97.37]

2.05[0.52,8.01]

3[0.13,67.06]

0.37[0.02,7.99]

1.91[0.8,4.61]

1.22[0.45,3.34]

0.35[0.11,1.09]

1[0.07,13.87]

5[0.26,97.37]

0.87[0.53,1.43]

3[0.13,67.06]

1[0.16,6.07]

5[0.27,94.34]

0.16[0.01,2.67]

0.87[0.59,1.28]

55.69%

44.31%

100%

1.05[0.07,16.21]

0.37[0.02,7.99]

0.66[0.09,5.1]

100%

100%

2.18[0.1,46.92]

2.18[0.1,46.92]

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

1.4.5 Lost to follow up: Short-term

Keefe 2008a

Subtotal (95% CI)

4/121

121

4/124

124

100%

100%

1.02[0.26,4.01]

1.02[0.26,4.01]

Total events: 4 (ACHI & Antipsychotic), 4 (Placebo and Antipsychotic)

Favours ACHI & AP

0.2

0.5

1

2

5

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & An-
tipsychotic

n/N

Placebo and
Antipsychotic

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.04(P=0.97)

1.4.6 Protocol violation: Short-term

Keefe 2008a

Schubert 2006

Subtotal (95% CI)

1/121

0/8

129

5/124

1/9

133

67.47%

32.53%

100%

0.2[0.02,1.73]

0.37[0.02,7.99]

0.25[0.04,1.43]

Total events: 1 (ACHI & Antipsychotic), 6 (Placebo and Antipsychotic)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.76); I2=0%

Test for overall effect: Z=1.56(P=0.12)

1.4.7 Unwilling to participate further in the study: Short-term

Keefe 2008a

Subtotal (95% CI)

5/121

121

5/124

124

Total events: 5 (ACHI & Antipsychotic), 5 (Placebo and Antipsychotic)

Heterogeneity: Not applicable

Test for overall effect: Z=0.04(P=0.97)

1.4.8 Due to intercurrent medical illness: Short-term

Buchanan 2008

Freudenreich 2005

Subtotal (95% CI)

1/42

1/19

61

0/44

0/17

61

Total events: 2 (ACHI & Antipsychotic), 0 (Placebo and Antipsychotic)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=0.94(P=0.35)

100%

100%

1.02[0.3,3.45]

1.02[0.3,3.45]

49.42%

50.58%

100%

3.14[0.13,74.98]

2.7[0.12,62.17]

2.91[0.31,27.07]

Favours ACHI & AP

0.2

0.5

1

2

5

Favours Placebo & AP

Analysis 1.5.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 5 Mental State: 1a. Average end point score on various outcomes - PANSS (low = favourable).

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.5.1 Short-term - PANSS total end point score (low = favourable)

Nahas 2003

Tugal 2003

Subtotal ***

70 (13.3)

62.7 (11.3)

3

6

9

71.6 (16.9)

57.8 (13.3)

3

6

9

Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%

Test for overall effect: Z=0.53(P=0.59)

1.5.2 Short-term - PANSS positive end point score (low = avourable)

Tugal 2003

Subtotal ***

14.2 (5.3)

6

6

12.7 (5.2)

6

6

Heterogeneity: Not applicable

Test for overall effect: Z=0.49(P=0.62)

1.5.3 Short-term - PANSS negative end point score (low = favourable)

Tugal 2003

Subtotal ***

6

6

17 (8)

6

6

13.5 (4)

24.77%

75.23%

100%

-1.6[-25.94,22.74]

4.9[-9.06,18.86]

3.29[-8.82,15.4]

100%

100%

1.5[-4.44,7.44]

1.5[-4.44,7.44]

100%

100%

3.5[-3.66,10.66]

3.5[-3.66,10.66]

Favours ACHI & AP

-50 -25

0

25

50

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.96(P=0.34)

1.5.4 Short-term - PANSS general psychopathology end point score (low =
favourable)

Tugal 2003

Subtotal ***

31.5 (5.1)

6

6

29.7 (6.5)

6

6

Heterogeneity: Not applicable

Test for overall effect: Z=0.53(P=0.59)

100%

100%

1.8[-4.81,8.41]

1.8[-4.81,8.41]

Favours ACHI & AP

-50 -25

0

25

50

Favours Placebo & AP

Analysis 1.6.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 6 Mental state:1b.Average end point score on various outcomes-PANSS (medium-term).

Study or subgroup

ACHI & AP

Placebo & AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.6.1 Medium-term - PANSS total end point score (low = favourable)

Fagerlund 2007

Sharma 2006

Subtotal ***

49.1 (9.3)

43.4 (11.2)

7

11

18

52.5 (9.1)

48.3 (10.3)

4

9

13

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.83); I2=0%

Test for overall effect: Z=1.17(P=0.24)

1.6.2 Medium-term - PANSS positive end point score (low = favourable)

Fagerlund 2007

Sharma 2006

Subtotal ***

10.8 (1.3)

9.8 (0.7)

7

11

18

10.8 (2.8)

9.1 (1.1)

4

9

13

Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%

Test for overall effect: Z=1.65(P=0.1)

1.6.3 Medium-term - PANSS negative end point score (low = favourable)

Fagerlund 2007

Sharma 2006

Subtotal ***

14.7 (3.5)

10.5 (1.4)

7

11

18

4

9

13

16.5 (4)

12.2 (1.2)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%

Test for overall effect: Z=2.96(P=0)

1.6.4 Medium-term - PANSS general psychopathology end point score (low =
favourable)

Fagerlund 2007

Sharma 2006

Subtotal ***

23.5 (5.1)

23 (1.8)

7

11

18

4

9

13

25.2 (5)

27 (1.8)

Heterogeneity: Tau2=0; Chi2=0.5, df=1(P=0.48); I2=0%

Test for overall effect: Z=4.91(P<0.0001)

41.21%

58.79%

100%

-3.4[-14.68,7.88]

-4.97[-14.41,4.47]

-4.32[-11.56,2.92]

7.15%

92.85%

100%

0.05[-2.86,2.96]

0.7[-0.11,1.51]

0.65[-0.12,1.43]

5.64%

94.36%

100%

-1.8[-6.5,2.9]

-1.68[-2.83,-0.53]

-1.69[-2.8,-0.57]

6.2%

93.8%

100%

-1.7[-7.89,4.49]

-4[-5.59,-2.41]

-3.86[-5.4,-2.32]

Favours ACHI and AP

-2

-1

0

1

2

Favours Placebo and AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 7 Mental State: 2. Short-term - Average end point score on HAM-D (low = favourable).

Study or subgroup

ACHI & AP

Placebo & AP

Akhondzadeh 2008

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.96(P=0.34)

Mean(SD)

7.6 (1.9)

N

15

15

Mean(SD)

8.2 (1.5)

N

15

15

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.6[-1.82,0.62]

100%

-0.6[-1.82,0.62]

Favours ACHI & AP

-5

-2.5

0

2.5

5

Favours Placebo & AP

Analysis 1.8.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 8 Mental State: 3. Short-term - Average end point score on SANS (low = favourable).

Study or subgroup

ACHI & AP

ACHI & Placebo

N

Mean(SD)

N

Mean(SD)

10

65.4 (16.3)

10

70.4 (20.7)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-5[-21.33,11.33]

Dyer 2008

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.6(P=0.55)

10

10

100%

-5[-21.33,11.33]

Favours ACHI & AP

-100

-50

0

50

100

Favours Placebo & AP

Analysis 1.9.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 9 Mental state: 4a. Short-term - Average end point score on CDSS (low = favourable).

Study

Intervention

Mean

SD

N

Mental state: 4a. Short-term - Average end point score on CDSS (low = favourable)

Dyer 2008

Dyer 2008

Tugal 2003

Tugal 2003

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

3.6

6.9

2.7

2.7

3.3

5.2

1.8

2.4

10

10

6

6

Analysis 1.10.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 10 Mental State: 4b. Medium-term - Average end point score on CDSS (low = favourable).

Study

Intervention

Mean

SD

N

Mental State: 4b. Medium-term - Average end point score on CDSS (low = favourable)

Fagerlund 2007

Fagerlund 2007

ACHI & AP

placebo & AP

1.71

3.25

2.13

4.57

7

4

Analysis 1.11.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 11 Mental State: 5. Short-term - Average change score on PANSS (low = favourable).

Mental State: 5. Short-term - Average change score on PANSS (low = favourable)

Study

Intervention

Mean change

total

SD

N

Schubert 2006

ACHI & AP

-12.2

14.4

8

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Intervention

Mean change

SD

N

Mental State: 5. Short-term - Average change score on PANSS (low = favourable)

Schubert 2006

AP & Placebo

Schubert 2006

Schubert 2006

Schubert 2006

Schubert 2006

ACHI & AP

AP & PLacebo

ACHI & AP

AP & Placebo

positive

negative

-13.5

-4.3

-4.0

-3.3

-2.5

4.7

6.0

4.2

4.4

2.9

6

8

6

8

6

Analysis 1.12.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 12 General functioning: Medium-term - average end point score on GAF.

Study or subgroup

ACHI & AP

Placebo & AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.12.1 GAF (high = favourable)

Fagerlund 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.86(P=0.39)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.86(P=0.39)

7

7

7

64.1 (11.6)

59.5 (6.1)

4

4

4

100%

100%

4.6[-5.88,15.08]

4.6[-5.88,15.08]

100%

4.6[-5.88,15.08]

Favours Placebo & AP

-100

-50

0

50

100

Favours ACHI & AP

Analysis 1.13.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 13 Cognitive function: 1. Short-term - Average end point score on KMMSE (high = favourable).

Study or subgroup

ACHI & AP

Placebo and AP

Kim 2005b

Lee 2005

Total ***

N

Mean(SD)

N

Mean(SD)

25.1 (3.5)

25.2 (2.1)

12

12

24

22.7 (3.7)

24.3 (2.2)

12

12

24

Heterogeneity: Tau2=0; Chi2=0.77, df=1(P=0.38); I2=0%

Test for overall effect: Z=1.72(P=0.09)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

26.29%

73.71%

2.4[-0.48,5.28]

0.9[-0.82,2.62]

100%

1.29[-0.18,2.77]

Favours Placebo & AP

-2

-1

0

1

2

Favours ACHI & AP

Analysis 1.14.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 14 Cognitive function: 2. Short-
term - Average end point score on various subscales of WMS-III (high = favourable).

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.14.1 Digit span forward

Lee 2005

12

4.9 (0.9)

12

5.9 (1.3)

78.34%

-1[-1.89,-0.11]

Favours Placebo & AP

-1

-0.5

0

0.5

1

Favours ACHI & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Tugal 2003

Subtotal ***

7.3 (1.4)

6

18

Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%

Test for overall effect: Z=2.21(P=0.03)

1.14.2 Digit span backward

Lee 2005

Tugal 2003

Subtotal ***

2.8 (0.7)

5.3 (2.6)

12

6

18

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%

Test for overall effect: Z=2.02(P=0.04)

1.14.3 Figural memory test

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.25(P=0.21)

1.14.4 Visual reproduction 1

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

1.14.5 Visual reproduction 2

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.41(P=0.68)

1.14.6 Verbal paired associates 1

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.54(P=0.12)

1.14.7 Verbal paired associates 2

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.89(P=0.37)

1.14.8 Logical memory 1

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.11(P=0.27)

1.14.9 Logical memory 2

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

6

6

6

6

6

6

6

6

6

6

6

6

6

6

8.3 (1.9)

34.5 (3.8)

32.2 (8.1)

18.8 (4.5)

7.2 (1.6)

22.7 (6.5)

20.2 (7.6)

7.8 (1.6)

3.5 (1)

5.8 (1.6)

7 (1.7)

33.2 (7.2)

33.7 (3.9)

22 (2.4)

7.8 (0.4)

27.3 (7.8)

24.8 (7.7)

6

18

12

6

18

6

6

6

6

6

6

6

6

6

6

6

6

6

6

Cochrane Database of Systematic Reviews

Weight

Mean Difference

21.66%

100%

Random, 95% CI

-0.5[-2.2,1.2]

-0.89[-1.68,-0.1]

92.6%

7.4%

100%

-0.7[-1.39,-0.01]

-0.5[-2.94,1.94]

-0.69[-1.35,-0.02]

100%

100%

1.3[-0.74,3.34]

1.3[-0.74,3.34]

100%

100%

1.3[-5.21,7.81]

1.3[-5.21,7.81]

100%

100%

-1.5[-8.69,5.69]

-1.5[-8.69,5.69]

100%

100%

-3.2[-7.28,0.88]

-3.2[-7.28,0.88]

100%

100%

-0.6[-1.92,0.72]

-0.6[-1.92,0.72]

100%

100%

-4.6[-12.72,3.52]

-4.6[-12.72,3.52]

100%

100%

-4.6[-13.26,4.06]

-4.6[-13.26,4.06]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

Favours Placebo & AP

-1

-0.5

0

0.5

1

Favours ACHI & AP

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=1.04(P=0.3)

Favours Placebo & AP

-1

-0.5

0

0.5

1

Favours ACHI & AP

Analysis 1.15.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 15 Cognitive function: 3. Short-term
- Average end point score on various subscales of of WAIS III (high = favourable).

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.15.1 Block design

Tugal 2003

Subtotal ***

30.8 (12)

6

6

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.47(P=0.64)

1.15.2 Letter number sequencing

Buchanan 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

1.15.3 Digit symbol score

Buchanan 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.21(P=0.03)

1.15.4 Symbol search score

Buchanan 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.48(P=0.63)

35

35

35

35

35

35

8.1 (2.2)

6.7 (2.7)

6.2 (3.1)

1.15.5 Letter number span without reordering

Dyer 2008

Subtotal ***

10

10

12 (3)

Heterogeneity: Not applicable

Test for overall effect: Z=1.21(P=0.23)

1.15.6 Letter number span with ordering

Dyer 2008

Subtotal ***

8.9 (3.4)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=0.35(P=0.72)

27.7 (10.6)

7.5 (2.5)

5.5 (1.8)

5.9 (2.1)

13.6 (2.9)

9.4 (2.9)

6

6

38

38

38

38

38

38

10

10

10

10

100%

100%

3.1[-9.71,15.91]

3.1[-9.71,15.91]

100%

100%

0.6[-0.48,1.68]

0.6[-0.48,1.68]

100%

100%

1.2[0.14,2.26]

1.2[0.14,2.26]

100%

100%

0.3[-0.92,1.52]

0.3[-0.92,1.52]

100%

100%

-1.6[-4.19,0.99]

-1.6[-4.19,0.99]

100%

100%

-0.5[-3.27,2.27]

-0.5[-3.27,2.27]

Favours Placebo & AP

-2

-1

0

1

2

Favours ACHI & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.16.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 16 Cognitive function: 4. Short-
term - Average end point score on various subscales of HVLT (high = favourable).

Study or subgroup

ACHI & AP

Placebo & AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.16.1 Immediate recall

Lee 2005

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.57(P=0.12)

1.16.2 Delayed recall

Lee 2005

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.73(P=0.08)

1.16.3 Recognition

Kim 2005b

Lee 2005

Subtotal ***

17.3 (3.4)

5.3 (1.8)

9.4 (1.4)

7.3 (2.2)

12

12

12

12

12

12

24

14.3 (5.7)

3.8 (2.4)

7.5 (2)

5.8 (3.2)

12

12

12

12

12

12

24

Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%

Test for overall effect: Z=2.99(P=0)

100%

100%

3[-0.76,6.76]

3[-0.76,6.76]

100%

100%

1.5[-0.2,3.2]

1.5[-0.2,3.2]

71.67%

28.33%

100%

1.9[0.52,3.28]

1.5[-0.7,3.7]

1.79[0.62,2.96]

Favours Placebo & AP

-5

-2.5

0

2.5

5

Favours ACHI & AP

Analysis 1.17.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 17 Cognitive function: 5. Short-term - Average end point score on VFT (high = favourable).

Study or subgroup

ACHI & AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.17.1 Verbal fluency

Lee 2005

Nahas 2003

Tugal 2003

Subtotal ***

14.6 (4.5)

29 (12)

29.3 (12.6)

12

3

6

21

Heterogeneity: Tau2=0; Chi2=1.3, df=2(P=0.52); I2=0%

Test for overall effect: Z=2.43(P=0.01)

Total ***

21

Heterogeneity: Tau2=0; Chi2=1.3, df=2(P=0.52); I2=0%

Test for overall effect: Z=2.43(P=0.01)

10.6 (2.6)

29.5 (5)

31.2 (5.8)

12

3

6

21

21

90.08%

3.6%

6.32%

100%

4[1.06,6.94]

-0.5[-15.21,14.21]

-1.9[-13,9.2]

3.46[0.67,6.26]

100%

3.46[0.67,6.26]

Favours Placebo & AP

-20

-10

0

10

20

Favours ACHI & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.18.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 18 Cognitive function: 6. Short-term - Average end point score on BVST (high = favourable).

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.18.1 Brief Visuospatial Memory Test

Buchanan 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.06(P=0.29)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.06(P=0.29)

35

35

35

5.3 (2.3)

4.8 (1.7)

38

38

38

100%

100%

-0.5[-1.42,0.42]

-0.5[-1.42,0.42]

100%

-0.5[-1.42,0.42]

Favours Placebo & AP

-50

-25

0

25

50

Favours ACHI & AP

Analysis 1.19.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 19 Cognitive function: 7. Short-term - Average end point score on various subscales of Stroop test.

Study or subgroup

ACHI and AP

AP and Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.19.1 Stroop letter end point score (high = favourable)

Lee 2005

Subtotal ***

103.4 (16)

12

12

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

1.19.2 Stroop color end point score (high = favourable)

Lee 2005

Subtotal ***

66.3 (25.8)

12

12

Heterogeneity: Not applicable

Test for overall effect: Z=2.04(P=0.04)

104.9 (9.9)

49.2 (13.2)

12

12

12

12

1.19.3 Stroop Interference T end point score (low = favourable)

Dyer 2008

Subtotal ***

50.4 (3.1)

10

10

10

10

53 (5.8)

Heterogeneity: Not applicable

Test for overall effect: Z=1.25(P=0.21)

100%

100%

-1.5[-12.15,9.15]

-1.5[-12.15,9.15]

100%

100%

17.1[0.7,33.5]

17.1[0.7,33.5]

100%

100%

-2.6[-6.68,1.48]

-2.6[-6.68,1.48]

Favours Placebo & AP

-20

-10

0

10

20

Favours ACHI & AP

Analysis 1.20.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 20 Cognitive function: 7. Short-
term - Average end point score on Trail making tests A & B (high = favourable).

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.20.1 Trail making A

Lee 2005

Tugal 2003

12

6

82 (32.3)

47.5 (28.4)

12

6

112.8 (52.3)

45 (12.4)

32.6%

47.03%

-30.8[-65.58,3.98]

2.5[-22.3,27.3]

Favours Placebo & AP

-2

-1

0

1

2

Favours ACHI & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI and AP

Placebo and AP

Subtotal ***

Mean(SD)

N

18

N

18

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

79.64%

-11.83[-44.14,20.49]

Heterogeneity: Tau2=316.98; Chi2=2.33, df=1(P=0.13); I2=57.17%

Test for overall effect: Z=0.72(P=0.47)

113.7 (55.4)

1.20.2 Trail making B

Tugal 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

Total ***

6

6

24

Heterogeneity: Tau2=189.78; Chi2=3.21, df=2(P=0.2); I2=37.62%

Test for overall effect: Z=0.43(P=0.67)

Test for subgroup differences: Chi2=0.9, df=1 (P=0.34), I2=0%

97.3 (25.3)

6

6

24

20.36%

20.36%

16.4[-32.33,65.13]

16.4[-32.33,65.13]

100%

-5.53[-30.67,19.61]

Favours Placebo & AP

-2

-1

0

1

2

Favours ACHI & AP

Analysis 1.21.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 21 Cognitive function: 8. Short-term - Average end point score on CPT.

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.21.1 CPT - Reaction time (high = favourable)

Dyer 2008

Subtotal ***

550.5 (77.9)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=0.16(P=0.88)

1.21.2 CPT - Random errors (low = favourable)

Dyer 2008

Subtotal ***

-3.6 (1.4)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=0.26(P=0.8)

555.7 (71.5)

-3.4 (2)

10

10

10

10

100%

100%

-5.2[-70.74,60.34]

-5.2[-70.74,60.34]

100%

100%

-0.2[-1.71,1.31]

-0.2[-1.71,1.31]

Favours Placebo & AP

-1

-0.5

0

0.5

1

Favours ACHI & AP

Analysis 1.22.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic
versus placebo plus antipsychotic, Outcome 22 Cognitive function: 9. Short-
term - Average end point score on Grooved pegboard test ( high = favourable).

Study or subgroup

ACHI and AP

Placebo and AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.22.1 Grooved pegboard - Average pegs

Buchanan 2008

Dyer 2008

Subtotal ***

110.9 (38.9)

15.9 (3.1)

35

10

45

114.7 (38.6)

16.1 (3.4)

38

10

48

Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%

Test for overall effect: Z=0.2(P=0.84)

2.5%

97.5%

100%

-3.8[-21.6,14]

-0.2[-3.05,2.65]

-0.29[-3.11,2.53]

Favours Placebo and AP

-4

-2

0

2

4

Favours ACHI and AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI and AP

Placebo and AP

Total ***

Mean(SD)

N

45

N

48

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.29[-3.11,2.53]

Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%

Test for overall effect: Z=0.2(P=0.84)

Favours Placebo and AP

-4

-2

0

2

4

Favours ACHI and AP

Analysis 1.23.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 23 Cognitive function: 10. Short-term - Average end point score on various scales (skewed data).

Study

Intervention

Mean

SD

N

Cognitive function: 10. Short-term - Average end point score on various scales (skewed data)

Lee 2005

Lee 2005

Lee 2005

Lee 2005

Lee 2005

Lee 2005

Dyer 2008

Dyer 2008

Dyer 2008

Dyer 2008

Tugal 2003

Tugal 2003

Tugal 2003

Tugal 2003

Tugal 2003

Tugal 2003

Dyer 2008

Dyer 2008

Dyer 2008

Dyer 2008

Tugal 2003

Tugal 2003

ACHI and AP

Placebo & AP

ACHI and AP

Placebo & AP

ACHI and AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ROCFT-Immediate recall ( high = favourable)

13.4

8.0

8.4

6.0

ROCFT-Delayed recall (high = favourable)

13.0

8.5

8.3

5.4

ROCFT-Recognition (high = favourable)

6.4

3.9

2.1

2.3

WAIS III-Letter number span without reordering (high = favourable)

12

13.6

3

2.9

WAIS III-Letter number span with reordering (high = favourable)

8.9

8.7

3.4

2.5

WCST-Categories completed (high = favourable)

2.7

3.3

1.8

2.9

WCST-Perseverative errors (low = favourable)

21.7

18.3

9.1

13.3

Visual paired associates 1 (high = favourable)

10.8

14.3

6.4

5.4

CPT-random errors (low = favourable)

ACHI & Placebo

Placebo & AP

-3.6

-3.4

1.4

2.0

ACHI & AP

AP & Placebo

ACHI & AP

Placebo & AP

Stroop Interfernece Test (low = favourable)

50.4

48.5

3.1

3.2

Visual paired associates 2 (high = favourable)

3.8

5.7

2.4

0.8

12

12

12

12

12

10

10

10

10

6

6

6

6

6

6

10

10

10

10

6

6

Analysis 1.24.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 24 Cognitive function: 11a. Short-term - Average change score on various scales (skewed data).

Study

Intervention

Mean change

SD

N

Cognitive function: 11a. Short-term - Average change score on various scales (skewed data)

RAVLT-Delayed recall (high = favourable)

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Intervention

Mean change

SD

N

Cognitive function: 11a. Short-term - Average change score on various scales (skewed data)

Friedman 2002c

Friedman 2002c

Schubert 2006

Schubert 2006

Friedman 2002c

Friedman 2002c

Friedman 2002c

Friedman 2002c

Schubert 2006

Schubert 2006

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

1.5

1.6

2.6

4.4

CPT-Omission of errors (low = favourable)

-3.8

-1.7

5.2

3.4

RAVLT-total word list learning (high = favourable)

6.5

7.4

.42

.03

CPT (high = favourable)

8.8

12

.57

.46

RBANS total score (high = favourable)

12.1

-.5

12.8

7.3

8

18

8

6

9

9

8

18

8

6

Analysis 1.25.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 25 Cognitive function: 11b. Medium-term - Average change score on various scales (skewed data).

Study

Intervention

Mean change

SD

N

Cognitive function: 11b. Medium-term - Average change score on various scales (skewed data)

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

Tuma 2003

ACHI & AP

Placebo and AP

ACHI & AP

Placebo and AP

ACHI & AP

Placebo and AP

ACHI & AP

Placebo & AP

Category fluency test (high = favourable)

-7.4

-3.6

9.9

10.5

Trail making test A-time (high = favourable)

14.7

13.3

15.4

14.3

Stroop test-interference index (low = favourable)

12.1

8.0

Logical memory (high = favourable)

-10.6

-8.3

17.1

7.3

5.6

8.1

Wisconsin Card Sorting Test-perseverative errors (low = favourable)

ACHI & AP

Placebo and AP

3.3

6.1

4.8

25.2

Wisconsin Card Sorting-number of completed categories (high = favourable)

ACHI & AP

Placebo and AP

-0.2

-0.6

1.1

3.4

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

Rey Osterrieth Complex Figure Test (high = favourable)

-2.4

2.8

2.8

4.0

Verbal pair Association-global score (high = favourable)

-5.0

-8.4

7.9

10.7

9

7

9

7

9

7

9

7

9

7

9

7

9

7

9

7

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.26.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 26 Adverse event: 1a. Short-term - Central nervous system.

Study or subgroup

Experimental

1.26.1 Dizziness

Akhondzadeh 2008

Buchanan 2008

Keefe 2008a

Lee 2005

Subtotal (95% CI)

n/N

3/12

1/42

3/121

2/12

187

Total events: 9 (Experimental), 12 (Control)

Heterogeneity: Tau2=0.1; Chi2=3.35, df=3(P=0.34); I2=10.32%

Test for overall effect: Z=0.57(P=0.57)

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/12

0/44

7/124

4/12

192

17.91%

8.34%

40.54%

33.21%

100%

3[0.36,24.92]

3.14[0.13,74.98]

0.44[0.12,1.66]

0.5[0.11,2.23]

0.76[0.3,1.94]

1.26.2 Sialorrhea

Freudenreich 2005

Subtotal (95% CI)

Total events: 3 (Experimental), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.25(P=0.21)

3/19

19

0/17

17

100%

100%

6.3[0.35,113.81]

6.3[0.35,113.81]

1.26.3 Headache

Keefe 2008a

Lee 2005

Subtotal (95% CI)

8/121

1/12

133

14/124

4/12

136

Total events: 9 (Experimental), 18 (Control)

Heterogeneity: Tau2=0; Chi2=0.58, df=1(P=0.45); I2=0%

Test for overall effect: Z=1.67(P=0.09)

1.26.4 Insomnia

Akhondzadeh 2008

Keefe 2008a

Subtotal (95% CI)

1/12

5/121

133

2/12

11/124

136

Total events: 6 (Experimental), 13 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%

Test for overall effect: Z=1.58(P=0.12)

85.75%

14.25%

100%

0.59[0.25,1.35]

0.25[0.03,1.92]

0.52[0.24,1.12]

17.08%

82.92%

100%

0.5[0.05,4.81]

0.47[0.17,1.3]

0.47[0.19,1.2]

1.26.5 Somnolence

Keefe 2008a

Subtotal (95% CI)

Total events: 3 (Experimental), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.21(P=0.22)

3/121

121

7/124

124

100%

100%

0.44[0.12,1.66]

0.44[0.12,1.66]

1.26.6 Deterioration in mental state: 1b. Medium-term

Tuma 2003

Subtotal (95% CI)

1/10

10

0/7

7

Total events: 1 (Experimental), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

100%

100%

2.18[0.1,46.92]

2.18[0.1,46.92]

Favours ACHI & AP

0.5

0.7

1

1.5

2

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.27.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 27 Adverse event: 1b. Medium-term - Central nervous system.

Study or subgroup

ACHI & AP

Placebo & AP

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Fagerlund 2007

Total (95% CI)

1/7

7

0/4

4

Total events: 1 (ACHI & AP), 0 (Placebo & AP)

Heterogeneity: Not applicable

Test for overall effect: Z=0.41(P=0.68)

M-H, Random, 95% CI

100%

1.88[0.09,37.63]

100%

1.88[0.09,37.63]

Favours ACHI & AP

0.01

0.1

1

10

100

Favours Placebo & AP

Analysis 1.28.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 28 Adverse event: 2. Short-term - Metabolic and nutritional.

Study or subgroup

Experimental

1.28.1 Weight loss

Buchanan 2008

Lee 2005

Subtotal (95% CI)

n/N

2/39

1/12

51

Total events: 3 (Experimental), 10 (Control)

Heterogeneity: Tau2=2.14; Chi2=2.4, df=1(P=0.12); I2=58.28%

Test for overall effect: Z=0.47(P=0.64)

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

10/39

0/12

51

63.38%

36.62%

100%

0.2[0.05,0.85]

3[0.13,67.06]

0.54[0.04,6.96]

1.28.2 Glucose

Keefe 2008a

Subtotal (95% CI)

4/121

121

9/124

124

100%

100%

0.46[0.14,1.44]

0.46[0.14,1.44]

Total events: 4 (Experimental), 9 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.34(P=0.18)

ACHI & AP

0.01

0.1

1

10

100

Placebo & AP

Analysis 1.29.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 29 Adverse event: 3. Short-term - Deterioration in menal state.

Study or subgroup

Experimental

Buchanan 2008

Schubert 2006

Total (95% CI)

n/N

1/42

0/8

50

Total events: 1 (Experimental), 2 (Control)

Heterogeneity: Tau2=0; Chi2=0.3, df=1(P=0.58); I2=0%

Test for overall effect: Z=0.44(P=0.66)

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/44

1/8

52

55.58%

44.42%

1.05[0.07,16.21]

0.33[0.02,7.14]

100%

0.63[0.08,4.86]

Favours ACHI & AP

0.01

0.1

1

10

100

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.30.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 30 Adverse event: 4. Short-term - Biochemical abnormalities.

Study or subgroup

ACHI & AP

AP & Placebo

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

1.30.1 Creatine kinase

Keefe 2008a

Subtotal (95% CI)

Total events: 8 (ACHI & AP), 7 (AP & Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.32(P=0.75)

8/121

121

7/124

124

100%

100%

1.17[0.44,3.13]

1.17[0.44,3.13]

Favours ACHI & AP

0.01

0.1

1

10

100

Favours Placebo & AP

Analysis 1.31.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus
placebo plus antipsychotic, Outcome 31 Adverse event: 5. Short-term - Non specific.

Study or subgroup

ACHI & AP

AP & Placebo

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

10/121

121

11/124

124

100%

100%

0.93[0.41,2.11]

0.93[0.41,2.11]

7/121

121

7/124

124

100%

100%

1.02[0.37,2.83]

1.02[0.37,2.83]

1/42

42

3/12

1/10

22

2/18

18

0/44

44

1/12

0/10

22

0/18

18

100%

100%

3.14[0.13,74.98]

3.14[0.13,74.98]

68.05%

31.95%

100%

3[0.36,24.92]

3[0.14,65.9]

3[0.52,17.2]

100%

100%

5[0.26,97.37]

5[0.26,97.37]

Favours ACHI & AP

0.02

0.1

1

10

50

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

1.31.1 Severe AE

Keefe 2008a

Subtotal (95% CI)

Total events: 10 (ACHI & AP), 11 (AP & Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.17(P=0.87)

1.31.2 Serious AE

Keefe 2008a

Subtotal (95% CI)

Total events: 7 (ACHI & AP), 7 (AP & Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.05(P=0.96)

1.31.3 Relapse of alcohol

Buchanan 2008

Subtotal (95% CI)

Total events: 1 (ACHI & AP), 0 (AP & Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.48)

1.31.4 Muscle cramp

Akhondzadeh 2008

Dyer 2008

Subtotal (95% CI)

Total events: 4 (ACHI & AP), 1 (AP & Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%

Test for overall effect: Z=1.23(P=0.22)

1.31.5 Agitation and uncooperativeness

Friedman 2002c

Subtotal (95% CI)

Total events: 2 (ACHI & AP), 0 (AP & Placebo)

Heterogeneity: Not applicable

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & AP

AP & Placebo

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.06(P=0.29)

Favours ACHI & AP

0.02

0.1

1

10

50

Favours Placebo & AP

Analysis 1.32.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus
placebo plus antipsychotic, Outcome 32 Adverse event: 6. Short-term - Cardiovascular.

Study or subgroup

ACHI & AP

AP & Placebo

Risk Ratio

Weight

Risk Ratio

Keefe 2008a

8/121

16/124

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.51[0.23,1.15]

Total (95% CI)

121

124

100%

0.51[0.23,1.15]

Total events: 8 (ACHI & AP), 16 (AP & Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.62(P=0.11)

Favours ACHI & AP

0.02

0.1

1

10

50

Favours Placebo & AP

Analysis 1.33.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus
placebo plus antipsychotic, Outcome 33 Adverse event: 7. Short-term - Gastrointestinal.

Study or subgroup

Ach Inhibitor
+ antipsych

Placebo

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

1.33.1 Vomiting

Akhondzadeh 2008

Buchanan 2008

Keefe 2008a

Lee 2005

Subtotal (95% CI)

1/12

7/39

3/121

0/12

184

1/12

3/39

8/124

2/12

187

Total events: 11 (Ach Inhibitor + antipsych), 14 (Placebo)

Heterogeneity: Tau2=0.5; Chi2=4.79, df=3(P=0.19); I2=37.43%

Test for overall effect: Z=0.4(P=0.69)

1.33.2 Abdomial pain and diarrhoea

Kim 2005b

Subtotal (95% CI)

1/12

12

0/12

12

Total events: 1 (Ach Inhibitor + antipsych), 0 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1.33.3 Diarrhoea

Akhondzadeh 2008

Keefe 2008a

Lee 2005

Schubert 2006

Subtotal (95% CI)

2/12

7/121

3/12

0/8

153

2/12

5/124

2/12

1/8

156

Total events: 12 (Ach Inhibitor + antipsych), 10 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.88, df=3(P=0.83); I2=0%

14.57%

36.86%

36.19%

12.38%

100%

1[0.07,14.21]

2.33[0.65,8.37]

0.38[0.1,1.41]

0.2[0.01,3.77]

0.79[0.25,2.48]

100%

100%

3[0.13,67.06]

3[0.13,67.06]

19.44%

49.62%

24.3%

6.63%

100%

1[0.17,5.98]

1.43[0.47,4.4]

1.5[0.3,7.43]

0.33[0.02,7.14]

1.23[0.56,2.7]

Favours ACHI & AP

0.5

0.7

1

1.5

2

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Ach Inhibitor
+ antipsych

Placebo

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.51(P=0.61)

1.33.4 Nausea

Akhondzadeh 2008

Keefe 2008a

Lee 2005

Subtotal (95% CI)

1/12

7/121

1/12

145

0/12

7/124

1/12

148

Total events: 9 (Ach Inhibitor + antipsych), 8 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%

Test for overall effect: Z=0.24(P=0.81)

8.55%

79.74%

11.72%

100%

3[0.13,67.06]

1.02[0.37,2.83]

1[0.07,14.21]

1.12[0.45,2.78]

1.33.5 Any

Keefe 2008a

Subtotal (95% CI)

26/121

121

29/124

124

100%

100%

0.92[0.58,1.46]

0.92[0.58,1.46]

Total events: 26 (Ach Inhibitor + antipsych), 29 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.36(P=0.72)

Favours ACHI & AP

0.5

0.7

1

1.5

2

Favours Placebo & AP

Analysis 1.34.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus
placebo plus antipsychotic, Outcome 34 Adverse event: 9. Short-term - Respiratory system.

Study or subgroup

Experimental

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.34.1 Pneumonia

Buchanan 2008

Subtotal (95% CI)

Total events: 1 (Experimental), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.48)

1/42

42

0/44

44

100%

100%

3.14[0.13,74.98]

3.14[0.13,74.98]

Favours ACHI & AP

0.01

0.1

1

10

100

Favours Placebo & AP

Analysis 1.35.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus
placebo plus antipsychotic, Outcome 35 Adverse event: 10. Medium-term - EPSE.

Study or subgroup

ACHI AND AP

Placebo and AP

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Fagerlund 2007

Total (95% CI)

3/7

7

0/4

4

Total events: 3 (ACHI AND AP), 0 (Placebo and AP)

Heterogeneity: Not applicable

Test for overall effect: Z=1.05(P=0.29)

M-H, Random, 95% CI

100%

4.38[0.28,68.06]

100%

4.38[0.28,68.06]

Favours ACHI & AP

0.01

0.1

1

10

100

Favours Placebo & AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.36.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 36 Adverse event: 11a. Short-term - Average end point score on EPSEs scale (low = favourable).

Study or subgroup

ACHI & an-
tipsychotic

antipsychotic
and placebo

Mean Difference

Weight

Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.36.1 AIMS

Caroff 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=6.34(P<0.0001)

18

18

9.1 (0.7)

17

17

7.6 (0.7)

100%

100%

1.5[1.04,1.96]

1.5[1.04,1.96]

Favours Placebo & AP

-4

-2

0

2

4

Favours ACHI & AP

Analysis 1.37.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 37 Adverse event: 11b. Medium-term - Average end point score on EPSEs scale (low = favourable).

Study or subgroup

ACHI & AP

Placebo & AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.37.1 SAS

Sharma 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.45(P=0.15)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.45(P=0.15)

11

11

11

0.9 (0.2)

0.7 (0.3)

10

10

10

100%

100%

-0.16[-0.38,0.06]

-0.16[-0.38,0.06]

100%

-0.16[-0.38,0.06]

Favours Placebo & AP

-100

-50

0

50

100

Favours ACHI & AP

Analysis 1.38.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 38 Adverse event: 12a. Short-term - Average end point score on EPSEs scale (low = favourable).

Adverse event: 12a. Short-term - Average end point score on EPSEs scale (low = favourable)

Study

Intervention

Buchanan 2008

Buchanan 2008

Buchanan 2008

Buchanan 2008

Akhondzadeh 2008

Akhondzadeh 2008

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

ACHI & AP

Placebo & AP

Mean

SARS

AIMS

ESRS

1.1

1.6

2.1

1.6

1.53

1.46

1.8

1.9

3.0

3.0

1.06

1.18

SD

N

42

42

42

42

15

15

Analysis 1.39.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus antipsychotic,
Outcome 39 Adverse event: 12b. Medium-term - Average end point score on EPSEs scales (skewed data).

Adverse event: 12b. Medium-term - Average end point score on EPSEs scales (skewed data)

Study

Intervention

Mean

AIMS

SD

N

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Adverse event: 12b. Medium-term - Average end point score on EPSEs scales (skewed data)

Study

Intervention

Sharma 2006

Sharma 2006

Sharma 2006

Sharma 2006

ACHI and AP

Placebo and AP

ACHI & AP

Placebo and AP

Mean

BARS

0.36

0.00

0.36

2.11

0.24

0.00

0.27

0.27

SD

N

11

10

11

10

Analysis 1.40.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 40 Adverse event: 13. Short-term - Average change score on EPSEs scales (skewed data).

Adverse event: 13. Short-term - Average change score on EPSEs scales (skewed data)

Study

Intervention

Schubert 2006

Schubert 2006

Schubert 2006

Schubert 2006

ACHI & AP

AP & Placebo

ACHI & AP

AP & Placebo

Mean change

AIMS

SAS

-2.7

0.2

-3.5

0.0

1.7

-0.7

4.5

2.6

SD

N

8

6

8

6

Analysis 1.41.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo plus
antipsychotic, Outcome 41 Adverse event: 14. Short-term - Average change interval on ECG (skewed data).

Adverse event: 14. Short-term - Average change interval on ECG (skewed data)

Study

Intervention

Buchanan 2008

Buchanan 2008

Buchanan 2008

Buchanan 2008

Buchanan 2008

Buchanan 2008

ACHI & AP

AP & Placebo

ACHI & AP

AP & Placebo

ACHI & AP

AP & Placebo

Mean change

PR interval

QRS interval

QTc interval

25.7

-3.0

11.4

-1.6

3.03

3.03

56.0

12.0

25.1

11.7

28.83

27.68

SD

N

42

44

42

44

42

44

Analysis 1.42.   Comparison 1 Acetylcholinesterase inhibitors plus antipsychotic versus placebo
plus antipsychotic, Outcome 42 Behaviour: 15. Short-term - Smoking (low = favourable).

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.42.1 Expired CO measures

Buchanan 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.03(P=0.98)

1.42.2 FTND intervew score

Buchanan 2008

Subtotal ***

21.1 (10.3)

5.2 (2.2)

18

18

18

18

23

23

23

23

21 (10.3)

3.7 (2.4)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

100%

100%

0.1[-6.25,6.45]

0.1[-6.25,6.45]

100%

100%

1.5[0.09,2.91]

1.5[0.09,2.91]

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

Favours ACHI & AP

-1

-0.5

0

0.5

1

Favours Placebo & AP

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & AP

AP & Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=2.08(P=0.04)

Favours ACHI & AP

-1

-0.5

0

0.5

1

Favours Placebo & AP

Comparison 2.   Acetylcholinesterase inhibitors plus antipsychotics versus antipsychotics alone

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Leaving the study early

1.1 Any reason

1.2 Deterioration in mental
state

1.3 Suicidal ideas

2 Mental state: Short-term -
Average end point score on
PANSS (low = favourable)

2.1 Negative

2.2 Positive

2.3 Disorganisation/cogni-
tive

2.4 Hostility/excitement

2.5 Anxiety/Depressive

2.6 Total

1

1

1

1

1

1

1

1

1

1

1

72

24

24

24

18

18

18

18

18

18

Risk Ratio (M-H, Random, 95% CI)

3.89 [0.69, 22.02]

Risk Ratio (M-H, Random, 95% CI)

7.71 [0.46, 129.18]

Risk Ratio (M-H, Random, 95% CI)

2.57 [0.12, 57.44]

Risk Ratio (M-H, Random, 95% CI)

2.57 [0.12, 57.44]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.60 [-4.14, 2.94]

Mean Difference (IV, Random, 95%
CI)

1.10 [-2.59, 4.79]

Mean Difference (IV, Random, 95%
CI)

0.5 [-2.04, 3.04]

Mean Difference (IV, Random, 95%
CI)

0.20 [-1.56, 1.96]

Mean Difference (IV, Random, 95%
CI)

0.0 [-0.93, 0.93]

Mean Difference (IV, Random, 95%
CI)

1.80 [-4.47, 8.07]

Analysis 2.1.   Comparison 2 Acetylcholinesterase inhibitors plus
antipsychotics versus antipsychotics alone, Outcome 1 Leaving the study early.

Study or subgroup

2.1.1 Any reason

Chouinard 2007

Subtotal (95% CI)

Total events: 4 (ACHI & AP), 0 (AP)

Heterogeneity: Not applicable

ACHI & AP

n/N

AP

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

4/13

13

0/11

11

37.79%

37.79%

7.71[0.46,129.18]

7.71[0.46,129.18]

Favours ACHI plus AP

0.01

0.1

1

10

100

Favours AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & AP

n/N

AP

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.42(P=0.16)

2.1.2 Deterioration in mental state

Chouinard 2007

Subtotal (95% CI)

Total events: 1 (ACHI & AP), 0 (AP)

Heterogeneity: Not applicable

Test for overall effect: Z=0.6(P=0.55)

2.1.3 Suicidal ideas

Chouinard 2007

Subtotal (95% CI)

Total events: 1 (ACHI & AP), 0 (AP)

Heterogeneity: Not applicable

Test for overall effect: Z=0.6(P=0.55)

1/13

13

1/13

13

0/11

11

0/11

11

31.1%

31.1%

2.57[0.12,57.44]

2.57[0.12,57.44]

31.1%

31.1%

2.57[0.12,57.44]

2.57[0.12,57.44]

Total (95% CI)

39

33

100%

3.89[0.69,22.02]

Total events: 6 (ACHI & AP), 0 (AP)

Heterogeneity: Tau2=0; Chi2=0.37, df=2(P=0.83); I2=0%

Test for overall effect: Z=1.54(P=0.12)

Test for subgroup differences: Chi2=0.36, df=1 (P=0.83), I2=0%

Favours ACHI plus AP

0.01

0.1

1

10

100

Favours AP

Analysis 2.2.   Comparison 2 Acetylcholinesterase inhibitors plus antipsychotics versus antipsychotics
alone, Outcome 2 Mental state: Short-term - Average end point score on PANSS (low = favourable).

Study or subgroup

ACHI & AP

AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

2.2.1 Negative

Chouinard 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.33(P=0.74)

2.2.2 Positive

Chouinard 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.58(P=0.56)

2.2.3 Disorganisation/cognitive

Chouinard 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

2.2.4 Hostility/excitement

Chouinard 2007

Subtotal ***

9

9

9

9

9

9

9

9

14.7 (2.7)

20.4 (4.9)

11.7 (3.2)

14.2 (1.8)

15.3 (4.7)

19.3 (2.8)

11.2 (2.2)

14 (2)

9

9

9

9

9

9

9

9

100%

100%

-0.6[-4.14,2.94]

-0.6[-4.14,2.94]

100%

100%

1.1[-2.59,4.79]

1.1[-2.59,4.79]

100%

100%

0.5[-2.04,3.04]

0.5[-2.04,3.04]

100%

100%

0.2[-1.56,1.96]

0.2[-1.56,1.96]

Favours ACHI plus AP

-4

-2

0

2

4

Favours AP

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

ACHI & AP

AP

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.22(P=0.82)

2.2.5 Anxiety/Depressive

Chouinard 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.2.6 Total

Chouinard 2007

Subtotal ***

8.9 (0.9)

73.7 (7.8)

9

9

9

9

8.9 (1.1)

71.9 (5.6)

9

9

9

9

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.56(P=0.57)

100%

100%

0[-0.93,0.93]

0[-0.93,0.93]

100%

100%

1.8[-4.47,8.07]

1.8[-4.47,8.07]

Favours ACHI plus AP

-4

-2

0

2

4

Favours AP

W H A T ' S   N E W

Date

Event

Description

17 October 2012

Amended

Contact details updated.

C O N T R I B U T I O N S   O F   A U T H O R S

Jasvinder Singh - protocol development, searching, study selection, data extraction, report writing.
Kamalpreet Kour - protocol development, searching, study selection, data extraction.
Mahesh B Jayaram - protocol development, study selection, report writing.

D E C L A R A T I O N S   O F   I N T E R E S T

None known.

S O U R C E S   O F   S U P P O R T

Internal sources

• Leeds Partnership Foundation Trust, Leeds, UK.
• Bradford District Care Trust,Bradford, UK.

External sources

• Bradford District Care Trust,Bradford, UK.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

We did not present NNT or NNH for significant results as stated in our protocol as these have been superseeded by presentation of data
in the Summary of findings for the main comparison

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Cochrane Database of Systematic Reviews

Antipsychotic Agents  [*therapeutic use];  Cholinesterase Inhibitors  [*therapeutic use];  Donepezil;  Galantamine  [therapeutic use]; 
Indans  [therapeutic use];  Phenylcarbamates  [therapeutic use];  Piperidines  [therapeutic use];  Psychotic Disorders  [*drug therapy]; 
Randomized Controlled Trials as Topic;  Rivastigmine;  Schizophrenia  [*drug therapy];  Schizophrenic Psychology

MeSH check words

Humans

Acetylcholinesterase inhibitors for schizophrenia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82
